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ABSTRACT 
 
Reported herein is an investigation into palladium-catalysed -allylation employing sulfonamide nucleophiles. 
Anions of benzylsulfonamides have been shown to react with a series of allyl acetates in the presence of Pd0 
catalysts, phosphine ligands and base at room temperature, enabling the synthesis of sp3-functionalised 
sulfonamides. The developed methodology has allowed access to a library of novel allylated sulfonamides, 
varying both amine substituent and allylic functionality. In addition, we have applied our methodology to a 
series of known sulfonamide drug targets, to demonstrate our reaction as a useful late-stage functionalisation 
tool, whilst populating chemical space.  
 
 
 
The performed mechanistic study using a stereospecific electrophile confirms benzylsulfonamides behave as 
soft carbon nucleophiles in the Tsuji-Trost reaction, as a ‘net retention’ of stereochemistry is observed 
(confirmed by X-ray crystallography). 
Moreover, the asymmetric synthesis of allylated sulfonamides is probed, although obtaining enantioselectivity 
- to SO bonds is naturally difficult, due to the conformational preferences of sulfonamide carbanions.  
Traditional methods for direct -alkylation of sulfonamides require strong bases, reactive electrophiles, low 
temperatures and use of stoichiometric amounts of additives. Therefore, in addition to a catalytic method, we 
report an alternative method reacting benzylsulfonamides with allyl bromide electrophiles via a nucleophilic 
substitution reaction, using mild conditions (LDA, THF at –20 °C).  
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ABBREVIATIONS 
 
Abbreviation Meaning 
AAA asymmetric allylic alkylation 
Ac acetyl 
AcOH acetic acid 
APTS (3-aminopropyl)triethoxysilane 
bp boiling point 
bs broad singlet 
d doublet 
DACH diaminocyclohexane 
Davephos 2-dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl 
dba dibenzylidieneacetone  
DBU 1,8-diazobicyclo[5.4.0]undec-7-ene 
DIAD diisopropyl azodicarboxylate 
DIOP (+)-2,3-O-isopropylidene-2,3-dihydroxy-1,4-bis(diphenylphosphino)butane 
DME dimethoxyethane 
DMF N,N-dimethylformamide 
dppb  1,4-bis(diphenylphosphino)butane 
dppe 1,2-bis(diphenylphosphino)ethane 
dppf  1,1’-bis(diphenylphosphino)ferrocene 
d.r diastereomeric ratio 
ESI electrospray ionisation 
Et ethyl 
EtOH ethanol 
IR infrared 
IPA isopropanol 
KOtBu potassium tert-butoxide 
LDA lithium diisopropylamide 
LiHMDS lithium bis(trimethylsilyl)amide 
m multiplet 
Me methyl 
MeCN acetonitrile 
MeOH methanol 
mp melting point 
NaHMDS sodium bis(trimethylsilyl)amide 
n-BuLi n-butyllithium 
NMR nuclear magnetic resonance 
NMP N-methyl-2-pyrrolidinone 
Ph phenyl 
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PMTDA N,N,N′,N′′,N′′-pentamethyldiethylenetriamine 
ppm parts per million 
Py pyridine 
RF retention factor 
r.t room temperature 
s singlet 
t triplet 
TBAF tetra-n-butylammonium fluoride  
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TLC thin layer chromatography 
TMEDA N,N,N′,N′-tetramethylethylenediamine 
TMS trimethylsilyl 
Troc trichloroethyloxycarbonyl 
X-Phos 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl 
Xantphos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene 
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CHAPTER 1 INTRODUCTION 
1.1 Palladium-Catalysed Cross-Coupling Overview 
 
The ability to form carbon-carbon bonds using sustainable methods has become a major focus of research 
and development, in particular for medicinal chemistry and the total synthesis of natural products.1,2 Since 
Kolbe demonstrated the first laboratory example of a C-C bond forming reaction (1845) in a synthesis of acetic 
acid, carbon-carbon bond forming reactions have been at the epicentre of the development of organic 
synthesis. There are a plethora of methods available that have become essential to the synthetic chemists’ 
toolbox, allowing the extension of complex carbon backbone structures and the synthesis of a myriad of 
organic compounds.3  
In the late 20th century, a new approach to the formation of carbon-carbon bonds emerged. The introduction 
of transition-metal catalysis transformed the way synthetic chemists design syntheses, producing new 
opportunities in total synthesis, medicinal chemistry and process chemistry.4 The development of transition-
metal catalysed reactions has played an important role in asymmetric synthesis and the production of 
enantioenriched material. 5  The demand for enantiomerically pure bioactive compounds has driven the 
development of catalytic reactions, as more efficient and sustainable synthetic methods have been sought.  
Among transition-metal catalysed processes, palladium-catalysed cross-coupling reactions have become an 
essential part of organic synthesis and the formation of carbon-carbon bonds. Cross-coupling reactions 
generally involve the combination of an organic electrophile with a nucleophilic coupling partner, reacting in 
the presence of sub-stoichiometric transition-metal catalyst.6 
The most commonly applied palladium-catalysed cross-couplings include: the Mizoroki-Heck, Stille, Suzuki-
Miyaura, Sonogashira, Negishi and Tsuji-Trost reactions. These reactions can be grouped into three 
categories based on mechanism: migratory insertion (Heck), transmetalation (Suzuki, Stille, Sonagashira, and 
Negishi) and -allyl (Tsuji-Trost). The impact of these methods was recognised in 2010 as Richard Heck, Ei-
Ichi Negishi and Akira Suzuki were awarded the Nobel Prize in Chemistry7 for their contributions towards 
palladium catalysed reactions, highlighting the pivotal role they played in the development of modern 
chemistry.  
The Mizoroki-Heck reaction reported first by Mizoroki (1971) and later improved by Heck (1972), generally 
couples sp2 aryl halides or triflates with olefins, resulting in a product formally arising from the substitution of a 
hydrogen in the alkene coupling partner (Scheme 1).8,9  Firstly, a palladium(II) catalyst is reduced to generate 
a Pd(0) species (step a), allowing for the oxidative addition of an aryl halide to the Pd(0) complex, to give a -
aryl palladium(II) halide (step b). Co-ordination of the alkene to the palladium(II) complex (step c), followed by 
migratory insertion (step d) enables the formation of the new carbon-carbon bond. Syn -hydride elimination 
(step e) allows the cross-coupled product to be released, leaving Pd-hydride complex to undergo reductive 
elimination with base to reform the active Pd(0) catalytic species (step f).10    
12 
 
 
Scheme 1: Heck reaction 
 
The Stille, Suzuki-Miyaura, Sonagashira, and Negishi reactions are similar to each other mechanistically as 
they all feature a transmetallation step, as shown in the catalytic cycle (Scheme 2). Again, oxidative addition 
(step b) of an aryl halide (or pseudohalide) to the Pd(0) complex generates a stable trans--palladium(II) 
complex. Transmetalation of an organometallic species (depending on named reaction) forms a palladium(II) 
complex bearing both coupling partners (step c). Subsequent reductive elimination (step d) allows the cross 
coupled product to be released and the regeneration of Pd(0) into the catalytic cycle.7  
The Stille reaction, reported first in 1978, is recognised by the reaction of aryl halides with organostannane 
coupling partners (2, Scheme 2). Although organotin nucleophiles have proven toxic,11 the Stille reaction 
remains one of the most versatile palladium-catalysed cross-coupling reactions, owing to its wide application 
and sensitive functional group tolerance.12  
In 1979, Suzuki et al. reported a new palladium-catalysed carbon-carbon bond forming reaction using organo-
boron nucleophiles and organic (pseudo) halide electrophile in the presence of a base (3, Scheme 2).13 Since 
its discovery and development, the Suzuki-Miyaura reaction has become the most widely used cross-coupling 
reaction in medicinal chemistry, its popularity residing in the mild operating reaction conditions and broad 
functional group tolerance.14  
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An alternative palladium-catalysed carbon-carbon bond formation protocol allows the coupling of terminal 
alkynes with aryl or vinyl halides, generally in the presence of a copper co-catalyst to accelerate the reaction. 
This transformation is known as the Sonogashira reaction and has proved an effective method in the synthesis 
of substituted alkynes (4, Scheme 2).15  
The Negishi reaction is a versatile palladium-catalysed cross coupling reaction employing organozinc reagents 
with aryl, alkyl, alkynyl or vinyl halides (5, Scheme 2). This reaction has been significantly developed due to 
the low toxicity of zinc reagents and their commercial availability.16  
 
 
Scheme 2: Transmetallation reactions: Stille, Sonagashira, Suzuki-Miyaura and Negishi 
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Unlike typical palladium-catalysed cross-couplings, the Tsuji-Trost reaction is mechanistically very different, 
proceeding occurs via a -allyl palladium intermediate (6, Scheme 3).4,7 This palladium-catalysed cross-
coupling reaction of allyl electrophiles (most commonly allyl acetates) with nucleophilic coupling partners (most 
commonly soft anions, generally formed from malonates or -dicarbonyl compounds) is a synthetically useful 
strategy in the formation of carbon-carbon bonds.5  
The Tsuji-Trost allylic alkylation reaction constructs carbon-carbon bonds between sp3 hybridised carbons and 
can proceed via two mechanistic routes depending on the hardness (pKa) of the pronucleophile. The catalytic 
species is generated by reduction of Pd(II) precatalyst to Pd(0) (a, Scheme 3), or alternatively the reaction can 
begin with a Pd(0) catalyst. The Pd(0) species can coordinate to the allylic substrate (b, Scheme 3), which in 
turn undergoes displacement of the leaving group (c, Scheme 3) to give a palladium -allyl intermediate. 
Stabilised or ‘soft’ pronucleophiles (those which derive from conjugate acids with pKas ≤ 25), such as malonate, 
proceed through direct attack of the nucleophile on the -allylic termini, with no prior coordination to the Pd-
complex (d, Scheme 3). Here, the product retains the stereochemistry of the carbon bonded to the leaving 
group (f, Scheme 3). Unstabilised or ‘hard’ pronucleophiles (those which derive from conjugate acids with pKas 
≥ 25, for example Grignard reagents) coordinate to the Pd(II) species, forming intermediate (g, Scheme 3), 
after which reductive elimination takes place to form the allylated product (h, Scheme 3) with a net inversion 
of stereochemistry.5  
15 
 
 
Scheme 3: Tsuji-Trost  
 
A plethora of palladium-catalysed cross couplings have emerged in the past half century, transforming the art 
of chemical synthesis.7 Palladium-catalysed cross-coupling reactions is an ever-expanding area of research 
both in academic and industrial research groups. This review will solely focus on the Tsuji-Trost reaction, 
specifically the extension of this methodology to encompass sulfonamide nucleophiles. 
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1.2 Asymmetric Allylic Alkylation  
1.2.1 Overview 
 
Asymmetric allylic alkylation (AAA) reactions use a transition metal catalyst to generate an asymmetric centre 
in the -position of a racemic starting material (Scheme 4).17,18 AAA reactions have become a powerful method 
in constructing compounds with stereogenic centres, and have played an important role in the synthesis of 
biologically relevant compounds.5 Such transformations have been described with a large number of transition 
metal catalysts, including: gold,19 molybdenum,20 platinum,21 rhodium22 and more commonly palladium and 
iridium.23,24  
 
 
Scheme 4: General reaction scheme for AAA 
 
This review will aim to focus on palladium-catalysed allylic alkylation reactions to give an insight into this ever-
expanding area of chemistry. Both mechanistic discussion and application of the Tsuji-Trost reaction to various 
nucleophiles will be addressed. 
 
1.2.2 The Tsuji-Trost Reaction 
 
The first palladium mediated allylation was reported first by Tsuji in 1965, demonstrating that the anion of 
diethyl malonate (1) attacked stoichiometric allyl palladium(II) chloride dimer to yield both the mono and di-
allylated malonate 2a and 2b, respectively (Scheme 5).25  
 
 
 Scheme 5: First palladium-catalysed allylation reaction by Tsuji  
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This new carbon-carbon bond-forming transformation was later developed by Trost in 1973 (Scheme 6).26 
Formation of the -allyl palladium complex with stoichiometric PdCl2 and 1,1-dipropylethene (3) enables the 
reaction with the anion of diethylmalonate (1) in the presence of triphenylphosphine, accessing a mixture of 
three allylated compounds (4a, 4b and 4c).   
 
 
Scheme 6 Trost’s developed palladium-mediated reaction (1973) 
 
Since these discoveries, significant progress has been made in this area, including the introduction of catalytic 
conditions,27,28 as well as the development of asymmetric alkylation.29 The Tsuji-Trost reaction has been the 
subject of many investigations in the past half century, from mechanistic discussion,26 its application in both 
medicinal chemistry and total synthesis,4 as well as presenting itself as a key player in asymmetric synthesis.18 
This thesis will aim to discuss these factors in detail and highlight key reactions.  
 
1.2.3 Electrophiles 
  
An extensive range of unsaturated electrophiles, both cyclic and acyclic, can be employed in palladium-
catalysed allylic alkylation reactions, making this a useful process for the formation of carbon-carbon bonds. 
Whilst the most commonly used substrates for this transformation are allylic acetates, a number of alternative 
leaving groups have also been exploited, including: alcohols,64, 30 , 31  boronic esters, 32  carbonates,89,90 
epoxides33 and halides34 (Figure 1). The broad range of functional group compatibility has made the Tsuji-
Trost reaction a versatile transformation.35 
 
 
Figure 1: Allylic electrophiles 
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1.2.4 Mechanism 
 
The Tsuji-Trost reaction has been widely developed to utilise mild reaction conditions, synthesising allylic 
compounds via palladium-catalysed allylic alkylation of a nucleophile.5,17,18,23  As discussed in Section 1.1 the 
mechanism can proceed via two routes, since the mode of attack of nucleophiles on palladium -allyl 
intermediates is related to the pKa of the pronucleophile. Based on this well-known paradigm, nucleophiles can 
be divided into two classes: ‘soft’ or stabilised nucleophiles (from pronucleophiles with pKas < 25), and ‘hard’ 
or unstabilised nucleophiles (from pronucleophiles with pKas > 25).5,23 Since pKa values are solvent and 
temperature dependent, 36 the values discussed in this thesis correspond to DMSO organic solvent at 25 °C, 
unless otherwise stated. 
‘Soft’ nucleophiles attack the -allyl chain of the intermediate, giving rise to a product with a net retention of 
configuration. ‘Hard’ nucleophiles, on the other hand, co-ordinate firstly to the palladium of the -allyl 
intermediate, and then transfer to the allylic carbon, thus forming a product with an overall net inversion of 
stereochemistry (Scheme 7).  
 
 
Scheme 7: Mechanistic detail of Tsuji-Trost reaction 
 
As shown in Scheme 7, depending on the substitution of the allyl substrate, regioselectivity can be an issue in 
allylic alkylation. When the R2 group is not hydrogen the nucleophile can attack at either end of the allylic 
termini, thus potentially forming regioisomeric products. The regioselectivity of these reactions is influenced by 
several factors, including: the nature of R groups (steric and electronic effect), the ligands attached to the Pd 
complex, and the ability of the Pd intermediate to undergo syn:anti isomerisation (Scheme 8).37  
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Scheme 8: syn:anti isomerisation 
Typically, palladium-catalysed allylation reactions using substituted -allyl systems occur at the least 
substituted allylic terminus, thus leading to linear products, whereas other transition metal catalysed AAA 
reactions, for example iridium, preferentially form branched products.38   
 
1.2.5 Mechanistic Study 
 
The division of nucleophiles into the two classes (hard or soft) was established by Trost in 1980. 39 The initial 
mechanistic study utilised isomers of 3-acetoxy-5-carbomethoxy-1-cyclohexane (7a and 7b) to determine the 
stereochemical outcome of the cross-coupled product with a malonate nucleophile. Cis-isomer 7a was 
prepared from methanolysis of racemic lactone 5 and subsequent acylation of alcohol 6a (1, Scheme 9).  
Trans-isomer 7b was prepared by a one-pot acid-catalysed isomerisation using perchloric acid and acylation 
with acetic anhydride of alcohol 6a gave the acylated compound as a mixture of isomers. Base-catalysed 
hydrolysis of the acetate gave alcohol 7ab, which could be selectively transformed to trans-alcohol 6b and 
subsequently acylated to give trans-isomer 7b (2, Scheme 9).39  
 
 
Scheme 9: Preparation of isomers of 3-acetoxy-5-carbomethoxy-1-cyclohexene 7a & 7b 
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Cis-acetate 7a was subjected to palladium-catalysed allylation conditions with the sodium salt of 
dimethylmalonate 8 to obtain allylated compound 9a in a 92 % yield as a 98:2 mixture of cis:trans isomers. 
Structure 9a was confirmed by 1H NMR, as the essential coupling (JAD = JBD = JCD = 12 Hz) indicated that HA 
and HB are pseudoaxial (Scheme 10). 
Similarly, dimethylmalonate nucleophile was successfully alkylated with trans-stereoprobe 7b, giving 9b in 80 
% yield. Structure 9b was also confirmed by 1H NMR, signals for HC (1.96, ddd J 13.5 Hz 9.5 Hz 5.5 Hz) and 
HD ( 1.80, dt J 13.5 Hz 4 Hz) were readily observed, thus suggesting that HA is pseudoequitorial and HB is 
pseudoaxial (Scheme 10). 
In both cases the stereochemistry is retained, therefore this study demonstrates that dimethylmalonate 8 
behaves as a soft nucleophile, as the nucleophile attacks the chain of the -allyl palladium intermediate, 
juxtaposed with the co-ordination of the nucleophile to the palladium.  
 
 
Scheme 10: Allylations of both isomers of 3-acetoxy-5-carbomethoxy-1-cyclohexane  
 
This study paved the way to a better understanding of allylic alkylation reactions and their mechanistic 
pathway. The Trost cis-stereoprobe 7a remains the most commonly used and is facile to synthesise in 
comparison to its trans-isomer 7b, however some mechanistic studies require access to a stereoprobe that 
cannot undergo competing deprotonation, for example when strong/excess base is used in the reaction. 
Therefore an alternative electrophile used is cis-5-phenyl-2-cyclohexen-1-yl acetate (13a) or its trans-isomer 
21 
 
13b. 40  These stereoprobes can be synthesised from readily available phenylcyclohexane-1,3-dione (10) 
(Scheme 11).40,41,42 Phenyldione 10 can be converted to enone 11 (step a, Scheme 11), which can undergo a 
Luche reduction to afford the racemic cis-alcohol 12 (step b, Scheme 11) in high diastereoselectivity (99 %). 
Cis-alcohol 12 can be acylated using standard conditions to afford cis-acetate 13a (step c, Scheme 11). 
Access to the trans-acetate 13b can be achieved by reacting compound 12 under Mitsonobu conditions (step 
d).  
 
 
Scheme 11: Synthesis of isomers of 5-phenyl-2-cyclohexen-1-yl acetate 
 
The development of the mechanistic study has been pivotal in understanding the behaviour of nucleophiles in 
the Tsuji-Trost reaction. Although the study has been modified throughout time with different stereodefined 
electrophiles, it is a widely accepted model to distinguish between hard or soft nucleophiles. 
 
1.3 Soft Nucleophiles 
1.3.1 Carbon Nucleophiles 
 
The ability to form carbon-carbon bonds by allylic alkylation reactions has become a major focus in organic 
synthesis, therefore it is no surprise that since the discovery of the Tsuji-Trost reaction, there are a myriad of 
examples in the literature with ‘soft’ carbon nucleophiles. 
From the initial reaction by Tsuji in 1965 with diethylmalonate (1) (Scheme 5), other carbon nucleophiles have 
been reported to undergo palladium-catalysed allylic substitution reactions including: -ketoesters,43 ketone 
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enolates,44,45 aldehydes,46 amides,47 as well as stabilised carbanions of sulfones48 and thioamides,49 to name 
but a few (Scheme 12). 
The ability to create quaternary carbon centres in which the absolute stereochemistry can be controlled is of 
great importance in the synthesis of biologically active material.18 In 1988 Hayashi et al. demonstrated that -
ketoester 14 can undergo asymmetric allylic alkylation reactions with chiral ferrocene ligand L1, to yield 
alkylated product 15 (86 % ee) at –60 °C for 44 hours (1a, Scheme 12). 50 Later in 1997, Trost developed this 
methodology (milder reaction conditions, 0 °C, and shorter reaction times, 3 hours) to obtain compound 15 in 
86 % ee with the introduction of a new class of chiral phosphine ligand L2 (1b, Scheme 12).43 
Similarly, in 1999, Trost described the first asymmetric allylic alkylation of ketone enolates 16, also generating 
an all carbon chiral quaternary centre, with chiral ligand L2 (2, Scheme 12).44 These examples show the birth 
of a new class of chiral ligands that have since become extremely important in the design of ligands and the 
achievement of enantioselectivity in AAA reactions (further discussion in Section 1.6.2).51  
The 1990’s and early 2000 saw the expansion of this chemistry and its application to other soft carbon 
nucleophiles. In 2001, Tamaru et al. described the direct -alkylation of aldehydes, both cyclic and acyclic to 
give 12 previously unreported compounds 19 (3,Scheme 12).46  
In 2008, the asymmetric -allylation of amides was described by Hou et al. using chiral ferrocene ligand L1 to 
obtain compounds 21 with high enantioselectivities (4, Scheme 12). This reaction provides access to --
unsaturated amides, as well as demonstrating a useful tool to functionalise compounds that are valuable 
building blocks in organic synthesis.  
In the same year, the -C-H functionalisation of sulfones was also described via decarboxylative allylation of 
sulfones derivatives 22, yielding compounds 23 in generally high yields (5, Scheme 12). In 2010, the same 
group were able to gain access into non-racemic compounds, although enantioselectivity was only achieved 
when using enantioenriched sulfone starting material.52 The difficulties of enantioselective functionalisation -
to sulfur will be discussed in detail later in Section 1.7. 
The final example is the palladium-catalysed allylic alkylation of thioamide nucleophiles 24, which was reported 
firstly in 2013 by Zhao et.al and again in 2015 with the development of enantioselective synthesis (6, Scheme 
12).53 Thioamides are synthetically useful and can easily be transformed into other functional groups such as 
amines,54 amides55 and acids.56  
The examples highlighted in Scheme 12 demonstrate the versatility of the palladium-catalysed allylic alkylation 
reactions and functional group tolerance. The examples presented show only a small number of the ever-
growing library of soft carbon nucleophiles that can be applied to the Tsuji-Trost reaction.  
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Scheme 12: Examples of soft carbon nucleophiles 
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AAA using carbon nucleophiles have also been used in various total syntheses, including the synthesis of (–
)-wine lactone (28) (Scheme 13).5,23,57,58 In 2000, Helmchen et al. used palladium-catalysed allylic substitution 
reaction of 8 and 2-cyclohexen-1-yl acetate (26) to provide compound 27 in high enantioselectivity, as a key 
first step in the total synthesis. 
 
 
Scheme 13: Palladium catalysed allylation in total synthesis of (-)-wine lactone 
 
1.3.2 Nitrogen Nucleophiles 
 
Nitrogen nucleophiles are the second most commonly used nucleophiles in the Tsuji-Trost reaction. N-
allylation has been reported for numerous nitrogen nucleophiles, including aliphatic and aromatic 
amines,59,60,100 amides,61 aziridines,62,63 and sulfonamides59 to name a few (Scheme 14). 
In 1985 Inoue et al. reported a novel direct N-allylation of amides 29 with 2-allylisourea 30 under palladium-
catalysed reaction conditions, obtaining a series of N-allylated amides in generally good yields (1, Scheme 
14). In most cases a mixture of monoallylation 31a and diallylation 31b was observed, whereas in some cases 
only monoallylation was observed.  
N-Allylation of primary amines has proven challenging due to potential over alkylation, whereas alkylation of 
secondary amines is more facile.5,64 In 1989, Hayashi et al. demonstrated an asymmetric allylic amination of 
both primary amines 32 and sulfonamide 35 with chiral ferrocene ligand L1 yielding compound 34 and 36 (2, 
Scheme 14).59 By using a bulkier electrophile 33 only monoallylation was observed.  
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Later in 2004, Yudin et al. reported the first example of allylic amination using unprotected aziridines 37 with 
allylic acetates to generate a library of compounds 38 (3, Scheme 14). In the cases where prenyl, geranyl and 
cinnamyl acetates were employed, branched isomers were formed exclusively over linear products.  
 
 
Scheme 14: Allylic alkylation with nitrogen nucleophiles 
 
N-allylation highlights the Tsuji-Trost reaction as a useful method in the formation of carbon-nitrogen bonds, 
with only a few of many examples presented in Scheme 14.65  Although N-allylation is widely reported, 
controlling chemo-, regio-, and stereo-selectivities remains challenging, as well as over alkylation.66  
 
1.3.3 Oxygen and Sulfur Nucleophiles 
 
The scope of palladium catalysed AAA reactions has also been demonstrated with oxygen and sulfur 
nucleophiles.67,68,69 AAA reactions with oxygen nucleophiles include; alcohols,70 carboxylates,71 carbonates72 
and phenols.73 
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Phenols represent a superior class of oxygen nucleophiles since stereogenic carbon atoms bearing an oxygen 
are present in many natural products.74 Palladium catalysed allylic substitution reactions of phenols have been 
applied in Trost’s total synthesis of (–)-morphine, (–)-codeine and (–)-galanthamine.75,76,77 These syntheses all 
feature a palladium-catalysed allylic substitution reaction as a key step in installing chirality, accessing the 
highly functionalised phenolic compound 40 in high enantioselectivity (Scheme 15). 
 
 
Scheme 15: Allylic alkylation of phenol in total synthesis 
 
Furthermore, a variety of sulfur nucleophiles can be applied to palladium-catalysed allylic alkylation reactions, 
including sulfones78 and thiocarboxylates.79  
The Tsuji-Trost reaction is a powerful tool in the formation of C-C, C-N, C-O and C-S bonds. Despite the high 
level of activity in this area, there are challenges that remain and nucleophiles that are yet to be studied. 
 
1.4 Hard Nucleophiles 
1.4.1 Reactions with Hard Nucleophiles 
 
The Tsuji-Trost reaction has been intensely explored mechanistically, using a variety of nucleophiles. As 
discussed, the use of soft nucleophiles dominate the literature and reports of reactions with hard nucleophiles, 
those which are derived from conjugate acids whose pKas are ≥ 25, are rare. This may be due to the difficulty 
of deprotonating a ‘hard’ position, which generally requires excess base, leading to the enantiomeric excess 
values being typically low for hard nucleophiles. 
In 1990, Buono et al. reported the first example of a palladium-catalysed cross coupling of an unstabilised 
Grignard reagent 41 and allylic acetate 26 affording the cross coupled product 42 in an 85 % yield (Scheme 
16). Although 42 was obtained in high yield, low ees were observed and high enantioselectivity could not be 
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obtained, despite screening an extensive array of chiral ligands. Proliphos (L6) was the most effective chiral 
ligand in the screening, giving compound 40 in 30 % ee.80   
 
 
Scheme 16: First palladium catalysed allylation with ‘hard’ nucleophile 
 
One of the most successful application of non-stabilised nucleophiles involves hydride transfer with formic acid 
acting as the hydride donor. First reported by Yamamoto in 1991,81 Hayashi and co-workers later reported the 
first asymmetric example; chiral allylsilane 44 was obtained in high yield and high enantioselectivity from allyl 
carbonate 43 in the presence of chiral monodentate phosphine palladium catalyst L7 (Scheme 17).82  
 
 
Scheme 17: Asymmetric reaction with hydride transfer, Hayashi 1994 
 
More recent advances of the Tsuji-Trost reaction with hard nucleophiles have been reported by Maulide and 
Morken (Scheme 18). In 2011, Morken et al. reported an asymmetric palladium-catalysed allylation reaction of 
allyl boronates to generate compounds 46 with an all carbon quaternary centre in high enantioselectivity.83 In 
2013 Maulide et al. exploited this chemistry by employing allyl boronates as nucleophiles with lactones 47 to 
yield trans-cyclobutene carboxylic acid derivatives 48 in generally good yields and with moderate 
enantioselectivity.84   
Additionally, in 2014, Maulide et al. demonstrated that dialkyl zinc reagents behave as hard nucleophiles in 
palladium-catalysed allylic substitution reactions with cyclic electrophiles 49 by developing the first asymmetric 
reaction of this kind, accessing compounds 50 with high enantioselectivity.85  
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Scheme 18: Reactions using hard nucleophiles 
 
1.4.2 Softening Hard Nucleophiles 
 
Despite the recent success in obtaining high enantioselectivity in AAA using hard nucleophile, it is widely 
accepted that obtaining reactivity or enantioselectivity with hard pronucleophiles is difficult. Studies by Trost in 
2008 showed how hard pronucleophiles could be ‘softened’ by use of activating agents that stabilise the 
resultant anionic charge. 86  Trost showed that 2-methylpyridine derivatives 51 could be allylated using 
palladium-catalysed conditions with BF3 complex as an activating agent, yielding compounds 52 in high 
enantioselectivity (1, Scheme 19). Prior to this work, when 2-methylpyridine (51a) anion was generated with 
n-BuLi and subjected to AAA reaction conditions, no conversion to the desired allylated product was observed. 
Trost confirmed that the anion of 2-methylpyridine (51a) behaved as a soft nucleophile as the reaction with 
trans-stereoprobe 53a proceeds with a net retention of configuration 54 (2, Scheme 19). Trost later applied 
this methodology to 2-substituted pyridine nucleophiles to expand the scope of softening hard nucleophiles.87 
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Scheme 19: Softening 2-methylpyridine nucleophiles 
 
Walsh focused on the softening of ‘harder’ pronucleophiles in an attempt to broaden the scope of nucleophiles 
that can be applied to the Tsuij-Trost reaction. In 2011, Walsh demonstrated that toluene pronucleophile 
derivatives (pKa ~ 43)36 can undergo allylic alkylation by activation of the pronucleophiles with 6-tricarbonyl 
chromium.88 More recently, in 2016, this chemistry was transferred to asymmetric allylic alkylation to access 
chiral compounds. 89  High enantioselectivities of a library of toluene-based compounds 55 were obtained using 
the Ph-Taniaphos chiral ligand L12 (1, Scheme 20). 
A mechanistic study was performed using cis-stereoprobe 53b and chromium compound 55a, to yield cis-
compound 57 in 63 % with 64 % ee, the net-retention of stereochemistry confirms the soft nature of the 
nucleophile (2, Scheme 20).  
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Scheme 20: AAA with toluene based nucleophiles 
 
1.4.3 Lowering the pKa barrier 
 
The route to establish whether a nucleophile follows the hard or soft catalytic pathway has been very well 
established, however some nucleophiles have been reported to not follow this trend. 
In 2013 Walsh and co-workers reported that diarylmethane derivative (pKa’s of ~ 32)36 behave as ‘soft’ 
nucleophiles in palladium-catalysed allylic substitution reactions. A library of allylic functionalised 
diarylmethane compounds were described, as well as heterocyclic diarylmethanes. The mechanistic study for 
diphenylmethane (58) and di-(3-pyridyl)methane (60) was carried out using cis-stereoprobe 53b. In both cases 
a net retention of stereochemistry was observed, suggesting both diphenylmethane and di-(3-pyridyl)methane 
behave as soft nucleophiles in the Tsuji-Trost reaction (Scheme 21). 90 These results raise a question as to 
whether the pKa limit for ‘soft’ nucleophiles should be raised from 25 to 32.  
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Scheme 21: Allylic substitution with retention of configuration 
 
1.6 Enantioselectivity 
1.6.1 Mechanism for Enantiodiscrimination 
 
A significant advantage of transition-metal catalysed processes is the possibility of using chiral ligands to 
induce asymmetry.91 The general catalytic cycle of an AAA reaction offers at least five opportunities for 
enantiodiscrimination: enantiotopic complexation (A), ionisation (B), nucleophilic attack at the enantiotopic 
termini (C), enantioface discrimination of -allyl complex (D), as well as enantiodiscrimination in the nucleophile 
(E) (Figure 2).18,23 
Enantiotopic complexation (mechanism A) shows how palladium can differentiate between the enantiotopic 
faces of the -allyl system if the olefin is unsymmetrical. In meso substrates (mechanism B), palladium may 
insert into either end of the -allyl system, therefore enantioselection occurs by desymmetrisation of the meso 
intermediate. If the 3 allyl intermediate is not symmetrically 1,3-disubstituted (mechanism C), enantioselection 
will be dictated by the transition metal choosing a face of the allyl fragment to coordinate. Mechanism D is 
similar to that of mechanism A, whereby the -allyl intermediates interconvert faster than they are attacked by 
a nucleophile, therefore enantioselectivity is derived from the differential rates of reaction. Enantioselectivity 
can also be obtained via enantiofacial discrimination by prochiral nucleophiles (mechanism E). In mechanism 
A and B, the metal induced ionisation of the leaving groups represents the enantiodiscrimination step; while 
in mechanisms C and D nucleophilic addition is the enantiodiscrimination step. 

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 Figure 2: Mechanisms for enantiodiscrimination  
 
1.6.2 Chiral Ligands 
1.6.2.1 C2 Symmetric Ligands 
 
The design and synthesis of chiral ligands has played an important role in the ability to achieve 
enantioselectivity in AAA reactions.23 The ability for a chiral catalyst to transfer asymmetry to a substrate 
generally relies on steric biasing and electronic effects. Many of the chiral ligands used in AAA reactions are 
bidentate and are either C1 or C2 symmetric.92   
C2 symmetric ligands offer significant advantages in asymmetric reactions since the presence of a symmetry 
axis not only reduces the number of catalyst-substrate arrangements, but also reduces the number of 
competing reaction pathways.93 The first C2 symmetric ligand developed for asymmetric catalysis was (–)-
DIOP L13, pioneered by Dang and Kagan in 1971 (Figure 3).94,95  
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Figure 3: (–)-DIOP Ligand 
 
Trost and co-workers used (–)-DIOP in the first asymmetric allylic alkylation performed in 1977, reacting cis-
3-acetoxy-5-carbomethoxycyclohexene (7a) with nucleophile 62 to obtain cis-functionalised product 63 in 77 
% yield and 46 % ee (Scheme 22).29  
 
 
Scheme 22: First asymmetric Tsuji-Trost reaction with (+) - DIOP ligand 
 
The design principles of DIOP have influenced the development of diphosphine ligands that have been 
synthesised in the past few decades.96 Of the vast library of chiral ligands synthesised so far, a small class of 
ligands, referred to as ‘privileged ligands’, have emerged due to of their broad applicability. These ligands have 
been widely used in AAA reactions, with ligands possessing C2 symmetry dominating the literature.  
The most popular of the ‘privileged ligands’ in AAA reactions are a class of C2 symmetric diphosphine ligands, 
developed by Trost in the early 1990s. 43,44 Trost developed a working model for the design of his chiral ligands, 
in which the chiral environment created around the allyl group is closely related to the P-Pd-P bite angle; 
increasing the bite angle moves the aryl groups away from the ligand backbone and further envelops the 
substrate (Figure 4).92,97 The P-Metal-P bite angle in transition metal complexes is generally measured by 
either crystal structures found in Cambridge Crystallographic Database, or by computer modelling.98 There are 
several factors known to affect the bite angle, including steric interactions of the ligand backbone, as well as 
electronic differentiation of coordinating atoms.99   
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Figure 4: Model design for chiral ligands 
 
Based on the model in Figure 4, the Trost ligands were made so that the N-C-C-N linkage maximises the 
dihedral angle, restricting the number of degrees of rotational freedom in the phosphine-metal complex (Figure 
5).100  By limiting the specific degrees of freedom, the number of competing transition states is lowered, 
therefore there is greater probability of accessing high enantioselectivity.101  Ligands L2, L14 and L15 are three 
of the more commonly used Trost ligands in AAA reactions and were designed to be stable in asymmetric 
catalysis and have the ability to form highly stereoselective systems.102 
 
 
Figure 5: Sample of Trost ligands 
 
In contrast to Trost’s chiral diphosphine ligands, another class of privileged ligands used in AAA reactions are 
the C2 symmetric oxazoline ligands.103 Chiral oxazoline based ligands, such as; bis(oxazoline) (Box) L16, 
azabis(oxazoline) (azaBox) L17 and pyridinebis(oxazoline) (pyBox) L18, are a class of typical N,N-bidentate 
ligands, containing two oxazoline rings separated by a spacer (Figure 6). Since their synthetic development in 
1990-1991, 104 , 105  Box ligands and their derivatives have been successfully applied to AAA reactions, 
demonstrating high enantioselectivity.106  
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Figure 6: Examples of chiral oxazoline ligands 
 
Other key privileged ligands used in AAA reactions include BINAP L19, BINOL L20 and phosphoramidite L21 
derivatives, all of which contain a binapthyl core but vary in the co-ordination atom to the catalyst (Figure 7).107 
These classes of ligands are stable to racemisation due to the high barrier of rotation about the central C-C 
bond, therefore are found in numerous applications in asymmetric reactions.108 Binaphthyl derived ligands are 
a large class of ligands that are extremely versatile as their structure allows for facile modification.109 
 
 
Figure 7: Binapthyl core ligands 
  
1.6.2.2 C1 Symmetric Ligands 
 
Although the use of C2 symmetric ligands remains dominant in AAA reactions, C2 symmetric ligands can 
struggle to distinguish between diastereotopic carbons of the allylic moiety.110 Therefore in the early 1990’s a 
new class of ligands were established, containing a mixture of P-N properties, as opposed to the more usual 
P-P and N-N in C2 symmetric ligands. 111,112,113 These C1 symmetric ligands are more commonly known as the 
phosphinooxazolines (PHOX) L22 ligands, and were developed by Williams, Helmchen, Werner and Pfaltz 
(Figure 8).114 
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Figure 8: Typical backbone structure of a PHOX ligand 
 
These ligands were designed so that the contrasting (P-N) properties are able to constrain the reactivity of the 
metal centre to a single site of the ligand, giving rise to selective attack of the nucleophile at the allylic carbon.114 
C1 symmetric PHOX ligands have become extremely versatile ligands in allylic alkylation reactions, as 
numerous examples with differing backbone frameworks have demonstrated their ability to control 
enantioselectivity.115  
 
1.7 Sulfonamides 
1.7.1 Sulfonamides in Medicinal Chemistry 
 
The sulfonamide functional group is a frequently seen subunit in medicinal chemistry. Compounds bearing a 
sulfonamide functionality often exhibit anti-bacteria, 116  anti-cancer, 117  anti-inflammatory 118  and anti-
psychotic119 properties, demonstrating the widespread application of the sulfonamide moiety in drug-design. 
Sulfonamides are pharmacologically reliable motifs and appear in several drug substances, for example 
Sumatriptan, the first of the triptan class (Figure 9). Sumatriptan (Imitrex®, GlaxoSmithKline) a licensed drug 
developed in 1991 is used in the treatment of migraines and cluster headaches.120 
 
 
Figure 9: Sumatriptan, FDA approved 1991 
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More recently, the sulfonamide functional group has appeared in drug-like molecules (Figure 10). In 2013, a 
series of arylalkylsulfonyl piperazines 64 were shown to exhibit nanomolar binding affinities for sigma receptor 
ligands; varying the position of the phenyl substituent on piperazine ring proved to be the key to 
improvements.121  
In addition, sulfonamides have been screened in the development of anti-psychotic drugs. Cyclic sulfonamide 
65 and varying derivatives have been screened as potential dopamine D2 and D4 selective receptor agonists, 
in the development of drugs to target and treat schizophrenia. Sultam 65 gave promising results in the study 
as it was a fully selective D4 compound.122  
Finally, in 2015 Torok et al. reported sulfonamide linker based inhibitors, for example compound 66, as a new 
class of potential drug candidates for the treatment of Alzheimer’s disease.123  
 
 
Figure 10: Sulfonamides in drug-like molecules 
 
1.7.2 Functionalisation of Sulfonamides 
 
The ability to form carbon-carbon or carbon-heteroatom bonds from a generally unreactive C-H bond has led 
to an array of C-H transformations reported in literature.124,125 C-H functionalisation techniques have become 
an important addition to the medicinal chemists’ toolbox, and as such, novel methods to functionalise at sp2 
and sp3 centres has vastly expanded.126  
The literature is filled with a myriad of C-H functionalisation reactions, some of which include: arylation,127,128 
alkylation,129 amination,130 oxidation,131 borylation132 and halogenation.133,134 Such C-H transformations have 
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paved the way in exploring chemical space and enabling access to diverse analogues of potential lead-like 
compounds.135,136 Therefore, C-H functionalisation has become a quintessential approach, rather than relying 
solely on conventional synthetic approaches.137,138  
Despite the wide pharmaceutical interest in sulfonamides, few methods to functionalise - to the sulfur have 
been reported. Bearing this in mind, along with the drive to develop practical late-stage functionalisation 
methods, there has been significant interest in the development of new methods to functionalise - to the 
sulfonyl moiety.  
 
1.7.3 Traditional Alkylation of Sulfonamides 
 
Traditional alkylation of sulfonamides often demands use of strong bases, reactive electrophiles, low 
temperatures and use of stoichiometric additives, such as tetramethylenediamine (TMEDA) and 
hexamethylphosphoramide (HMPA).139, 140  
In 2002, Enders demonstrated that - functionalisation of sulfonamides was possible using chiral sulfonamide 
67. Reacting 67 with allyl bromide under relatively harsh reaction conditions (n-BuLi, HMPA, 78 °C for 24 
hours) -allylated compound 68 was obtained in 68 % yield and high diastereoselectivity (Scheme 23).140  
 
 
Scheme 23: -Alkylation of sulfonamides via nucleophilic substitution reaction 
 
Although there are reported alkylation methods to functionalise at the -carbon of sulfonamides,140,141 there is 
a lack of practical methods available, especially ones that do not use carcinogenic additives.  
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1.7.4 Catalytic sp2-sp3 Coupling of Sulfonamides 
 
Several reports have described metal-catalysed sp2-sp3 coupling of sulfonamides, demonstrated first by 
Parkinson et al. in 2005 with the palladium-catalysed -arylation of methylsulfonamide 69 with phenyl bromide, 
yielding compound 70 in 66 %. (Scheme 24).142 However, when varying substituents on the nitrogen subunit, 
as well as the on the aryl bromide, the yields of -arylated product decreased (less than 30 %) due to both 
steric and electronic effects. 
 
 
Scheme 24: First palladium catalysed arylation of methanesulfonamides 
 
In 2007 Northrup, at Merck, developed Parkinson’s previous work by introducing an ester group to activate the 
-CH position, which after functionalisation could be removed easily by decarboxylation. -Arylation of 71 was 
achieved using palladium-catalysed reaction conditions with various aryl and pyridyl bromides to yield 
compounds 72 (Scheme 25).143 Nonetheless, lower yields were obtained for sterically bulkier aryl bromides, 
for example 2-bromo-m-xylene gave only 7 % yield of the desired arylated sulfonamide.  
 
 
Scheme 25: Northrup synthesis of benzylic sulfonamides 
 
After the C-H arylation reaction, Northrup described how the functionalised compound (72a Scheme 26) can 
undergo a one pot sulfonamide metathesis with dimethylamine and subsequent decarboxylation to afford the 
desired product 73 (Scheme 26). This example highlights a practical method in obtaining -arylated 
sulfonamides, with the ability to replace the amine group after the functionalisation reaction. 
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Scheme 26: One pot metathesis and decarboxylation 
 
In 2008, Zhou et al. reported a new strategy for providing a practical route to benzylic sulfonamides.144 Their 
method highlighted a Negishi cross-coupling of sulfonamide zinc reagents, prepared in situ, with varying aryl 
coupling partners (Scheme 27). This methodology allows -arylation of sulfonamide 74, without the need for 
an electron withdrawing group present, such as an ester in the previous Northrup’s example. 
 
 
Scheme 27: Direct -arylation of methanesulfonamides 
 
Similarly, Knauber and Tucker have explored the Negishi type -arylation of sulfonamides and sulfones, 
developing a method in which TMP•ZnCl•LiCl can be used dually as a base and source of zinc in the coupling 
reaction. Using microwave irradiation, which reduced reaction times to two hours (from 16 hours at 60 °C in a 
sealed vial), a broad reaction scope of aryl bromides (aromatic and heteroaromatic) and alkyl sulfonamides 76 
(several different nitrogen substituents) were coupled in modest to good yields, demonstrating the significant 
scope of the reaction (Scheme 28).145 
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Scheme 28: Negishi type -arylation of sulfonamides 
 
1.7.5 Catalytic Sp3-Sp3 Coupling of Sulfonamides 
 
To date, there have been few disclosures of methods to enable catalytic sp3-sp3 coupling of sulfonamides, 
functionalising at the carbon - to the sulfur moiety. In 2014, Fu et al. developed an enantioselective nickel-
catalysed Negishi arylation and alkenylation of both sulfones and sulfonamides.146 Fu showed that racemic 
bromosulfonamides 78 could undergo Negishi alkenylation with alkenylzirconium reagents 79 with chiral 
bisoxazoline ligands. The desired cross-coupled products 80 were obtained in good yields and high 
enantioselectivity (Scheme 29). This work was the first method for catalytic asymmetric synthesis of 
sulfonamides, whereas asymmetric synthesis of sulfones had been previously reported.147,148  
 
 
Scheme 29: Negishi coupling of sulfonamides 
 
Prior to the work of Fu et al, there had been no reported catalytic methods to obtain enantioenriched 
sulfonamides and few reports for sulfones,147 as controlling the stereochemistry at the carbon - to the sulfur 
is inherently difficult.  
Investigations into the configurational stability of -sulfonyl carbanions were led by Gais et al. in the late 1980s- 
early 1990s.149,150 The crystal structure presented in (Figure 11) shows that lihiosulfone anions prefer a 
staggered confirmation, in which the filled p-orbital at C is gauche to both oxygens.151,152 The stabilisation of 
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the negative charge by inductive effects of the R3 group dictates the conformational stability, which in turn 
controls the asymmetric outcome of potential reactions.149  
 
 
Figure 11: Conformation of lithiosulfone anion 
 
In 1989, Gais et al. found that lithiotrifluoromethyl sulfones (lithiotriflones) are more configuratively stable than 
lithio(phenyl)sulfones i.e. the barrier of racemisation of lithiotriflones is larger than that of 
lithio(phenyl)sulfones.153 Extensive studies have since shown that fluorine substitution has a significant effect 
on the energy of -sulfonyl carbanions. Not only does fluorination strongly affect the acidity of sulfones, since 
trifluoromethylsulfones are approximately 10 pKa units more acidic than phenyl sulfones, it also affects the 
height of the C-S rotational barrier.154 Studies in 1996 showed that when the R3 substituent of the favoured 
staggered conformer (Figure 11) is electron withdrawing F or CF3, the S-CF3 and S-O bonds are lengthened, 
highlighting that the interaction between the anionic lone pair orbital and S-R3 is more effective than the less 
stable eclipsed conformer.154  
These results gave evidence that negative hyperconjugation (nC – *SR) plays an important role in the 
configurational stability of -sulfonyl carbanions.154,155,156 When an electronegative atom (F or CF3) is attached 
to the sulfur that is bound to the anionic carbon, the S-F/CF3 bond becomes strongly polarised. This 
polarisation allows for strong overlap between the non-bonding electron pair of the anionic centre and the anti-
bonding orbital of the S-X bond. Subsequently, this interaction leads to the stabilisation of the anion and partial 
double bond character between the C-S bond, raising the barrier to rotation and therefore racemisation.153,154 
In contrast, when CF3 is replaced with a more electropositive group, such as CH3, the anion is less stable and 
is able to rotate more freely, therefore racemisation is more likely to occur. 
In 2007, Nakamura described the first catalytic and enantioselective reaction with -lithiated 
trifluoromethylsulfone (81) and various aromatic aldehydes to give syn products 82 in excellent 
diastereoselectivity and high enantioselectivity (Scheme 30). Attempts at asymmetric lithiation using benzyl 
sulfones that do not bear the CF3 group  to sulfur were unsuccessful and low ee values were obtained (4 % 
- 32 %), thus confirming previous reports that an electron withdrawing fluorine substituent is essential to 
generate a more configurationally stable anion.147   
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Scheme 30: Enantioselective reaction of -sulfonyl carbanions of trifluoromethylsulfone 
 
The results of these studies highlight the difficulty in controlling the stereoselectivity of the -carbon of sulfonyl 
functional groups. Although success has been achieved with enantioselective -functionalisation of 
trifluoromethylsulfones, this remains a challenging research area, and little has been achieved with sulfones 
that do not bear a CF3 group.  
To date, asymmetric -CH functionalisation of sulfonamides has been achieved using chiral auxiliaries, for 
example Enders work in 2002, previously described in Scheme 23.140 Scheme 31 shows how chiral 
sulfonamides 84 can be synthesised from readily available chiral amine auxiliaries 82. These sulfonamides 84 
can then undergo alkylation via a nucleophilic substitution reaction with strong base, yielding compounds 85 
in high diastereoselectivity. Finally, sulfonamides 85 can undergo racemisation-free cleavage of the auxiliary 
in acidic conditions, to give sulfonamides 86 in excellent enantioselectivity. 
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Scheme 31: Synthesis of -alkyl substituted sulfonamides  
 
Based on previous structural investigations, Enders hypothesised that the lone pair of electrons would be 
orientated gauche to both sulfonyl oxygen atoms, with the sulfonamide group occupying the axial position on 
the dioxane core and the biphenyl group in the equatorial position (Figure 12). Therefore, asymmetric induction 
is achieved by the steric hindrance of the “biphenyl wall”, with the carbanionic centre being accessible from 
the less shielded face.   
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Figure 12 
 
1.8 Project Goals 
 
The main aim of this project was to develop a palladium-catalysed method to enable sp3-sp3 coupling of 
sulfonamides, leading to the formation of novel compounds containing linear and cyclic allylic functionality - 
to the sulfonyl moiety. This Tsuji-Trost type chemistry would intend to use mild reaction conditions that could 
be easily transferrable in drug synthesis. Therefore, a significant objective of the project was to apply the 
developed chemistry to reported drug-like molecules to demonstrate our method as a potentially useful late-
stage functionalisation tool.  
Performing a mechanistic study was essential to understand the behaviour of sulfonamide nucleophiles in the 
Tsuji-Trost reaction, learning whether they behave in a ‘hard’ or ‘soft’ manner. 
Having successfully reached the targets set, further aims for this project would be to move into the asymmetric 
-functionalisation of sulfonamides. Obtaining enantioselectivity - to sulfur is known to be innately difficult, 
therefore to obtain any enantioselectivity would be a success in this area of chemistry. By screening a series 
of chiral ligands, we aimed to access enantioselective compounds with allylic functionality.  
In addition, alongside the palladium-catalysed project, we sought to develop a simple and practical method for 
the -alkylation of various benzylsulfonamides using lithiation conditions. The objective here was to synthesise 
similar novel compounds to those reported with catalytic conditions and present an alternative alkylation 
method, utilising mild reaction conditions. Ultimately, this project could also move into asymmetric synthesis 
by looking into the effect of chiral base (sparteine), as well as the use of chiral electrophiles. 
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CHAPTER 2 RESULTS AND DISCUSSION 
2.1 Palladium-Catalysed Allylation of Sulfonamides 
2.1.1 Investigation 
 
Whilst palladium-catalysed -arylation of alkyl sulfonamides has been widely reported,142,143,144,145 there have 
been few disclosures of sp3-sp3 coupling involving sulfonamides.146 We report herein the first palladium-
catalysed -allylation of sulfonamides which can be applied to simple substrates, as well as medicinally 
relevant drug targets. 
We hypothesised that anions from benzyl sulfonamides would be responsive to palladium-catalysed allylation, 
therefore began with the synthesis of N,N-dimethyl-1-phenylmethanesulfonamide (89) from 
phenylmethanesulfonyl chloride (88) (Scheme 32). 
 
 
Scheme 32: Synthesis of N,N-dimethyl-1-phenylmethanesulfonamide (89) 
 
We commenced our study with the reaction of N,N-dimethyl-1-phenylmethanesulfonamide (89) and allyl 
acetate using palladium-catalysed allylation conditions, based on a report of the C-H allylation of thioamides.49 
Firstly, [Pd(C3H5)Cl]2, dppb ligand and NaOt-Bu were stirred at 25 °C in THF solvent for one hour, after which, 
the sulfonamide 89 and allyl acetate were added to the catalytic mixture and reacted at room temperature for 
20 hours. Since this transformation had not previously been reported in literature, we were encouraged by the 
isolation of the desired sp3 functionalised product 90a, albeit in modest 54 % yield (Scheme 33). 
   
 
Scheme 33: First palladium-catalysed -allylation of sulfonamide 
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In an attempt to optimise the initial conditions, a series of screening reactions were carried out. Firstly, we 
performed a solvent screen, with solvents co-ordinating via nitrogen (MeCN), oxygen (THF, dioxane, EtOAc, 
DME, NMP, DMF) and non-coordinating solvents (CH2Cl2, benzene), with corresponding yields given in (Table 
1).  
 
Table 1: Solvent screen 
 
 
 
 
 
 
 
 
 
The solvent proved to be extremely important in the reaction as it can play a role in the co-ordination to the 
palladium complex. It is evident that polar solvents (THF, dioxane, DMF, NMP and DME) work better in this 
reaction than non-polar solvents (C6H6 and CH2Cl2). Furthermore, DME (entry 9) was the leading solvent of 
those investigated and subsequently used in all future reactions. 
To expand the scope of the reaction, several allylic electrophiles were submitted to the reaction conditions, 
varying the chain length (Table 2). It was clear that further investigation and screening reactions were 
necessary as the yields of the initial acetate screen proved extremely low, with neryl acetate (entry 6) providing 
no conversion to the desired allylated product. 
 
Table 2: Initial acetate screen 
 
Entry Solvent Yield % 
1 THF 54 
2 Dioxane 40 
3 DMF 48 
4 EtOAc 12 
5 NMP 55 
6 MeCN 30 
7 CH2Cl2 27 
8 C6H6 11 
9 DME 79 
48 
 
Entry Acetate Yield, % 
1 
 
79 
2  6 
3 
 
3 
4  5 
5  28 
6 
 
 
0 
 
 
In order to achieve higher yields in the acetate screen, various bases were trialled in the reaction. Since allyl 
acetate was already performing at optimal conditions (NaOtBu, 1 eq), crotyl acetate was used as the 
electrophile of choice (Table 3). Lithium counterion bases (LiHMDS and n-BuLi, entries 5 and 7) do not give 
any conversion to 90b using both 1.2 equivalents and 3 equivalents of each base. Sodium counter ion bases 
NaOtBu ( entry 1) and NaH (entry 9) were the only bases in the screen to give any conversion to allylated 
compound 90b using 1.2 equivalents of base, albeit the yields were very low, 5 % and 10 %, respectively. 
Upon increasing the amount of base in the reaction, the yields also increased, more so for sodium hydride, 
with 70 % being the highest yield obtained using six equivalents of sodium hydride (entry 9).     
 
Table 3: Base screen 
 
Entry Base 1.2 eq yield (%) 3.0 eq yield (%) 6.0 eq yield (%) 
1 NaOtBu 5 10 30 
2 DBU 0 - - 
3 NEt3 0 - - 
5 n-BuLi 0 0 - 
6 NaHMDS 0 - - 
7 LiHMDS 0 0 - 
8 KOtBu 0 0 - 
9 NaH 10 30 70 
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The results of the base screen suggest the deprotonation of the C-H sulfonamide is slow since conversion to 
allylated product is low even when an excess of NaH is used (3 equivalents). Deuteration experiments show 
that both protons are removed when using excess NaH (six equivalents) as both deuterons are incorporated 
in the 1H NMR (Figure 13).  
 
  
Figure 13: 1H NMR data for D2O quench  
 
Although both deuterons are incorporated in the deuteration study, no diallylation of 89 was observed in the 
reaction using excess sodium hydride (6 eq), only unreacted starting material was left. In addition, NaH is not 
soluble in DME, therefore the reaction is heterogeneous. This may also be why more NaH is required for the 
reaction to proceed, as deprotonation is most likely slower. Moreover, the use of excess base could be an 
issue when attempting enantioselective allylation, however we did not see this as a problem in the development 
of a racemic method.  
The yield of 90b was further increased from 70 % at 20 hours, to 86 % after 48 hours, therefore the reaction 
time was adjusted for all future reactions (Table 4).  
 
Table 4: Time screen 
 
Entry Time, h Yield (%) 
1 4 42 
2 20 70 
3 48 86 
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Using the improved reaction conditions, we next turned our attention to the catalyst. Although we were already 
pleased with the performance of allyl palladium (II) chloride dimer catalyst {[PdCl(C3H5)]2}, it was important to 
screen for possible superior alternatives. The palladium catalyst screening was performed using N,N-dimethyl-
1-phenylmethanesulfonamide (89) and more hindered electrophiles [(E)-2-hexenyl (entries 1-6), geranyl 
entries 9 & 10) and prenyl (entries 7 & 8) acetate] (Table 5). 
 
Table 5: Palladium catalyst screen 
 
 
Entry Acetate Pd catalyst  Yield (%) 
1  [PdCl(C3H5)]2 96 
2  PdCl2(MeCN)2 90 
3  Pd(OAc)2 21 
4  Pd2(dba)3 30 
5  Pd(PPh)3 43 
6  No catalyst 0 
7 
 
[PdCl(C3H5)]2 31 
8 
 
PdCl2(MeCN)2 17 
9 
 
[PdCl(C3H5)]2 45 
10 
 
PdCl2(MeCN)2 30 
 
Both [PdCl(C3H5)]2 and PdCl2(MeCN)2 performed well in the reaction with (E)-2-hexenyl acetate (entries 1 and 
2). However [PdCl(C3H5)]2 performed consistently better when comparing entries 1 and 2, 7 and 8, 9 and 10, 
and was therefore selected for all future reactions. Background experiments show that no reaction occurs in 
the absence of palladium (Table 5, entry 6) or phosphine ligand (Table 6, entry 1), suggesting there is no 
competing nucleophilic substitution reaction. 
The final variable we screened was the phosphine ligand. Although dppb ligand had performed well in most of 
the previous screening reactions, it was important to screen alternatives to optimise the yields with bulkier 
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acetates (Table 6) since some examples (prenyl acetate, entry 7, Table 5 and neryl acetate, entry 9, Table 5) 
gave low conversion with dppb.  
We chose to perform the phosphine ligand screen using allyl and prenyl acetate. The reaction without a ligand 
(entry 1) gave no conversion to product, thus the use of a phosphine ligand was necessary for the reaction to 
proceed. Reactions with allyl acetate (entry 1 and 2) performed better with dppb ligand yielding the allylated 
product in 79 % and 60 % respectively, whereas the reaction with prenyl acetate performed better with dppe 
ligand, yielding the prenylated product in 62 % (entry 5).  
 
Table 6: Phosphine ligand screen 
 
Entry Electrophile  Phosphine Ligand 
(11 mol %) 
Yield (%) 
1 
 
None 0 
2 
 
dppb 82 
3 
 
dppe 60 
4 
 
dppb 31 
5 
 
dppe 62 
6 
 
dppf 30 
7 
 
Xantphos 0 
8 
 
PPh3 0 
9 
 
(rac)-BINAP 15 
10 
 
DavePhos 0 
 
 
It was clear that the relationship between the catalyst, ligand and electrophile was extremely important in 
relation to the conversion to -functionalised product. We were pleased with the performance of dppb ligand 
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throughout the screening reactions, therefore we chose this as our regular ligand going forward. However, if 
low conversion did occur in the substrate scope, we knew we could potentially optimise the yield by varying 
the ligand. 
After an extensive base, catalyst, solvent and ligand screen, we alighted to the use of [PdCl(C3H5)]2, dppb, 
NaH in DME solvent at 25 °C as our standard set of reaction conditions.  
The Tsuji-Trost reaction can be applied to a number of electrophiles including; acetates, alcohols, amines and 
carbamates. Therefore, we applied our chemistry to a series of allylic electrophiles (Table 7). The reaction with 
allyl alcohol and allyl amine were unsuccessful and no conversion to the desired allylated sulfonamide 90a 
was observed. Although allyl carbonate gave the allylated product in 54 % yield, allyl acetate gave a much 
higher yield (82 %), establishing the superiority of the acetate leaving group over carbonate, amine and alcohol. 
 
Table 7: Electrophile screen 
 
Entry Electrophile Yield (%) 
1 
 
82 
2 
 
0 
3 
 
0 
4 
 
54 
 
 
2.1.2 Substrate Scope 
 
Having established a set of standard reaction conditions through a series of optimisation reactions, we first 
screened a range of allylic acetates with sulfonamide 89. Successful application of the optimised procedure 
led to the formation of 11 novel sulfonamides 90a-k in good to excellent yields (Table 8).  
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Table 8: Acetate screen 
 
Entry Acetate Product Yield, % 
1  
 
90a 
82 
2  
 
90b 
86 
(E:Z = 67:33) 
3 
 
  
90c 
98 
(E:Z = 100:0) 
4 
  
90d 
74a 
5  
 
90e 
79b 
(E:Z = 100:0) 
6 
  
90f 
68a 
7 
 
 
90g 
74 
(d.r = 59:41) 
8 
 
 
90h 
79 
(d.r = 50:50) 
54 
 
9 
 
 
90i 
82 
10 
 
 
 
90j 
84a 
11 
  
90k 
87 
(d.r 80:20) 
12 
  
90b 
90 
13 
 
 
90e 
57b 
14 
 
 
90d 
58 
a dppe ligand, 5.0 eq acetate, b dppf ligand, 5.0 eq acetate 
d.r and E:Z ratio determined by 1H NMR 
 
The scope of the reaction demonstrates the use of simple allylic acetates, cyclic electrophiles, as well as bulky 
acetates with multiple alkene functionality. Experiments listed in entries 4, 6 and 10 (Table 8) were performed 
with dppe as the ligand and excess acetate (5 eq), whereas the experiments presented in entries 5 and 13 
were performed using dppf as the ligand and excess acetate (5 eq), as higher yields were obtained than when 
using dppb. 
Entries 12, 13 and 14 (Table 8) give interesting mechanistic insights into the reaction, especially about the -
allyl complex that is formed. In these examples, linear compounds 90b, 90e and 90d are formed preferentially 
to the branched compounds. This indicates the sulfonamide nucleophile attacks at the least sterically hindered 
position of the -allyl intermediate (Figure 14). 
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Figure 14: -allyl intermediates leading to linear compounds 
 
2.1.3 Diallylation 
 
All compounds described thus far are examples of monoallylated sulfonamides. However, the reaction 
conditions may be modified to obtain diallylation of 89 to yield compound 91 (Table 9). Increasing the amount 
of allyl acetate to two equivalents allowed isolation of diallyl compound 91 in moderate 36 % yield (entry 1). 
Further optimisation were achieved by increasing the amount of base (8 eq) and allyl acetate (5 eq) affording 
91 in 96 % yield (entry 3). 
 
Table 9: Diallylation of compound 64 
 
Entry Base (eq) Allyl acetate (eq) Yield % 
1 6 2 36 
2 6 5 70 
3 8 5 96 
 
 
Ring closing metathesis can be performed using Grubbs 2nd generation catalyst to obtain the previously 
unreported cyclic sulfonamide 92 in a 93 % yield. This reaction is synthetically useful as a cyclic alkene is 
installed, which could be further functionalised to populate unexplored chemical space. 
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Scheme 34: Ring closing metathesis  
 
2.1.4 Amine Substituent 
 
With a novel method in hand, we next looked to extend the scope of the reaction by varying the amine subunit. 
Sulfonamides 93-98 were synthesised from phenylmethanesulfonyl chloride (88) and their respective free 
amines in generally good yields (Table 10). 
 
Table 10: Sulfonamide precursors 
 
Entry Amine Product Yield % 
1 
 
 
93 
45 
2 
 
 
94 
91 
3 
 
 
95 
57 
4 
 
 
96 
81 
57 
 
5 
 
 
97 
61 
6 
  
98 
77 
 
 
Subsequently, the reaction with these sulfonamides and various allylic acetates using the standard palladium-
catalysed conditions, generated a range of novel allylated compounds (99a-l, Table 11) in moderate to 
excellent yields. Reactions of the piperazine, morpholine, piperidine, tetrahydropyridine and pyrrolidine 
sulfonamides with allyl acetate (entries 1, 6, 9, 10 & 11) all proceeded in generally good yields (52-82 %). 
Reactions of Boc-piperazine sulfonamides with more hindered acetates [crotyl (entry 2), hexenyl (entry 3), 
neryl (entry 4), and prenyl (entry 5)] were poorer than the reaction with the less hindered allyl acetate (entry 
1). Interestingly, methyl hydroxylamine sulfonamide 98 (entry 12) gave diallylated sulfonamide 99l exclusively 
using the standard reaction conditions. 
 
Table 11: Sulfonamide amine screen 
 
 
Entry Starting Material Product Yield % 
1 93 
 
99a 
71* 
2 93 
 
99b 
59* 
3 93 
 
99c 
52* 
58 
 
4 93 
 
99d 
52* 
5 93 
 
99e 
52* 
6 94 
 
99f 
52 
7 94 
 
99g 
79 
8 94 
 
99h 
45 
9 95 
 
99i 
77 
10 96 
 
99j 
82 
11 97 
 
99k 
61 
12 98 
 
99l 
 
35 
59 
 
* (entries 1-5) compounds synthesised by O. Abdulla using the methodology established in this work 
 
In order to access the mono-allylated compound of N-methoxy sulfonamide 98, we investigated the amount of 
base that was necessary for this reaction to occur, since all other examples prior to this required six equivalents 
of sodium hydride (Table 12). We found that three equivalents of sodium hydride gave a mixture of di- and 
mono-allylated sulfonamide, whereas only one equivalent of sodium hydride (entry 3) gave monoallylated 
product 100a in a 76 % yield. Similarly, mono allylation occurred with milder base NaOtBu in 75 % yield (entry 
4). This result interested us as we believed the methyl hydroxylamine group could potentially be acting as a 
directing group. Several possible explanations could support the fact that monoallylated sulfonamide 100a is 
more reactive; perhaps the alpha proton of monoallylated 100a is more labile (due to Na+ binding with OMe 
group) than the alpha proton of compounds 99a-k, therefore enabling disubstitution. Alternatively, binding of 
Na+ with OMe group may be less sterically hindered than Na+ bound to groups of sulfonamides 99a-k, which 
could favour disubstitution. 
 
Table 12: Base screen  
 
Entry Base (eq) 100a isolated yield % 99l isolated yield % 
1 NaH (6)  0 35 
2 NaH (3)  20 15 
3 NaH (1) 76 0 
4 NaOtBu (1) 75 0 
 
 
Since NaOtBu is a milder and easier to handle base, we decided to investigate this further to see if the reaction 
could proceed with alternative acetates (Table 13). With a new set of mild reaction conditions in hand, we were 
pleased to see that methyl hydroxylamine sulfonamide 98 could be functionalised with linear chained acetates 
(entries 1, 2, 3 and 6), bulky acetates (entry 4 and 6), as well as cyclic acetate (entry 5). 
In contrast to previous reaction conditions, we changed the ligand to (rac)-BINAP, as allylated compounds 
were generally obtained in much higher yields than when dppb was used as the ligand, thus demonstrating 
the importance of the behaviour of ligand within the reaction.  
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Table 13: Acetate screen with revised milder conditions
 
Entry Product  Yield with BINAP, % Yield with dppb, % 
1 
 
100a 
75 
 
 
75 
2 
 
100b 
71 
(E:Z = 79:21) 
45 
 
3 
 
100c 
85 
(E:Z = 100:0) 
75 
 
4 
 
100d 
56 0 
5 
 
100e 
30 
(d.r = 64:36) 
14 
6 
 
100f 
67 30 
7 
 
100g 
60 
(E:Z = 100:0) 
0 
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We hoped these milder reaction conditions would prove useful when used for the enantioselective synthesis 
of allylsulfonamides (Section 2.3). 
Following the screen of the amine substituent, we set out to use secondary sulfonamides, wondering if we 
could achieve allylation on both the N-H and at the C of the sulfonamide sequentially. N-allylation of 
sulfonamides has been previously reported,65 therefore using the developed palladium-catalysed reaction 
conditions, we would expect a free N-H to be allylated, as well as at the -carbon.   
N-Methyl-1-phenylmethanesulfonamide (101) was synthesised from phenylmethanesulfonyl chloride (88) and 
methylamine (Scheme 35). 
 
 
Scheme 35: Synthesis of N-Methyl-1-phenylmethanesulfonamide  
 
Under the standard palladium-catalysed conditions, and using two equivalents of allyl acetate, diallylation of 
101 was successful, yielding the desired product 102 in 93 % yield (Scheme 36). 
 
 
Scheme 36: Diallylation of sulfonamides 
 
Ring closing metathesis of 102 using Grubbs 2nd generation catalyst leads to the formation of the previously 
unreported seven-membered sultam 103 in an unoptimised 55 % yield (Scheme 37). Sultam 103 is a 
potentially interesting compound which could allow for further derivatisation to access diverse analogues of 
seven-membered functionalised sulfonamides. 
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Scheme 37: Ring closing metathesis accessing 7-membered sultam 
 
2.1.5 Medicinal Chemistry Targets 
 
Late-stage functionalisation of drug molecules is extremely desirable for medicinal chemists to develop 
structural complexity by creating new analogues of lead-like compounds. We envisaged applying our 
developed methodology to specific drug-like molecules to demonstrate our reaction as a useful late-stage 
functionalisation tool.  
Recent studies by Sadeghzadeh and co-workers121 have shown a series of arylalkylsulfonylpiperazine based 
derivatives as potential sigma receptor ligands, a sub-type of opioid receptor (Figure 15). Since one of the 
main aims of our work was to apply our reaction to known medicinal chemistry targets, it seemed reasonable 
to do so with these relatively easy to synthesis sulfonamides 64a-f.  
 
 
Figure 15: Medicinally relevant drug-like molecules 
 
Sulfonamides 64a-f were prepared in good yields using literature methods, by reacting phenylmethanesulfonyl 
chloride (88) with various benzyl piperazines (Table 14).121 
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Table 14: Synthesis of drug-like molecules 64a-f 
 
Entry Product Yield (%) 
1 
 
64a 
77 
2 
 
64b 
90 
3 
 
64c 
75 
4 
 
64d 
57 
5 
 
64e 
87* 
6 
 
64f 
90* 
*Entry 5 and 6 synthesised by O. Abdulla using the methodology established in this work 
 
Using our standard palladium catalysed conditions, sulfonamides 64a-f were subjected to the allylation 
reaction using various allylic acetates affording novel compounds 104a-h (Table 15).  
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Table 15: Allylation reaction screen using drug-like molecules 
 
Entry Sulfonamide Product Yield % 
1 
 
64a 
 
104a 
76 
2 
 
64a 
 
104b 
58 
3 
 
64b 
 
104c 
67 
4 
 
 
64f 
 
104d & 104e 
62* 
(60:40) 
5 
 
64e 
 
104f 
63* 
6 
 
64d 
 
104g 
53 
65 
 
7 
64c 
 
104h 
37 
**Entries 4 and 5 synthesised by O. Abdulla using methodology established in this work 
 
We were gratified to observe allylation of compounds 104a-h proceeded smoothly in generally good yields. A 
variety of allylic acetates; allyl (entry 1, 3, 6 & 7), cinnamyl (entry 4), crotyl (entry 5) and hexenyl (entry 2) 
acetate were reacted with benzylpiperazine sulfonamides 64a-f to demonstrate the scope of the reaction. 
Surprisingly, the substitution pattern on the phenyl ring of the benzyl moiety had quite a high impact on the 
reactions with yields ranging from 37 % (entry 7) with p-methoxybenzyl piperazinesulfonamide (64c), to 76 % 
(entry 1) with benzyl piperazinesulfonamide (64a) for which allyl acetate was used. Interestingly, when using 
cinnamyl acetate (entry 4), both branched and linear compounds 104d and 104e were isolated, the first 
example of branched functionality of our 35 examples. We were also pleased to observe no side reaction with 
bromo-substituted 104f as the bromobenzene moiety was left untouched, which provides interesting 
orthogonal reactivity and allows for possible further derivatisation. 
 
2.1.6 Conclusion 
 
We have demonstrated the first palladium-catalysed -allylation of a series of benzyl sulfonamides, generating 
a library of novel compounds. After a series of optimisation reactions, we were able to access functionalised 
sulfonamides, by varying both allylic chain length and amine substituent on the sulfonamide. Generally, 
allylated compounds were obtained in high yields, however we have demonstrated that higher yields for more 
difficult substrates can be obtained by changing the ligand. Furthermore, we have applied our chemistry to a 
range of drug-like molecules, highlighting our method as a potentially useful late-stage functionalisation tool.    
 
2.2 Mechanistic Study 
2.2.1 Investigation 
 
The mechanism of the Tsuji-Trost reaction has been studied in great detail, using a variety of approaches.90 
As previously discussed, the Tsuji-Trost reaction can proceed via one of two mechanistic pathways depending 
on the hardness of the pronucleophile (Scheme 38). Once the leaving group is displaced and the palladium -
allyl intermediate is formed (step c), soft pronucleophiles can attack the chain of the -allyl intermediate (step 
d) to form a product with a net retention of stereochemistry (step f). Whereas hard pronucleophiles can co-
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ordinate to the palladium (step e) and via reductive elimination form a product with a net inversion of 
stereochemistry (step h).    
 
 
Scheme 38: Catalytic cycle of Tsuji-Trost reaction 
 
To establish the route of our mechanism, it was important to perform a study to confirm the hardness of 
benzylsulfonamide nucleophiles since the pKa of our nucleophile was not precisely known. Based on literature 
precedent of compound 105157 (Figure 28), we hypothesised that sulfonamide 89 has an estimated pKa of 
approximately 24/25; therefore, based on the hard/soft nucleophile theory, our dimethylsulfonamide 89 should 
be on the border of behaving as either a hard or soft nucleophile. To understand the mechanistic pathway, we 
sought to confirm the hardness of our dimethylsulfonamide 89 by performing a mechanistic study. 
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Figure 16: pKa of sulfonamide -proton 
 
The first mechanistic study, pioneered by Trost in 1980, uses isomers of 3-acetoxy-5-carbomethoxy-1-
cyclohexene (7a &7b) as an electrophilic stereoprobe.158 This study confirmed malonates as soft nucleophiles 
since the reaction of cis-acetate 7a and malonate nucleophile 8, under palladium-catalysed allylation 
conditions, gives cis-compound 9a (with a retention of configuration) in 92 % yield. Similarly, the reaction with 
trans-acetate 7b and malonate nucleophile 8 gives the trans-product 9b (also with a net retention of 
configuration) in 90 % yield.  (Scheme 39).39  
 
 
Scheme 39: Mechanistic study using isomers of 3-acetoxy-5-carbomethoxy-1-cyclohexene 
 
Trost reported 1H NMR data for cis-compound 9a, highlighting the essential coupling constants of JAD, JBD, JCD 
= 12 Hz, indicating both Ha and Hb are pseudo-axial, therefore the reaction occurs with complete retention of 
configuration with regards to the carbon undergoing nucleophilic substitution. The important coupling constants 
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for the trans-product 9b are also highlighted: Jac = 5.5 Hz Jcd = 13.5 Hz Jbc = 9.5 Hz Jbd = 4 Hz Jad = 4 Hz, 
indicating Ha is pseudo-equatorial, whereas Hb is pseudo-axial.  
Since this discovery, cis-stereoprobe 7a has been the most common substrate used in mechanistic studies of 
allylation reactions. Following the synthesis reported in 1976, (Z)-3-acetoxy-5-carbomethoxy-1-cyclohexene 
(7a) was prepared in five steps from 3-cyclohexene-1-carboxylic acid (106) (Scheme 40).158 Iodolactonisation 
of 111, followed by elimination of iodide 107 with DBU gave the unsaturated lactone 5 in 86 % yield over two 
steps. Methanolysis of 5 with sodium methoxide in methanol converted 100 % to 6 as the sole isomer. The 
crude alcohol 6 was used without further purification in the acylation step to afford 3-acetoxy-5-carbomethoxy-
1-cyclohexene 7a:7b as an inseparable mixture of cis-7a: trans-7b (98:2) by 1H NMR.  
 
 
 
Scheme 40: Preparation of cis-3-acetoxy-5-carbomethoxy-1-cyclohexene 7a 
 
With our stereoprobe 7a in hand, the palladium-catalysed -allylation of N,N-dimethy-1-phenylsulfonamide 
(89) was carried out using the standard conditions (Scheme 41). However, no conversion to the desired cross-
coupled product 108 was observed, and all starting materials were recovered.  
 
 
Scheme 41: Mechanistic study using cis-3-acetoxy-5-carbomethoxy-1-cyclohexene 
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We rationalised this by assuming that the use of excess base in the reaction was deprotonating - to the 
methylester of stereoprobe 7a, preventing the reaction from proceeding. Although the Trost electrophile 7a is 
the most commonly applied to this type of study, other stereoprobes have been used, an example of which 
(compound 53b) is shown in Figure 17. 
 
 
Figure 17: Alternative stereoprobe used in mechanistic studies 
 
Therefore, to avoid competing deprotonation, we sought to synthesise an alternative stereoprobe. Starting 
from racemic cis-lactone 5, alcohol 109 was made following a known procedure. 159 Subsequent acylation of 
110 provided cis-5-([{tert-butyldimethylsilyl}oxy]methyl)cyclohex-2-en-1-yl acetate (111) as a new 
stereodefined acetate for our mechanistic study (Scheme 42).  
 
 
Scheme 42: Preparation of cis-5-([{tert-butyldimethylsilyl}oxy]methyl)cyclohex-2-en-1-yl acetate  
 
 
To our knowledge, acetate 111 had never been used in a mechanistic study of the Tsuji-Trost reaction, 
therefore to test its suitability as a stereoprobe we first sought to repeat Trost’s initial mechanistic study, 
substituting the methyl ester stereoprobe 7a for our cis-acetate 116. Gratifyingly, allylation of malonate 8 with 
111 yielded cis-compound 112 as a single diastereomer in 56 % yield (Scheme 43). 1H NMR data for 
compound 112 is similar to that of compound 9a, the essential coupling JAD = 12 Hz JCD = 12 Hz is present, 
indicating stereoprobe 111 behaves in the same way as 7a.  
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Scheme 43: Mechanistic study with new stereoprobe and dimethylmalonate 
 
With our newly developed cis-acetate 111, we then proceeded with the mechanistic study, reacting with 
sulfonamide 89 under the standard allylation conditions. We were pleased to see the reaction proceeded 
smoothly, obtaining the desired product 113 in 85 % yield as a mixture of two diastereomers in a 75:25 ratio 
based on 1H NMR spectroscopy (Scheme 44).    
 
 
Scheme 44: Mechanistic study to determine hardness of sulfonamide nucleophile 
 
Sulfonamide 113 has three asymmetric centres, therefore there are eight possible stereochemical structural 
outcomes (4 diastereomers and their enantiomers) according to the 2n rule (Figure 18). Structures 113a and 
113b present the stereochemical outcomes if the sulfonamide pronucleophile is soft, as the protons at C1’ and 
C5’ are on the same face. Whereas, structures 113c and 113d represent if the sulfonamide pronucleophile as 
hard, since protons at C1’ and C5’ are on the opposite face.  
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Figure 18: Stereoisomers of compound 117 
 
To understand the stereochemical outcome, a sample of crude sulfonamide 113 was analysed by chiral HPLC, 
indicating a presence of two diastereomers and their enantiomers (113a & 113b or 113c & 113d, Figure 19). 
We know from experiments (that will be discussed in Section 2.23) that the hydrogen at C1 is epimerised under 
the excess basic conditions. In addition, the stereochemistry at C5’ is fixed from the cis-acetate starting 
material, therefore it is reasonable to assume the allylation reaction is diastereoselective at C1’ position. This 
reasoning implies that the sulfonamide nucleophile attacks either at the carbon of the -allyl intermediate or at 
palladium, and not a mixture of the two. Therefore, based on the HPLC data (Figure 19), the four possible 
isomers are either structures 113a-b or 113c-d of Figure 18.    
 
 
Figure 19: Chiral HPLC trace for compound 117 
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The two diastereomers of 113 were separated via column chromatography and analysed by 1D and 2D NMR. 
Pseudo-chair structures shown in (Figure 20) highlight the essential protons by which the structure was 
elucidated. 1H NMR for major diastereomer of compound 113 showed a peak at 1.02 ppm, app dt, J 11.6 Hz 
and 12.6 Hz, indicating a diaxial relationship between proton H6’axial and H1’, similar to the coupling of the Trost 
example shown in Scheme 39.  
 
 
Figure 20 
 
nOesy data shows a clear interaction between proton H1 and H5 (Figure 21), therefore at this stage we were 
confident that proton H1 and H5 are pseudo-axial.  
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Figure 21: nOesy data for major diastereomer (117) 
 
Similarly, 1H NMR data for the minor diastereomer of 113 revealed a peak at 0.75 (app q, J 12.1 Hz), also 
indicative of a 1,3-diaxial relationship between H1’ and H6. 
Therefore, based on the evidence obtained by the NMR data, it was reasonable to assume the sulfonamide 
behaved as a soft pronucleophile (structures 113a & 113b) however we sought to confirm the structure of the 
major diastereomer by obtaining X-ray crystal data.  
Both the isolated major and minor diastereomer of compound 113 (113a &113b) were oily and crystallisation 
attempts of both proved unsuccessful, therefore an alternative approach was investigated. Deprotection of 
TBDMS group of the major diastereomer of 113 with TBAF gave alcohol 114 as a crude mixture (Scheme 45).  
 
74 
 
 
Scheme 45: Deprotection of TBDMS group 
 
Following this, crude alcohol 114 was coupled with bulky p-bromobenzoyl chloride (115) to yield 116 (single 
diastereomer) as an orange crystalline solid (Scheme 46).  
 
 
Scheme 46: Synthesis of compound 116 
 
Crystallisation of 116 (single diastereomer) from ethanol allowed a crystal structure to be obtained by single 
crystal X-ray crystallography (Figure 22). Coupled with the evidence from NMR data, the crystal structure 
shows that the protons at C1’ and C5’ are on the same face of the molecule, therefore the stereochemistry is 
retained. 
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Figure 22: Crystal structure of compound 116 
 
This retention of stereochemistry indicates benzylsulfonamides behave as soft carbon nucleophiles in the 
palladium-catalysed allylation reaction. Therefore, of the eight structures presented in Figure 18, 113a & 113b 
are the isomers indicative of a soft nucleophile. The major isomer isolated in the mechanistic study is 113a 
and its enantiomer. In addition, the minor isomer isolated (confirmed by NMR but not by crystal data) is 
structure 113b and its enantiomer (Figure 23).  
 
 
Figure 23: Structures from mechanistic study 
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2.2.2 Conclusion 
 
This study has shown that the anion of N,N-dimethy-1-phenylsulfonamide (89) behaves as a soft nucleophile 
when subjected to palladium-catalysed allylation reaction conditions. Structural evidence shows a net retention 
of stereochemistry, confirmed by extensive data analysis (NMR, HPLC and X-Ray Crystallography), thus 
indicating the anion of 89 attacks -allyl intermediate, with no co-ordination to the palladium.  
Although initial attempts using the common stereoprobe (cis)-3-acetoxy-5-carbomethoxy-1-cyclohexene (7a) 
failed, we were able to synthesise an alternative cis-stereoprobe, (cis)-5-([{tert-
butyldimethylsilyl}oxy]methyl)cyclohex-2-en-1-yl acetate (111), which proceeded smoothly as an electrophile 
in our reaction conditions. Prior to this, the novel stereoprobe 111 was subjected to Trosts initial mechanistic 
study reaction conditions using dimethylmalonate (8), to validate its suitability as a stereoprobe.  
 
2.3 Attempts at Enantioselective Synthesis 
2.3.1 Investigation of Chiral Ligands 
 
The natural progression of the project would be to develop an asymmetric version of the previous method, 
since the work thus far has delivered only racemic compounds. Although we knew enantioselective sp3-sp3 
coupling of sulfonamides would prove challenging, due to the difficulties of asymmetric -functionalisation of 
SO2 bonds, we sought to develop an asymmetric catalytic method for the -functionalisation of sulfonamides. 
Initial attempts at asymmetric reactions using the standard reaction conditions failed to induce any 
enantiomeric excesses, therefore we looked at the use of excess sodium hydride. It was highly likely that the 
excess base could cause racemisation at the C1 position. Therefore to confirm this, the enantiomers of 90a 
were separated by analytical chiral HPLC, obtaining ~5 mg of each enantiomer (Figure 24). Although the 
absolute stereochemistry of the proton at C1 is yet to be determined, the stereochemistry has been shown for 
clarity.  
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Figure 24: Chiral HPLC traces of both enantiomers of compound 89b 
Data obtained using OD-3 column (95:5 Hexane:IPA) 
 
Having separated the enantiomers of 90a, a single enantiomer of this compound (first peak) was resubmitted 
to the palladium-catalysed standard reaction conditions (Figure 25). The reaction mixture was analysed by 
chiral HPLC, where two peaks (indicative of a racemic mixture) were attained (Figure 25). This confirms that 
under the standard reaction conditions, the stereocentre at C1 is epimerised. Additionally, the single 
enantiomer was also stirred in DME solvent with six equivalents of NaH for one hour, in the absence of 
palladium and dppb ligand, to also give a racemic mixture. 
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Figure 25: Racemic mixture of compound NUM 89b 
 
It was clear that to prevent epimerisation at C1, less base had to be used. Since sulfonamide 89 required 
excess base in all reaction cases previously discussed, we turned to the methyl hydroxylamine sulfonamide 
98 that was shown to undergo allylation in 75 % yield using one equivalent of NaOtBu (Scheme 47).  
 
 
Scheme 47: Synthesis of compound 106a using NaOt-Bu 
 
We began investigating an enantioselective reaction by first substituting dppb for a variety of chiral ligands. 
The most common chiral ligands used in AAA reactions are the C2 symmetric Trost ligands, pioneered by Trost 
in the early 1990’s.43,44 Therefore, it seemed reasonable to begin the chiral ligand screening process using 
various Trost ligands (Table 16). Trost DACH-pyridyl ligand L15 (entry 1) gave compound 100a in 35 % yield, 
however the product was racemic. Whereas, ligands Trost DACH-naphthyl L14 (entry 2) and DACH-phenyl 
L2 (entry 3) gave no conversion to product and all the starting material was recovered.  
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Table 16: Chiral ligand screen with C2 symmetric Trost ligands 
 
 
Entry Chiral Ligand Yield % ee  
1 
 
L15 
 
35 
 
0 
2 
 
L16 
 
0 
 
- 
3 
 
L2 
 
0 
 
- 
 
 
We next turned our attention to the C1 symmetric PHOX ligands, (entry 1 and 2, Table 17), as well as bisoxaline 
C2 symmetric ligands (entries 3 and 4, Table 17). Only PHOX ligand L22a (entry 1) gave the desired allylated 
sulfonamide, in 65 % yield, however product 100a was racemic. Unfortunately, the reactions with PHOX ligand 
L24 (entry 2) and bisoxazolines L17a & L16a (entry 3 and 4) were unsuccessful and only starting materials 
were recovered.  
  
Table 17: Chiral ligand screen with C1 symmetric ligands 
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Entry Chiral Ligand Yield % ee % 
1 
 
L22a 
 
65 
 
0 
2 
 
L24 
 
0 
 
- 
3 
 
L17a 
 
0 
 
- 
4 
 
L16a 
0 - 
 
 
Since little success (in terms of conversion to product) had been obtained with the ligands screened thus far, 
we began looking closer into the properties of chiral ligands, in order to narrow down the examples that may 
provide conversion to product, potentially in non-racemic fashion.  
The electronic and steric properties of phosphine ligands have been found to have an influence on the reactivity 
of organometallic complexes.160 The concept of cone angle is widely accepted as a systematic approach to 
determine steric and electronic ligand effects.161 However, more recently, the introduction of ‘bite angle’ (P-M-
P angle) has been developed as a useful paradigm to predict chelation preferences of bidentate ligands. Bite 
angle can be defined as the preferred chelation angle determined by the ligand backbone (Figure 26).98,162,163  
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Figure 26: Bite angle 
 
Therefore, bearing the concept of bite angle in mind, we hypothesised that ligands with a similar bite angle to 
dppb, dppe and dppf would most likely lead to conversion to desired product, as these achiral ligands were 
successful in our previous allylation reactions. According to data from literature and the Cambridge 
Crystallographic Database, dppb and dppf have similar preferred bite angles, whereas dppe has a lower bite 
angle of 85° (Figure 27).98  
 
 
Figure 27: Ligand preferred bite angles of bidentate ligands98 
 
Chiral ligands BINAP L19, DIOP L13 and Josiphos L25 seemed the most appropriate ligands in terms of 
similarity of P-M-P angle and structure related to the three achiral ligands dppe, dppb and dppf. Therefore, we 
next carried out the palladium-catalysed allylation of methyl hydroxylamine sulfonamide 98 with allyl acetate 
and the chiral ligands chosen based on bite angles. We were gratified to see that in all cases, conversion of 
allylated sulfonamide was observed, in good yields with respect to (R)- and (S)-BINAP L19a & L19b (entry 1 
and 2, Table 18), and Josiphos L25 (entry 3, Table 18), as well as a modest yield for the example with (–)-
DIOP ligand L13 (entry 4, Table 18).  We were also pleased to see that (R) and (S)-BINAP (L19a & L19b) not 
only gave high yielding product, but also provided some enantioselectivity, albeit very low values (4 % ee).  
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Table 18: Chiral ligand screen 
 
Entry Chiral Ligand Yield % ee % 
1 
 
L19a 
 
75 
 
4 
2 
 
L19b 
 
72 
 
4 
3 
 
L25 
 
72 
 
0 
4 
 
L13 
26 0 
 
 
Next, we screened various BINAP type ligands in order to expand the ligand scope and attempt to improve the 
low ee’s (Table 19). Monophosphorous ligands L21a-d (entries 1-4) were not successful in the reaction, with 
no conversion to the desired product. Whereas, allylation with BINAP derivative ligands L19c-h (entries 5-10, 
Table 19) all gave conversion to the desired allylated product in varied yields (16 – 92 %). (R)-Segphos L19f 
(entry 8, Table 19) gave low conversion to product, however gave the highest enantioselectivity so far obtained 
8 % ee.  This result was encouraging as no such asymmetric catalytic C-H functionalisation of a sulfonamide 
has ever been reported. 
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Table 19: BINAP and monophosphorous ligand screen 
 
Entry Chiral Ligand Yield % ee % 
1 
 
L21a 
0 - 
2 
 
L21b 
0 - 
3 
 
L21c 
0 - 
4 
 
L21d 
0 - 
5 
 
 
L19c 
16 0 
84 
 
6 
 
 
L19d 
30 0 
7 
 
 
L19e 
66 0 
8 
 
 
 
L19f 
21 8 
9 
 
 
L19g 
92 0 
10 
 
 
L19h 
15 0 
 
 
It is not unusual to encounter some difficulty when moving into asymmetric synthesis. As discussed earlier, 
Walsh et al reported the enantioselective C-H allylation of toluene based nucleophiles (Scheme 20).89 This 
reaction required a screen of over 140 enantioenriched mono- and bidentate phosphine ligands, with only the 
Ph-Taniaphos L12 ligand giving substantial turnover and enantioselectivity, demonstrating the difficulties of 
enantioselective synthesis of challenging substrates. 
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2.3.2 Conclusion 
 
Having screened 21 chiral ligands in various asymmetric synthesis attempts, few examples were successful 
in terms of yielding the desired allylated product, whilst even fewer were successful in obtaining any 
enantioselectivity. Our correlation between the bite angle and conversion to product was a successful strategy, 
as ligands with similar bite angles to dppb and dppf (bite angle of less than 100 °) generally BINAP type ligands, 
provided allylsulfonamides in high yields. Despite obtaining allylsulfonamides in high yields with a series of 
chiral ligands, we struggled to obtain any enantioselectivity. (R)-Segphos L19f (Table 19, entry 8) gave 8 % 
ee as the highest enantiomeric excess, which remains extremely low. However, we were very pleased with 
this initial result as this transformation has never been reported enantioselectively.  
This part of the project requires further investigation as only a small number of chiral ligands have been 
screened thus far. Several experiments could be carried out to give more understanding of the reaction and 
formation of anion. It could be possible that NaOt-Bu also racemises the hydrogen at C1 of methyl 
hydroxylamine sulfonamide 100, as this would give evidence that the base may racemise the -protons at C1. 
Alternatively, investigation into the order of addition of reactants may be pivotal in obtaining enantioselective 
compounds. An experiment to pre-form the sulfonamide anion 100, and then react with the palladium, chiral 
ligand and acetate, could avoid the issue with racemisation when using base, as all the base should be 
consumed in forming the anion.  
 
2.4 Alternative Methods for -alkylation of Sulfonamides 
2.4.1 Investigation 
 
Although our fundamental interest was to develop a catalytic method, we believed we could also provide an 
alternative method to obtain similar compounds of interest. Typically, methods for direct alkylation of 
sulfonamides require strong bases, reactive electrophiles, low temperatures and use of polar additives such 
as TMEDA, HMPA and phenanthroline.139,140 Therefore, the focus of the work shifted to the development of a 
mild, simple, yet robust method for the nucleophilic substitution of both allyl and alkyl electrophiles with benzyl 
sulfonamides. 
We chose to carry out our initial study using N,N-dimethyl-1-phenylmethanesulfonamide (89) and crotyl 
bromide by varying reaction conditions, including: base, solvent and temperature (Table 20).  
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Table 20: Initial optimisation of nucleophilic substitution reaction 
 
Entry Temperature 
(°C) 
Solvent Base (eq) Electrophile 
eq 
Isolated Yield 
(%) 
1 –20 THF LDA (1.1) 2.1 51 
2 0 THF LDA (1.1) 2.1 39 
3 –20 DME LDA (1.1) 2.1 32 
4 –20 THF LDA (2.2) 2.1 57a 
5 –20 THF LDA (2.2) 1.0 86 
6 –20 THF NaH (1.1) 1.0 0 
a 14 % of diallylated product 
 
One would predict that the anion of sulfonamide 89 is fully deprotonated when one equivalent of LDA (pKa ~ 
35) is used,  since the pKa of our sulfonamide anion is predicted to be around 25 based on literature values of 
a similar benzylsulfonamide compound 105 (Figure 28). However, the conversion to allylated product is low 
when only one equivalent of LDA is used (between 32 % and 51 % depending on solvent, entries 1 – 3, Table 
20). The yield of product is much higher (86 %, entry 5) when 2.2 equivalents of LDA is used in THF at –20 
°C. The requirement of excess base for this reaction could be related to the absence of additives in this 
reaction. Lithium bases are known to form aggregates, therefore additives are generally used to breakdown 
the unreacted aggregates.164,165 Although we know that NaH deprotonates sulfonamide 89, as shown in 
previous palladium-catalysed -allylation reaction, the sodium counterion base (entry 6) did not give any 
conversion to allylated product and all starting material sulfonamide 89 was recovered.  
 
 
Figure 28: pKa of benzylsulfonamides 90 
 
Since we did not want to use any additives in this reaction, we chose to use the optimised conditions (entry 5, 
Table 20). The excess of base did not appear to cause issues with over alkylation, therefore we were happy 
87 
 
to proceed with a series of experiments using N,N-dimethyl-1-phenylmethanesulfonamide (89) with various 
allylic bromides to demonstrate the scope (Table 21). 
Compounds 90a-h, 117, 118 and 119 were obtained in generally good yields, allowing to install linear (entries 
1-5), branched (entry 6) or cyclic allyl groups (entry 7). When using dibromide electrophiles (entries 8 and 10), 
the reaction is selective to eliminating the primary allylic bromide.  
 
Table 21: Screening of allyl bromides   
 
Entry Electrophile (1 eq) Product Yield (%) 
1  
 
90b 
86 
(E:Z 85:15) 
2  
 
90a 
92 
3  
 
 
90d 
70 
4 
 
  
117 
88 
(E:Z 90:10) 
5  
 
90e 
62 
(E:Z 100:0) 
6 
  
90f 
99 
88 
 
7 
 
 
90g 
89 
(d.r 71:29) 
8 
  
117 
77 
9 
 
 
90h 
88 
10  
 
119 
79 
(E:Z 66:44) 
 
 
Interestingly, the ratio of diastereomers of compound 90g (71:29) were different to that of the ratio of 90g in 
the palladium-catalysed allylation reaction (59:41). The major diastereomer of the LDA reaction corresponds 
to the minor diastereomer in the palladium-mediated reaction and the minor diastereomer of the LDA reaction 
relates to the major diastereomer of the palladium-catalysed reaction.  
We next sought to vary both the amine and aryl substituent, all of which were synthesised from various 
arylmethanesulfonyl chlorides and their respective amines. Sulfonamides 94-97, 64a and 120-123 were 
allylated under the standard reaction conditions to yield the desired products 124a-g, 99j and 104a in generally 
high yields (Table 22). The reaction proceeded smoothly with various allylic bromides and differing amine 
substituents; morpholine (entry 1), pyrrolidine (entry 2), piperidine (entry 3), piperazine (entry 4) and 
tetrahydropyridine (entry 5). In addition, the reaction worked when varying the substituents on the aryl ring 
(entries 6-9). Reactions with electron withdrawing groups CF3 (entry 6), Br (entry 9) and Cl (entry 8) proceeded 
in good yields.  
 
Table 22: Expanding the substrate scope 
 
89 
 
Entry Electrophile Sulfonamide Product Yield (%) 
1 
  
94 
 
124a 
74 
2  
 
97 
 
124b 
57 
(E:Z 100:0) 
3 
 
 
95 
 
 
124c 
71 
4  
 
64a 
 
104a 
56 
5  
 
96 
 
99j 
60 
6  
 
120 
 
124d 
63 
(E:Z 100:0) 
 
7 
 
 
121 
 
124e 
49  
 
90 
 
8 
 
 
122 
 
124f 
53 
9  
 
123 
 
124g 
38 
(E:Z 75:25) 
 
 
Furthermore, this method was shown to work well with several alkyl bromides yielding compounds 125a-e 
(Table 23). We were pleased to see that alkylated sulfonamides could be accessed using these reaction 
conditions. Also, for the synthesis of compounds 125c and 125e (entries 3 and 5), higher reaction temperatures 
(r.t instead of –20 °C) and longer reaction times (overnight) were required to obtain any conversion to the 
desired products.  
 
Table 23: Alkylation of sulfonamides 
 
Entry Electrophile Product Yield (%) 
1  
 
125a 
86a 
2 
  
125b 
40a 
91 
 
3 
 
 
125c 
80b 
(d.r 77:23) 
4 
 
 
125d 
70 
5 
 
 
125e 
41b 
(d.r 100:0) 
a iodide used as leaving group;  b reaction time extended to 16 h at room temperature 
 
2.4.2 Enantioselective Synthesis 
 
Attempts at asymmetric synthesis, using a method extrapolated from the alkylation project discussed (Section 
2.4.1), was attempted by a member of the Sweeney group. Use of chiral base (+)-sparteine provided 
conversion to allylated product 90a in 41 % unoptimised yield, however the product was racemic (Scheme 48). 
Further optimisation and enantioselective synthesis using alternative chiral bases is currently under 
investigation in our laboratories.  
 
 
Scheme 48: Allylation using (+)-sparteine 
 
2.4.3 Conclusion 
 
We have demonstrated that -alkylation of sulfonamides, to access novel racemic compounds, can be 
achieved using mild conditions (LDA, –20 °C, 3 hours), without the requirement of polar additives and long 
reaction times. The developed method has been used to synthesise 25 benzylsulfonamides, 20 of which were 
previously unreported, in generally good yields. This area of research has allowed our group to investigate the 
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possibility of developing an asymmetric method using a chiral base to induce asymmetry, however little 
progress has been made thus far.  
 
2.5 Future Work 
 
We have described the first palladium-catalysed -allylation of benzylsulfonamides, leading to the formation 
of a library of novel functionalised sulfonamides.166 Although we have demonstrated a wide reaction scope by 
varying the allyl electrophile and sulfonamide amine moiety to gain access to over 40 novel compounds, 
research into catalytic sp3-sp3 coupling of sulfonamides remains under investigated. The use of alternative 
sulfonamide pronucleophiles have not yet been explored, for example, allylation of alkylsulfonamides and 
heteroaryl sulfonamides could allow for expansion of this chemistry and a greater scope of the reaction. 
Moreover, further investigation into enantioselective synthesis of sulfonamides remains a major challenge. 
Recent work within our group has begun focusing on -allylation of cyclic sulfonamides 126. Using similar 
palladium-catalysed conditions, -functionalised sultams 127 can be accessed (Scheme 49). The proton on 
the C to the sulfonyl moiety is more labile and requires less base than the examples described in this thesis. 
Therefore, exploration into using sultams as ideal candidates for enantioselective synthesis is desirable.   
 
 
Scheme 49: -Allylation of cyclic sulfonamides 
 
Finally, research into using alternative, more cost-effect transition metal catalysts for the -allylation of 
sulfonamides has become a focus in our research group. The use of nickel catalysts as cheaper alternatives 
for palladium has become of interest in recent years due to its efficiency in coupling reactions.167 Therefore 
correlation of our palladium-catalysed reaction to nickel catalysis would be an interesting strategy to apply to 
the -functionalisation of sulfonamides. 
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CHAPTER 3 EXPERIMENTAL 
 
Unless otherwise stated, all reactions were carried out under an inert atmosphere of dried nitrogen, in 
glassware which had been oven-dried. Reagents were purchased from Sigma-Aldrich, Acros, Alfa Aesar, 
Fisher Scientific, Fluorochem and Tokyo Chemical Industry UK, and were not purified except where stated. 
Solvents were purchased anhydrous and stored over molecular sieves, or distilled under nitrogen from an 
appropriate drying agent in accordance with the procedures of Perrin and Armarego. Dimethoxyethane and 
THF were distilled from sodium benzophenone ketyl radical while DCM was distilled from calcium hydride. All 
experiments were performed in oven-dry glassware under a protective atmosphere of nitrogen (dried by 
passage through anhydrous phosphorus pentoxide) as required. All acetates were commercial available or 
synthesised from their respected alcohols or ketones.  
Thin layer chromatography was performed on aluminium sheets coated with Merck silica gel 60 F254 with 
visualisation using potassium permanganate solution, phosphomolybdic acid and/or scrutinised under 254 nm 
UV light. Column chromatography was performed using Silica 60 (35-70 microns) supplied by Fisher unless 
otherwise stated.  
All melting points (mp) were obtained using a Smart SMP10 melting point instrument and are uncorrected. 
Nuclear magnetic resonance (NMR) spectroscopy was performed on a Bruker Avance 400 MHz spectrometer 
(1H NMR at 400 MHz, 13C NMR at 100 MHz) with samples dissolved in the appropriate deuterated solvent. 
Chemical shifts in 1H NMR spectra are expressed as ppm downfield from TMS and in 13C NMR, are relative to 
internal standard, and reported as singlet (s), doublet (d), triplet (t), quartet (q) and combinations thereof, or 
multiplet (m). Coupling constants (J) are quoted in Hz and are averaged between coupling partners and 
rounded to the nearest 0.2 Hz.  
All Fourier transform infrared (FTIR) data was acquired as thin films using Thermo Electron Corporation Nicolet 
380 FTIR with Smart Orbit diamond window instrument with wavenumber (max) being reported in cm-1. 
Mass spectrometry (MS) was performed using a Bruker MicroTOF-Q instrument with electrospray ionisation 
in the positive mode. FT-IR data was acquired using Thermo Electron Corporation Nicolet 380 FTIR with Smart 
Orbit diamond window instrument with wavenumbers being reported in cm-1.  
HPLC was performed using Agilent 1100 Series, G1311A Pump using a chiral OD-3 column. Samples were 
ran in Hexane:IPA (95:5), at 25 °C oven temperature with an injection volume of 5 l and 1 mL/min flow rate. 
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3.1 Palladium-Catalysed Allylation  
3.1.1 General Procedures 
 
General Procedure A: Palladium-catalysed sulfonamide allylation 
 
 
 
To an oven-dried 10 mL round-bottomed flask, flushed with nitrogen, was added sodium hydride 60 % in 
mineral oil (120 mg, 3.0 mmol, 6 eq) and was immediately washed with petroleum ether (1 mL) and the petrol 
removed via syringe. To this, allyl palladium (II) chloride dimer [PdCl(C3H5)]2 (4.7 mg, 0.0125 mmol, 0.025 eq), 
1,4-bis(diphenylphosphino)butane (dppb, 23 mg, 0.055 mmol, 0.11 eq) in anhydrous DME (1 mL) was added 
and stirred for one hour at 25 °C. To this mixture, benzylsulfonamide 89 (0.50 mmol, 1 eq) and allylic acetate 
(0.55 mmol, 1.1 eq) in anhydrous DME (1 mL) was added and stirred for 48 hours at 25 °C. After this time, the 
reaction mixture was quenched with H2O (0.5 mL) and passed through a silica plug, washing with CH2Cl2. The 
crude mixture was purified by flash column chromatography (toluene:EtOAc, 95:5) to yield the titled compound. 
General Procedure B: Palladium-catalysed allylation using modified reaction conditions 
 
 
 
To an oven-dried 10 mL round-bottomed flask, flushed with nitrogen, was added, sequentially NaOt-Bu (48 
mg, 0.5 mmol, 1 eq), allyl palladium (II) chloride dimer [PdCl(C3H5)]2 (4.7 mg, 0.0125 mmol, 0.025 eq), (±)-2,2′-
bis(diphenylphosphino)-1,1′-binaphthalene (rac-BINAP, 23 mg, 0.055 mmol, 0.11 eq) in anhydrous DME (1 
mL) and stirred for one hour at 25 °C. To this mixture, sulfonamide 98 (0.50 mmol, 1 eq) and allylic acetate 
(0.55 mmol, 1.1 eq) in anhydrous DME (1 mL) was added and stirred for 48 hours at 25 °C. After this time, the 
reaction mixture was passed through a silica plug, washing with CH2Cl2. The crude mixture was purified by 
flash column chromatography (toluene:EtOAc, 95:5) to yield the titled compound. 
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General procedure C: Synthesis of arylpiperazines168  
 
C1: Benzyl halide (10 mmol, 1.5 eq) and K2CO3 (5.25 g, 38 mmol, 5.5 eq) were added to a stirring solution of 
N-Boc piperazine (1.23 g, 6.6 mmol, 1 eq) in CH2Cl2 (40 mL). The mixture was heated to reflux and stirred for 
16 hours, after which the solution was cooled and diluted with EtOAc (100 mL) and H2O (100 mL). The organic 
phase was washed with brine (100 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude 
product was purified by column chromatography (5:1 Hexane:EtOAc) to yield the intermediate Boc-protected 
benzyl piperazine compound to be used in the next step. (Only 1H NMR was obtained for these intermediate 
compounds). 
C2: Trifluoroacetic acid (13.2 mL, 172 mmol, 36 eq) was added to a solution of the Boc-protected benzyl 
piperazine compound (4.8 mmol, 1 eq) in toluene (15 mL). The reaction was allowed to stir at room temperature 
for two hours, prior to the addition of 1M NaOH (50 mL). The mixture was extracted with CH2Cl2 (2 x 50 mL), 
dried over MgSO4, filtered and the filtrate concentrated in vacuo to yield the titled benzyl piperazine, which was 
used without further purification. (Only 1H NMR data was obtained for these starting materials). 
 
General procedure D: Synthesis of benzylpiperazine sulfonamides121 
 
To an oven-dried 25 mL round bottom flask, was added phenylmethanesulfonyl chloride (3 mmol, 1 eq), benzyl 
piperazine (3 mmol, 1 eq) and triethylamine (3 mmol, 1 eq) in CH2Cl2 (15 mL). The reaction mixture was  
allowed to stir for two hours at room temperature, prior to the addition of CH2Cl2 (25 mL) and H2O (25 mL). 
The organic phase was washed successively with H2O (2 x 25 mL) and sat. NaHCO3 solution (2 x 25 mL). The 
organic extracts were combined, dried over Na2SO4, filtered and the filtrate concentrated in vacuo to yield the 
titled compound. 
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3.1.2 Experimental Data 
 
N,N-Dimethyl-1-phenylmethanesulfonamide (89) 
 
Phenylmethanesulfonyl chloride (5.72 g, 30 mmol, 1 eq) was dissolved in CHCl3 (150mL) and cooled to 0 °C. 
Dimethylamine (8M aq solution, 37.5 mL, 300 mmol, 10 eq) was added and the reaction mixture was allowed 
to warm to room temperature and stir for overnight. The organic layer was subsequently extracted from the 
aqueous layer and the combined organic extracts were washed with water (2 x 50 mL). The organic layer was 
dried over MgSO4, filtered and concentrated in vacuo to yield N,N-dimethyl-1-phenylmethanesulfonamide as 
a colourless solid (5.73 g, 96 %); 1H NMR (CDCl3 400 MHz) H7.37-7.40 (5H, m, Ar-H); 4.24 (2H, s, CH2); 2.73 
(6H, s, N-(CH3)2); 13C NMR (100 MHz) H 130.6 (2 x Ar-CH); 129.1 (1 x Ar-C); 128.8 (1 x Ar-CH); 128.7 (2 x 
Ar-CH); 56.1 (1-CH2); 37.7 (N-CH3)2); max (solid, cm-1) 1150 & 1333 (S=O); m/z (ESI+) calculated for 
C9H13NO2S  [M-SO2+H]+; 135.1048, found 135.1047. 
 
N,N-Dimethyl-1-phenylbut-3-en-1-sulfonamide (90a) 
 
 
N,N-Dimethyl-1-phenylmethanesulfonamide (100 mg, 0.50 mmol, 1 eq) and allyl acetate (0.06 mL, 0.55 mmol, 
1.1 eq) were reacted following the general procedure A to yield N,N-dimethyl-1-phenylbut-3-en-1-sulfonamide 
(98 mg, 82 %) as a colourless solid; RF = 0.5 (95:5 toluene: EtOAc); mp: 91 - 92 °C; 1H NMR (CDCl3 400 MHz) 
H 7.34-7.42 (5H, m, Ar-H); 5.57 (1H, ddt, J 7.0 Hz 10.1 Hz 17.1 Hz, 3-H); 5.06 (1H, dd, J 1.4 Hz 17.0 Hz, 4-
Hb); 4.99 (1H, dd, J 0.8 Hz 10.1 Hz, 4-Ha); 4.15 (1H, dd, J 4.2 Hz 11.3 Hz 1-H); 3.00-3.10 (2H, m, 2-H2); 13C 
NMR (100 MHz) C 133.3 (3-CH); 129.6 (2 x Ar-CH); 128.9 (1 x Ar-CH); 128.7 (1 x Ar-CH); 118.2 (4-CH2); 37.6 
(N-(CH3)2); 34.3 (2-CH2); max (solid, cm-1) 1137 & 1310 (sulfonamide S=O); 969 (CH=CH); m/z (ESI+) 
calculated for C12H17NO2S [M+Na]+; 262.0872, found 262.0869.  
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(E)-N,N-Dimethyl-1-phenylpent-3-ene-1-sulfonamide (90b) 
 
N,N-Dimethyl-1-phenylmethanesulfonamide (92 mg, 0.5 mmol, 1 eq) and E-2-butenyl acetate (95 % E) (0.07 
ml, 0.55 mmol, 1.1 eq) was reacted following the general procedure A, to yield (E)-N,N-dimethyl-1-phenylpent-
3-ene-1-sulfonamide (E:Z 67:33) (103 mg, 82%) as a colourless solid; RF = 0.52 (95:5 toluene:EtOAc); mp: 92 
- 94 °C; Data for trans isomer 1H NMR (CDCl3 400 MHz) H 7.34-7.42 (m, 5H, Ar-H); 5.44-5.54 (1H, m, 3-H); 
5.11-5.19 (1H, m, 4-H); 4.11 (1H, dd, J 4.1 Hz 11.2 Hz, 1-H); 2.8-3.0 (2H, m, 2-H2); 2.50 (6H, s, N-(CH3)2); 1.5 
(3H, dd, J 0.8 Hz 6.5 Hz, 5-H3); 13C NMR (100 MHz) C 133.4 (1 x Ar-C); 129.6 (2 x Ar-CH); 128.9 (1 x Ar-CH); 
128.6 (2 x Ar-CH); 128.7 (3-CH); 125.6 (4-CH); 67.6 (1-CH); 37.6 (N-(CH3)2); 33.2 (2-CH2); 17.8 (5-CH3); max 
(solid, cm-1) 1137 & 1319 (sulfonamide S=O); m/z (ESI+) calculated for C13H19NO2S [M+Na]+; 267.1029, found 
276.1025. 
 
(E)-N,N-Dimethyl-1-phenylhept-3-ene-1-sulfonamide (90c) 
 
N,N-Dimethyl-1-phenylmethanesulfonamide (0.099 g, 0.5 mmol, 1 eq) and E-2-hexenyl acetate (0.09 mL, 0.55 
mmol, 1.1 eq) was reacted following the general procedure A to yield (E)-N,N-dimethyl-1-phenylhept-3-ene-1-
sulfonamide (137 mg, 98%) as a colourless solid; RF = 0.60 (95:5 toluene:EtOAc); mp: 65 - 67 °C; 1H NMRH 
7.34-7.41 (5H, m, Ar-H); 5.38-5.47 (1H, m, 4-H); 5.08-5.17 (1H, m, 3-H); 4.10 (1H, dd J 4.2 Hz 11.1 Hz, 1-H); 
2.81-3.04 (2H, m, 2-H2); 2.54 (6H, s, N-(CH3)2); 1.76-1.88 (2H, m, 5-H2); 1.19-1.26 (2H, m, 6-H2); 0.72 (3H, t, 
J 7.1 Hz, 7-H); 13C NMR (100 MHz) C 134.5 (4-CH); 133.4 (1 x Ar-C); 129.7 (2 x Ar-CH); 128.8 (1 x Ar-CH); 
128.6 (2 x Ar-CH); 124.5 (3-CH); 67.6 (1-CH); 37.6 (N-(CH3)2); 34.4 (2-CH2); 33.2 (5-CH2); 22.3 (6-CH2); 13.4 
(7-CH3); max (solid, cm-1) 1137 & 1320 (sulfonamide S=O); 964 (E-alkene); m/z (ESI+) calculated for 
C15H23NO2S [M+K]+; 320.1081, found 320.1083. 
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N,N-4-Trimethyl-1-phenylpent-3-ene-1-sulfonamide (90d) 
 
N,N-Dimethyl-1-phenylmethanesulfonamide (100 mg, 0.5 mmol, 1 eq) and prenyl acetate (0.075 mL, 0.55 
mmol, 1.1 eq) was reacted following the general procedure A, replacing dppb with 1,2-
bis(diphenylphosphino)ethane as the ligand (21 mg, 0.055 mmol, 0.11 eq) to yield N,N-4-trimethyl-1-
phenylpent-3-ene-1-sulfonamide (99 mg, 74 %) as a colourless solid; RF = 0.58 (95:5 toluene:EtOAc); mp: 90 
- 92°C; 1H NMR H 7.34-7.42 (5H, m, Ar-H); 4.87 (1H, ddt J 1.4 Hz 3.0 Hz 7.3 Hz, 3-H); 4.07 (1H, dd J 4.0 Hz 
11.3 Hz, 1-H); 3.05-2.84 (2H, m, 2-H2); 2.50 (6H, s, N-(CH3)2); 1.56 (6H, s, 5-CH3, 4’-CH3; 13C NMR (100 MHz) 
C 134.9 (1 x Ar-C); 133.6 (4-C); 129.6 (2 x Ar-CH); 128.7 (1 x Ar-CH); 128.6 (2 x Ar-CH); 118.9 (3-CH); 67.4 
(1-CH); 37.6 (N-(CH3)2); 28.8 (2-CH2); 25.6, 17.9 (4’-CH3, 5-CH3); max (solid, cm-1) 1133 & 1304 (sulfonamide 
S=O); m/z (ESI+) calculated for C14H21NO2S [M+H]+; 268.1366, found 268.1366. 
 
(E)-N,N-Dimethyl-1,4-diphenylbut-3-ene-1-sulfonamide (90e) 
 
N,N-Dimethyl-1-phenylmethanesulfonamide (100 mg, 0.5 mmol, 1 eq) and cinnamyl acetate (440 mg, 2.5 
mmol, 5 eq) was reacted following the general procedure A, replacing dppb with 1,1’-
bis(diphenylphosphino)ferrocene (31 mg, 0.055 mmol, 0.11 eq) as the ligand, to yield (E)-N,N-dimethyl-1,4-
diphenylbut-3-ene-1-sulfonamide (125 mg, 79 %) as a colourless solid; RF = 0.5 (95:5 toluene:EtOAc); mp: 88 
- 90 °C; 1H NMR H 7.36-7.46 (5H, m, Ar-H); 7.17 (5H, m, Ar-H); 6.43 (1H, d, J 15.6, 4-H); 5.93 (1H, dt, J 7.2, 
15.7, 3-H); 4.22 (1H, dd, J 4.2, 10.8, 1-H); 3.25 (1H, dddd, J 1.0 Hz 4.2 Hz 7.6 Hz 14.2 Hz, 2-H); 3.08 (1H, 
dddd, J 1.1 Hz 6.8 Hz 10.9 Hz 14.2 Hz, 2-H); 2.55 (6H, s, N-(CH3)2); 13C NMR (100 MHz) C 136.9 (1 x Ar-C); 
133.2 (1 x Ar-C); 133.1 (4-CH); 129.6 (2 x Ar-CH); 129.0 (1 x Ar-CH); 128.8 (2 x Ar-CH); 128.5 (2 x Ar-CH); 
127.4 (1 x Ar-CH); 126.2 (2 x Ar-CH); 124.8 (3-CH); 67.3 (1-CH); 37.6 ((N-CH3)2); 33.7 (2-CH2); max (solid, 
cm-1) 1135.6 & 1317 (sulfonamide S=O); 926 (E-alkene); m/z (ESI+) calculated for C18H21NO2S [M+Na]+; 
338.1185, found 338.1184.  
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(Z)-N,N,4,8-Tetramethyl-1-phenylnona-3,7-diene-1-sulfonamide (90f) 
 
N,N-Dimethyl-1-phenylmethanesulfonamide (108 mg, 0.5 mmol, 1 eq) and neryl acetate (490 mg, 2.5 mmol, 
5 eq) was reacted following the general procedure A, replacing dppb with dppe as the ligand (21 mg, 0.055 
mmol, 0.11 eq) to yield (Z)-N,N,4,8-tetramethyl-1-phenylnona-3,7-diene-1-sulfonamide (114 mg, 68 %) as a 
yellow oil; RF = 0.62 (95:5 toluene:EtOAc); 1H NMR H 7.35-7.42 (5H, m, Ar-H); 5.07-5.09 (1H, m, 3-H); 4.83-
4.87 (1H, t, J 7.2, 7-H); 4.05 (1H, dd, J 3.9 Hz 11.2 Hz, 1-H); 3.02-3.09 (1H, m, 2-H); 2.79-2.88 (1H, m, 2-H); 
2.54 (6H, s, (CH3)2); 2.00-2.03 (2H, m, 5-CH2); 1.70 (2H, bs, 6-CH2); 1.60 (3H, s, 8-CH3); 1.57 (3H, s, 8-CH3); 
1.53 (3H, s, 4-CH3). 13C NMR (100 MHz) C 138.6 (4-C); 133.6 (1 x Ar-C); 131.8 (8-C); 129.6 (2 x Ar-CH); 
128.8 (1 x Ar-CH); 128.6 (2 x Ar-CH); 123.9 (7-CH); 119.5 (3-CH); 67.6 (1-CH); 37.6 (N-(CH3)2); 32.0 (5-CH2); 
28.4 (2-CH2); 26.3 (6-CH2); 25.8 (8-CH3); 23.8 (8-CH3) 17.6 (4-CH3); 16.2 (4-CH3); max (solid, cm-1) 1136 & 
1329 (sulfonamide S=O); 700 (cis alkene); m/z (ESI+) calculated for C19H29NO2S [M+Na]+; 358.1811, found 
358.1805. 
 
1-(Cyclohex-2-en-1-yl)-N,N-dimethyl-1-phenylmethanesulfonamide (90g) 
 
N,N-Dimethyl-1-phenylmethanesulfonamide (98 mg, 0.5 mmol, 1 eq) and cyclohex-2-en-yl acetate (77 mg, 
0.55 mmol, 1.1 eq) was reacted following the general procedure A to yield 1-(cyclohex-2-en-1-yl)-N,N-dimethyl-
1-phenylmethanesulfonamide (d.r 59:41 determined by 1H NMR) (105 mg, 74 %) as a colourless solid; RF = 
0.42 (95:5 toluene:EtOAc); mp: 119 - 121 °C; data for major diastereomer: 1H NMR H (400 MHz, CDCl3) 7.36-
7.43 (5H, m, Ar-H); 5.69-5.72 (1H, m, 3’-H); 5.46 (1H, bd, J 10.2 Hz, 2’-H); 3.99 (1H, d J 8.5 Hz, 1-H); 3.19-
3.22 (1H, m, 1’-H); 2.44 (6H, s, (N-CH3)2); 2.13 (1H, dt J 6.3 Hz 11.0 Hz, 6’-H); 1.88-1.97 (2H, m, 4’H); 1.58-
1.63 (2H, m, 1-H, 6’-H); 13C NMR (100 MHz) C 133.4 (1 x Ar-C); 130.1 (2 x Ar-CH); 129.7 (3’-CH); 128.8 (1 x 
Ar-CH); 128.6 (2 x Ar-CH); 127.0 (2’-CH); 71.8 (1-CH); 37.5 (N-CH3)2); 37.4 (1’-CH); 28.0 (6’-CH); 24.9 (4’-
CH); 21.2 (5’-CH). Data for minor diastereomer: 1H NMR H (400 MHz, CDCl3) 7.36-7.43 (5H, m, Ar-H); 6.22 
(1H, dd J 2.3 Hz 10.5 Hz, 2’-H); 5.78-5.83 (1H, m, 3’-H); 4.07 (1H, d J 9.9 Hz, 1-H); 3.12-3.17 (1H, m, 1’-H); 
2.42 (6H, s, N-(CH2)2);  1.92-1.97 (2H, m, 4’-H2); 1.52-1.63 (3H, 5’-H2, 6’-H); 1.09-1.16 (1H, m, 6’-H); 13C NMR 
(100 MHz) C 133.6 (1 x Ar-C); 130.0 (1 x Ar-CH); 128.7 (3’-CH2, 4 x Ar-CH); 128.6 (2’-CH); 72.6 (1-CH); 36.5 
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(N-(CH3)2); 30.9 (1’-CH); 26.7 (6’-CH2); 25.0 (4’-CH2); 20.6 (5’-CH2); max (solid, cm-1) 1319 & 1136 
(sulfonamide S=O); m/z (ESI+) calculated for C15H21NO2S [M+Na]+; 302.1185, found 302.1180. 
 
1-(Cyclopent-2-en-1-yl)-N,N-dimethyl-1-phenylmethanesulfonamide (90h) 
 
N,N-Dimethyl-1-phenylmethanesulfonamide (100 mg, 0.5 mmol, 1 eq) and cyclopent-2-en-1-yl acetate (70 mg, 
0.55 mmol, 1.1 eq) was reacted following the general method A to yield 1-(cyclopent-2-en-1-yl)-N,N-dimethyl-
1-phenylmethanesulfonamide (d.r 50:50 determined by 1H NMR) (114 mg, 79 %) as a colourless solid; RF = 
0.45 (95:5 toluene:EtOAc); mp: 88 - 91 °C; data for diastereomer 1: 1H NMR (400 MHz CDCl3) H 7.35-7.37 
(5H, m, Ar-H); 5.77 (1H, dd J 2.3 Hz 5.6 Hz, 2’-H); 5.42 (1H, dd J 1.7 Hz 5.5 Hz, 3’-H); 3.98 (2H, d J 8.8 Hz, 
1-H); 3.72-3.79 (1H, m, 1’-H); 2.47 (6H, s, N-(CH3)2); 2.31-2.36 (1H, m, 5’-H); 2.27-2.29 (2H, m, 4’-H2); 1.88-
1.93 (1H, m, 5’-H); 13C NMR (100 MHz) C 134.2 (1 x Ar-C); 133.3 (2’-CH); 131.1 (3’-CH); 128.7 (2 x Ar-CH); 
128.6 (1 x Ar-CH); 128.5 (2 x Ar-CH); 71.6 (1-CH); 46.7 (1’-CH); 37.5 (N-CH3)2); 32.3 (5’-CH); 29.2 (4’-CH). 
Data for diastereomer 2: 1H NMR (400 MHz CDCl3) H 7.38-7.43 (5H, m, Ar-H); 6.27 (1H, dd J 2.2 Hz 5.7 Hz, 
2’-H); 5.86 (1H, dd J 2.4 Hz 5.6 Hz, 3’-H); 3.98 (1H, d J 10.4 Hz, 1-H); 3.66-3.70 (1H, m 1’-H); 2.45 (6H, s, N-
(CH3)2); 2.19-2.26 (2H, 4’-H2);1.83-1.86 (1H, m, 5’-H); 1.22-1.32 (1H, m, 5’-H); 13C NMR (100 MHz) C 133.7 
(1 x Ar-C); 132.9 (2’-CH); 132.2 (3’-CH); 130.0 (2 x Ar-CH); 129.7 (1 x Ar-CH); 128.7 (2 x Ar-CH); 72.4 (1-CH); 
46.9 (1’-CH); 37.4 (N-(CH3)2); 30.9 (4’-CH2); 29.0 (5’-CH); max (solid, cm-1) 1316 & 1131 (sulfonamide S=O); 
m/z (ESI+) calculated for C14H19NO2S [M+Na]+; 288.1029, found 288.1028. 
 
N,N-3-Trimethyl-1-phenylbut-3-ene-1-sulfonamide (90i) 
  
N,N-Dimethyl-1-phenylmethanesulfonamide (97 mg, 0.49 mmol, 1 eq) and 2-methylallyl acetate (72 mg, 0.55 
mmol, 1.1 eq) was reacted following the general procedure A to yield N,N-3-trimethyl-1-phenylbut-3-ene-1-
sulfonamide (102 mg, 82 %) as a colourless solid; RF = 0.50 (95:5 toluene:EtOAc); mp: 127 - 128 °C; 1H NMR 
H 7.35-7.42 (5H, m, Ar-H); 4.67 (1H, bs, 3’-H); 4.61 (1H, bs, 3’-H); 4.30 (1H, dd, J 3.7 Hz 11.6 Hz, 1-H); 2.88-
3.06 (2H, m, 2-H); 2.54 (6H, s, N-(CH3)2); 1.61 (3H, 4-H3); 13C NMR (100 MHz) C 140.3 (3-C); 133.3 (1 x Ar-
C); 129.6 (2 x Ar-CH); 128.9 (1 x Ar-CH); 128.6 (2 x Ar-CH); 114.1 (3’-CH2); 66.0 (N-(CH3)2); 37.7 (N-(CH3)2); 
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22.3 (4-CH3); max (solid, cm-1) 1132 & 1323 (sulfonamide S=O); 895 (geminal alkene); m/z (ESI+) calculated 
for C13H19NO2S [M+Na]+; 276.1029, found 276.1030. 
 
(E)-N,N,4,8-Tetramethyl-1-phenylnona-3,7-diene-1-sulfonamide (90j) 
 
N,N-Dimethyl-1-phenylmethanesulfonamide (101 mg, 0.5 mmol, 1 eq) and geranyl acetate (490 mg, 2.5 mmol, 
5 eq) was reacted following the general procedure A, replacing dppb with dppf ligand (30 mg, 0.055 mmol, 
0.11 eq) to yield (E)-N,N,4,8-tetramethyl-1-phenylnona-3,7-diene-1-sulfonamide (140 mg, 84 %) as a 
colourless solid; RF = 0.6 (95:5 toluene:EtOAc); mp: 52 - 53 °C ; 1H NMR (400 MHz) H 7.34-7.42 (5H, m, Ar-
CH); 4.87-4.9 (1H, m, 7-H); 4.83-4.85 (1H, m, 3-H); 4.07 (1H, dd J 3.8 Hz 11.3 Hz, 1-H); 3.00-3.07 (1H, m, 2-
H); 2.82-2.89 (1H, m, 2-H); 2.54 (6H, s, N-CH3)2); 1.90-1.94 (2H, m, 6-H2); 1.83-1.89 (2H, m, 5-H2); 1.61 (3H, 
s, 8-CH3); 1.56 (3H, s, 4-CH3); 1.51 (3H, s, 9-CH3); 13C NMR (100 MHz) C 138.5 (4-C); 133.6 (1 x Ar-C); 131.4 
(8-C); 129.6 (2 x Ar-CH); 128.7 (1 x Ar-CH); 128.5 (2 x Ar-CH); 123.9 (7-CH); 118.9 (3-CH); 67.4 (1-CH); 39.5 
(5-CH2); 37.7 (N-CH3)2); 28.7 (2-CH2); 26.4 (6-CH2); 25.6 (8-CH3); 17.6 (9-CH3); 16.2 (4-CH3); max (solid, cm-
1) 1323 & 1135 (sulfonamide S=O); 926 (trans alkene); m/z (ESI+) calculated for C19H29NO2S [M+Na]+; 
358.1811, found 358.1815. 
 
(E)-N,N-Dimethyl-1,2,4-triphenylbut-3-ene-1-sulfonamide (90k) 
 
N,N-Dimethyl-1-phenylmethanesulfonamide (99 mg, 0.5 mmol, 1 eq) and (±)-trans-diphenylallyl acetate (138 
mg, 0.55 mmol, 1.1 eq) was reacted following the general procedure A to yield (E)-N,N-dimethyl-1,2,4-
triphenylbut-3-ene-1-sulfonamide (d.r 80:20 determined by 1H NMR) (172 mg, 87 %) as a colourless solid; RF 
= 0.6 (95:5 toluene:EtOAc); mp: 131 - 133 °C; data for major diastereomer: 1H NMR H 7.17-7.47 (15H, m, Ar-
CH); 6.32-6.39 (2H, m, 3-H, 4-H); 4.61 (1H, t J 7.1 Hz, 2-H), 4.51 (1H, d J 7.1 Hz, 1-H); 2.44 (6H, s, N-(CH3)3); 
13C NMR (100 MHz) C 141.4 (Ar-C); 137.2 (Ar-CH); 132.6 (4-CH); 132.4 (Ar-CH); 130.7 (2 x Ar-CH); 128.9 (1 
x Ar-CH); 128.8 (3-CH); 128.6 (2 x Ar-CH); 128.5 (2 x Ar-CH); 128.4 (2 x Ar-CH); 128.3 (2 x Ar-CH); 127.4 (1 
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x Ar-CH); 127.1 (1 x Ar-CH); 126.3 (2 x Ar-CH); 71.8 (1-CH); 50.2 (2-CH); 37.4 (N-(CH3)2); max (solid, cm-1) 
1133 & 1459 (sulfonamide S=O); m/z (ESI+) calculated for C24H25NO2S [M+K]+; 430.1238, found 430.1234. 
 
N,N-Dimethyl-4-phenylhetpa-1,6-diene-4-sulfonamide (91) 
 
To an oven dried 10 mL round-bottomed flask flushed with nitrogen, sodium hydride 60 % in mineral oil (160 
mg, 4 mmol, 6 eq) was added and immediately washed with petrol. To this, [PdCl(C3H5)]2 (4.8 mg, 0.0125 
mmol, 0.025 eq) and dppb (22 mg, 0.055 mmol, 0.11) was added in DME (1 mL), stirred for one hour at 25 °C. 
To this mixture, N,N-dimethyl-1-phenylmethanesulfonamide (100 mg, 0.5 mmol, 1 eq) and allyl acetate (250 
mg, 2.5 mmol, 5 eq) was added in DME (1 mL) stirring at 25 °C for 48 hours. The reaction was quenched with 
water (0.2 mL) and purified using column chromatography to yield N,N-dimethyl-4-phenylhetpa-1,6-diene-4-
sulfonamide (131 mg, 96 %) as a colourless solid; RF = 0.52 (95:5 toluene:EtOAc); mp: 80 - 83 °C; 1H NMR 
(400 MHz) H 7.59-7.61 (2H, m, Ar-CH); 7.35-7.42 (3H, m, Ar-CH); 5.86 (2H, ddt J 7.0 Hz 10.2 Hz 14.0 Hz, 2-
CH, 6-CH); 5.19 ( 2H, dd J 1.2 Hz 17.0 Hz, 1-CHb, 7-CHb); 5.12 (2H, d J 10.3 Hz, 1-CHa, 7-CHa); 3.27 (2H, dd 
J 6.7 Hz 15.1 Hz, 3-CH, 5-CH); 3.01 (2H, dd J 7.1 Hz 15.1 Hz, 3-CH, 5-CH); 2.46 (6H, s, N-(CH3)2); 13C NMR 
(100 MHz) C 135.9 (1 x Ar-C); 132.4 (1-CH, 6-CH), 129.3 (2 x Ar-CH); 128.4 (1 x Ar-CH); 128.2 (2 x Ar-CH); 
119.3 (1-CH2, 7-CH2); 71.7 (4-C); 38.7 (N-(CH3)2); 36.7 (2-CH2, 7-CH2); max (solid, cm-1) 1312 & 1131 
(sulfonamide S=O); 919 (mono-substituted alkene); m/z (ESI+) calculated for C15H21NO2S [M+Na]+; 302.1185, 
found 302.1190. 
 
N,N-Dimethyl-1-phenylcyclopent-3-ene-1-sulfonamide (92) 
 
To an oven-dried 10 mL round bottomed flask, N,N-dimethyl-4-phenylhetpa-1,6-diene-4-sulfonamide (100 mg, 
0.36 mmol, 1 eq) and Grubbs 2nd generation catalyst (15.2 mg, 0.018 mmol, 0.05 eq) was dissolved in CH2Cl2 
(6 mL). The reaction mixture was allowed to stir at 25 °C for overnight. The reaction mixture was passed 
through a silica plug and the solvent evaporated to dryness to yield N,N-dimethyl-1-phenylcyclopent-3-ene-1-
sulfonamide (84 mg, 93 %) as a grey solid; mp: 111 - 114 °C; 1H NMR (400 MHz, CDCl3) H 7.50-7.52 (2H, m, 
Ar-CH); 7.31-7.39 (3H, m, Ar-CH); 5.83 (2H, s, 3-CH, 4-CH); 3.55 (2H, d J 15.7, 2/5-CH2); 3.15 (2H, d J 16.6, 
2/5-CH2); 2.64 (6H, s, (N-(CH3)2); 13C NMR (100 MHz) C 139.1 (1 x Ar-C); 129.6 (2 x Ar-CH); 128.3 (3-CH, 4-
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CH); 128.2 (1 x Ar-CH); 128.1 (2 x Ar-CH); 41.9 (2-CH2, 5-CH2); 38.9 (N-(CH3)2), max (solid, cm-1) 1312 & 1131 
(sulfonamide S=O); 705 (cis-alkene); m/z (ESI+) calculated for C13H17NO2S [M+Na]+; 274.0872, found 
274.0873. 
 
4-(Benzylsulfonyl)morpholine (94) 
 
To an oven-dried 100 mL round bottomed flask, phenylmethanesulfonylchloride (4.8 g, 25 mmol. 1 eq) was 
dissolved in dry benzene (50 mL) with stirring. To this, morpholine (4.3 mL, 50 mmol, 2 eq) was slowly added 
and stirred at room temperature for overnight. The solvent was removed under pressure and the resultant oil 
was added to water (50 mL) and subsequently extracted with CH2Cl2 (3 x 25 mL). The organic layers were 
combined, dried over MgSO4, filtered and the filtrate concentrated in vacuo to yield 4-
(benzylsulfonyl)morpholine as a colourless solid (5.5 g, 91 %); mp: 173 - 175 °C; 1H NMR (400 MHz, CDCl3) 
H 7.36-7.43 (5H, m, Ar-H); 4.24 (2H, s, CH2); 3.62 (4H, t J 4.7 Hz, N-O-(CH2)2); 3.10 (4H, t J 4.7 Hz, N-(CH2)2); 
13C NMR (100 MHz) C 130.7 (2 x Ar-CH); 128.9 (1 x Ar-CH); 128.8 (2 x Ar-CH); 128.5 (Ar-C); 66.7 (O-(CH2)2; 
56.7 (1-CH2); 46.1 (N-(CH2)2); m/z (ESI+) calculated for C11H15NO3S [M-SO2+H]+; 177.1154, found 177.1150. 
 
4-([1-Phenylbut-3-en-1-yl]sulfonyl)morpholine (99f) 
 
4-(Benzylsulfonyl)morpholine (120 mg, 0.5 mmol, 1 eq) and allyl acetate (60 mg, 0.55 mmol, 1.1 eq) was 
reacted following the general procedure A to yield 4-[(1-phenylbut-3-en-1-yl)sulfonyl]morpholine (274 mg, 98 
%) as a colourless solid; RF = 0.25 (95:5 Toluene:EtOAc); mp: 84 - 87 °C; 1H NMR (400 MHz) H 7.36-7.40 
(5H, m, Ar-CH); 5.52 (1H, ddt J 7.0 Hz 10.0 Hz 17.0 Hz, 3-H); 5.04 (1H, dd J 1.2 Hz 17.0 Hz, 4-H); 4.96 (1H, 
d J 10.1 Hz, 4-H); 4.09 (2H, dd J 4.1 Hz 11.2 Hz, 1-H); 3.53 (2H, ddd J 3.0 Hz 6.3 Hz 11.5 Hz, O-CH2); 3.44 
(2H, ddd J 3.0 Hz 6.2 Hz 11.2 Hz, O-CH2); 3.08-3.13 (1H, m, 2-H); 2.89 (1H, ddd J 6.8 Hz 11.2 Hz 14.0 Hz, 2-
H); 3.02-3.07 (2H, m, N-CH2); 2.76 (2H, bs, N-CH2); 13C NMR (100 MHz) C 133.0 (3-CH); 132.8 (1 x Ar-C); 
129.7 (2 x Ar-CH); 129.2 (1 x Ar-CH); 128.9 (2 x Ar-CH); 118.4 (4-CH2); 67.9 (1-CH); 66.8 (N-(CH2)2); 46.1 (O-
(CH2)2); 34.4 (2-CH2); max (solid, cm-1) 1335 & 1125 (sulfonamide S=O); 1110 (mono-substituted alkene); m/z 
(ESI+) calculated for C14H19NO3S [M+Na]+; 304.0978, found 304.0978. 
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(E)- 4-([1-Phenylhept-3-en-1-yl]sulfonyl)morpholine (99g) 
 
4-(Benzylsulfonyl)morpholine (124 mg, 0.5 mmol, 1 eq) and trans-2-hexenyl acetate (82 mg, 0.55 mmol, 1.1 
eq) was reacted following the general procedure A to yield (E)- 4-([1-phenylhept-3-en-1-yl]sulfonyl)morpholine 
(102 mg, 79 %) as a colourless solid; RF = 0.25 (95:5 Toluene:EtOAc); mp: 69 - 71 °C; 1H NMR (400 MHz) H 
7.36-7.38 (5H, m, Ar-CH); 5.43 (1H, dt J 6.9 Hz 14.3 Hz, 4-H); 5.09 (1H, dt J 6.9 Hz 14.5 Hz, 3-H); 4.04 (1H, 
dd J 4.0 Hz 11.2 Hz, 1-H); 3.54 (2H, ddd J 2.8 Hz 6.3 Hz 11.2 Hz, O-CH2); 3.45 (2H, ddd J 2.9 Hz 6.3 Hz 9.2 
Hz, O-CH2); 2.99-3.07 (3H, m, N-CH2, 2-H); 2.78 (3H, m, N-CH2, 2-H); 1.77-1.87 (2H, m, 5-H2); 1.16-.25 (2H, 
m, 6-H2); 0.71 (3H, t J 7.4, 7-H3); 13C NMR (100 MHz) C 134.6 (4-CH); 132.9 (1 x Ar-C); 129.8 (2 x Ar-CH); 
128.9 (1 x Ar-CH); 128.7 (2 x Ar-CH); 124.3 (3-CH); 68.4 (1-CH); 66.8 (N-(CH2)2); 46.1 (O-(CH2)2); 34.4 (5-
CH2); 33.4 (2-CH2); 22.3 (6-CH2); 13.4 (7-CH3); max (solid, cm-1) 1106 & 1322 (sulfonamide S=O); 952 (trans 
alkene); m/z (ESI+) calculated for C17H25NO2S [M+Na]+; 346.1447, found 346.1446. 
 
(Z)-4-([4,8-Dimethyl-1-phenylnona-3,7-dien-1-yl]sulfonyl)morpholine (99h) 
 
4-(Benzylsulfonyl)morpholine (120 mg, 0.5 mmol, 1 eq) and neryl acetate (118 mg, 0.55 mmol, 1.1 eq) was 
reacted following the general procedure A, to yield (Z)-4-([4,8-dimethyl-1-phenylnona-3,7-dien-1-
yl)sulfonyl]morpholine (83 mg, 45 %) as a yellow oil; RF = 0.30 (95:5 Toluene:EtOAc); 1H NMR (400 MHz) H 
7.36-7.41 (5H, m, Ar-H); 5.06-5.07 (1H, m, 7-H); 4.84 (1H, t J 7.1, 3-H); 3.98 (1H, dd J 3.8 Hz 11.2 Hz, 1-H); 
3.54 (3H, ddd J 2.9 Hz 6.4 Hz 11.5 Hz, O-(CH2)2); 3.45 (2H, ddd J 2.9 Hz 6.3 Hz 9.1 Hz, O-(CH2)2); 3.01-3.10 
(3H, m, 2-H, N-(CH2)2); 2.77-2.85 (2H, m, 2-H, N-(CH2)2); 1.98-2.14 (4H, m, 6-H2, 5-H2); 1.69 (3H, s); 1.59 (3H, 
s); 1.57 (3H, s, 4-CH3); 13C NMR (100 MHz) C 138.8 (4-C); 133.2 (1 x Ar-C); 131.9 (8-C); 129.7 (2 x Ar-CH); 
129.0 (1 x Ar-CH); 128.8 (2 x Ar-CH); 123.9 (7-CH); 119.2 (3-CH); 68.4 (1-CH); 66.8 (N-(CH2)2); 46.1 (O-
(CH2)2); 32.0 (5-CH2); 28.6 (2-CH2); 26.3 (6-CH2); 25.7 (-CH3); 23.3 (-CH3); 17.7 (4-CH3); max (oil, cm-1) 1339 
& 1112 (sulfonamide S=O); 702 (cis alkene); m/z (ESI+) calculated for C21H31NO3S [M+Na]+; 400.1917, found 
400.1919. 
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1-(Benzylsulfonyl)piperidine (95) 
 
To an oven-dried 100 mL round bottom flask, piperidine (1.25 mL, 12.5 mmol, 1 eq) and triethylamine (1.8 mL, 
12.5 mmol, 1 eq) was dissolved in CH2Cl2 (20 mL) at cooled to –20 °C. To this, phenylmethanesulfonylchloride 
(2.39 g, 12.5 mmol, 1 eq) was added slowly over ten minutes at –20 °C. The reaction mixture was allowed to 
warm to room temperature and stir for six hours, after which aqueous NH4Cl (3 mL) was added. The reaction 
organic extracts were washed with water (3 x 25 mL) and brine (25 mL) successively, dried over MgSO4 and 
the solvent was evaporated to dryness to yield 1-(benzylsulfonyl)piperidine as a colourless solid (1.71 g, 57 
%); mp: 128 - 130 °C; 1H NMR (400 MHz) δH 7.36-7.41 (5H, m, Ar-H); 4.19 (2H, s, 1-H2); 3.06-3.08 (4H, m, N-
(CH2)2); 1.51-1.54 (6H, m, (-CH2)3; 13C NMR (100 MHz) C 130.7 (2 x Ar-CH); 129.1 (1 x Ar-C); 128.7 (2 x Ar-
CH); 128.6 (1 x Ar-CH); 56.7 (1-CH2); 46.9 (N-CH2)2); 25.8 (CH2)2); 23.7 (CH2); max (solid, cm-1) 1158 & 1335 
(sulfonamide S=O); m/z (ESI+) calculated for C12H17NO2S [M+H]+ 240.1053, found [M-SO2+H]+ 176.1429. 
 
1-[(1-Phenylbut-3-en-1-yl)sulfonyl]piperidine (99i) 
 
1-(benzylsulfonyl)piperidine (119 mg, 0.5 mmol) and allyl acetate (57 mg, 0.55 mmol) was reacted following 
general procedure A, to yield 1-[(1-phenylbut-3-en-1-yl)sulfonyl]piperidine as a colourless solid (107 mg, 77 
%); RF = 0.42 (95:5 toluene:EtOAc); mp: 78 - 80 °C;   1H NMR (400 MHz, CDCl3); δH 7.34-7.41 (5H, m, Ar-H); 
5.53 (1H, ddt J 6.9 Hz 10.0 Hz 13.9 Hz, 3-H); 5.00 (1H, dd J 1.4 Hz 17.0 Hz, 4-H); 4.95 (1H, d J 10.0 Hz, 4-
H); 3.06-3.12 (1H, m, 2-H); 2.97-3.03 (2H, m, 2’-CH2); 2.85-2.93 (1H, m, 2-H); 2.76 (2H, bs, 2’-CH2); 1.39-1.44 
(6H, m, 3’-(CH2)2, 4’-CH2); 13C NMR (100 MHz) C 133.4 (3-CH); 133.3 (1 x Ar-C); 129.7 (2 x Ar-CH); 128.8 (1 
x Ar-CH); 128.6 (2 x Ar-CH); 118.1 (4-CH2); 67.7 (1-CH); 46.9 (2’-(CH2)2); 34.5 (2-CH2); 25.9 (3’(CH2)2); 23.7 
(4’-CH2); max (solid, cm-1) 1132 & 1276 (sulfonamide S=O); m/z (ESI+) calculated for C15H21NO2S [M+K]+; 
318.0925, found 318.0926. 
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1-(Benzylsulfonyl)-1,2,5,6-tetrahydropyridine (96) 
 
To an oven-dried 100 mL round bottomed flask, 1,2,5,6-tetrahydropyridine (1 mL, 11 mmol, 1 eq) and 
triethylamine (1.55 mL, 11 mmol, 1 eq) was dissolved in CH2Cl2 (20 mL) and cooled to –20 °C. To this, 
phenylmethanesulfonylchloride (2.09 g, 11 mmol, 1 eq) in CH2Cl2 (10 mL) was slowly added. The reaction 
mixture was allowed to warm to room temperature and stir for six hours, after which aqueous NH4Cl (3 mL) 
was added. The mixture was extracted with CH2Cl2 (50 mL), washing with water (3 x 25 mL) and brine (25 
mL). The organic extracts were combined, dried over MgSO4, filtered and the filtrate concentrated in vacuo to 
yield 1-(benzylsulfonyl)-1,2,5,6-tetrahydropyridine as a beige solid (2.11 g, 81 %); mp: 148 - 150 °C; 1H NMR 
(400 MHz CDCl3)H 7.36-7.41 (5H, m, Ar-H); 5.76-5.82 (1H, m, 4-H); 5.57-5.61 (1H, m, 3-H); 4.23 (2H, s, 1’-
H); 3.65 (2H, dt J 6.6 Hz 6.8 Hz, 2-H2); 3.21 (2H, t J 5.7 Hz, 6-H2); 2.04-2.09 (2H, m, 5-H2); 13C NMR (100 
MHz) C 130.7 (2 x Ar-CH); 129.1 (1 x Ar-C); 128.7 (1 x Ar-CH); 128.6 (2 x Ar-CH); 125.4 (4-CH); 123.3 (3-
CH); 57.1 (1’-CH2); 44.7 2-CH2); 42.6 (6-CH2); 25.5 (5-CH2); max (solid, cm-1) 1149 & 1323 (sulfonamide S=O); 
m/z (ESI+) calculated for C12H15NO2S [M+H]+; 238.0896, found 238.0894. 
 
1-([1-Phenylbut-3-en-1-yl]sulfonyl)-1,2,5,6-tetrahydropyridine (99j) 
 
1-(Benzylsulfonyl)-1,2,5,6-tetrahydropyridine (116 mg, 0.5 mmol, 1 eq) and allyl acetate (63 mg, 0.55 mmol, 
1.1 eq) was reacted following the general procedure A, to yield 1-([1-phenylbut-3-en-1-yl]sulfonyl)-1,2,3,6-
tetrahydropyridine (113 mg, 82 %) as an orange oil; RF  = 0.50 (95:5 Toluene:EtOAc); 1H NMR (400 MHz 
CDCl3) H 7.34-7.41 (5H, Ar-H); 5.68-5.71 (1H, m, 4-H); 5.52-5.58 (1H, m, 3’-H); 5.47-5.51 (1H, m, 5-H); 5.04 
(1H, dd J 1.1 Hz 17.0 Hz, 4’-H); 4.95 (1H, d J 10.0 Hz, 4’-H); 4.11 (1H, dd J 4.1 Hz 11.0 Hz, 1’-H); 3.61 (1H, 
dt J 2.5 Hz 5.1 Hz, 6-H); 3.35-3.36 (1H, m, 6-H); 3.06-3.14 (2H, m, 2’-H, 3-H); 2.87-2.95 (2H, m, 2’-H, 3-H); 
2.04-2.00 (1H, m, 2-H); 1.84-1.88 (1H, m, 2-H); 13C NMR (100 MHz) C 133.3 (3’-CH); 133.1 (1 x Ar-C); 129.7 
(2 x Ar-CH); 128.8 (1 x Ar-CH); 128.7 (2 x Ar-CH); 125.2 (5-CH); 123.3 (4-CH); 118.2 (4’-CH2); 67.8 (1’-CH); 
44.7 (6-CH2); 42.7 (3-CH2); 34.3 (2’-CH2); 25.6 (2-CH2); max (oil, cm-1) 1144 & 1309 (sulfonamide S=O); 920 
(mono-substituted alkene); m/z (ESI+) calculated for C15H19NO2S [M+Na]+; 300.1029, found 300.1029. 
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1-(Benzylsulfonyl)pyrrolidine (97) 
 
To an oven-dried 100 mL round bottom flask, pyrrolidine (1.1 mL, 13.3 mmol, 1 eq) and triethylamine (1.9 mL, 
13.3 mmol, 1 eq) was dissolved in CH2Cl2 (20 mL) and cooled to –20 °C. To this, 
phenylmethanesulfonylchloride (2.53 g, 13.3 mmol, 1 eq) was slowly added over ten minutes at –20 °C. The 
reaction mixture was allowed to warm to room temperature and stir for six hours. Aqueous NH4Cl (3 mL) was 
added to the reaction and extracted in CH2Cl2 (3 x 25 mL). The organic layer was washed with water (2 x 25 
mL) and brine (25 mL) successively, dried over MgSO4 and the solvent was evaporated to dryness to yield 1-
(benzylsulfonyl)pyrrolidine as a colourless solid (1.84 g, 61 %); mp: 82 - 84 °C; 1H NMR (400 MHz) δH 7.36-
7.41 (5H, m, Ar-H); 4.26 (2H, s, 1-CH2); 3.15 (4H, t J 6.7 Hz, (N-CH2)2); 1.80 (4H, dt J 3.5 Hz 6.7 Hz, (CH2)2); 
13C NMR (100 MHz) σC 137.3 (1 x Ar-C); 130.6 (2 x Ar-CH); 128.7 (1 x Ar-CH); 128.6 (2 x Ar-CH); 56.5 (1-
CH2); 48.1 (N-(CH2)2); 25.9 (-CH-2)2)  max (solid, cm-1) 1139 & 1323 (sulfonamide S=O); m/z (ESI+) calculated 
for C11H15NO2S [M+H]+ 226.0896, found [M+H-SO2]+ 162.1272. 
 
1-[(1-Phenylbut-3-en-1-yl)sulfonyl]pyrrolidine (99k) 
 
1-(benzylsulfonyl)pyrrolidine (112 mg, 0.5 mmol) and allyl acetate (57 mg, 0.55 mmol) was reacted following 
general procedure A to yield 1-[(1-phenylbut-3-en-1-yl)sulfonyl]pyrrolidine as a colourless solid (109 mg, 83 
%); RF = 0.48 (95:5 toluene:EtOAc); 1H NMR (400 MHz) δH 7.35-7.41 (5H, m, Ar-H); 5.56 (1H, ddt J 7.0 Hz 
10.0 Hz 140 Hz, 3-H); 5.06 (1H, dd J 1.3 Hz 17.0 Hz, 4-H); 4.97 (1H, dd J 10.0 Hz 1.3 Hz, 4-H); 4.18 (1H, dd 
J 4.0 Hz 11.2 Hz, 1-H); 3.14-3.32 (2H, m, 2’-CH2); 3.10 (1H, m, 2-H); 2.94 (1H, m, 2-H); 2.79-2.84 (2H, m, 2’-
CH2); 1.62-1.73 (4H, m, 3’-(CH2)2); 13C NMR (100 MHz) σC 133.5 (3-CH); 133.4 (1 x Ar-C); 129.7 (2 x Ar-CH); 
128.8 (1 x Ar-CH); 128.6 (2 x Ar-CH); 118.1 (4-CH2); 67.1 (1-CH); 48.1 (2’-(CH2)2); 34.0 (2-CH2); 25.8 (3;-
(CH2)2); max (solid, cm-1) 1107 & 1334 (sulfonamide S=O); m/z (ESI+) calculated for C14H19NO2S [M+K]+; 
304.0768, found 304.0769. 
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N-Methoxy-N-methyl-1-phenylmethanesulfonamide (98) 
 
To an oven dried 150 mL round bottom flash, phenylmethanesulfonylchloride (5.0 g, 26 mmol, 1 eq) and N,N-
dimethylhydroxylamine (3.06 g, 31 mmol, 1.2 eq) was dissolved in CH2Cl2 (70 mL) and cooled to 0 °C. To this, 
triethylamine (8.0 mL, 57 mmol, 2.2 eq) was slowly added with stirring. The reaction mixture was allowed to 
warm to room temperature and stir for overnight before washing with H2O (2x 50 mL), dried over MgSO4, 
filtered and the filtrate evaporated to dryness to give a yellow solid. The solid was purified by column 
chromatography (5:1 Hexane:EtOAc) to yield  N-Methoxy-N-methyl-1-phenylmethanesulfonamide as a cream 
solid (3.0 g, 53 %); RF = 0.33 (5:1 Hexane:EtOAc); mp: 73 - 77 °C;   1H NMR (400 MHz, CDCl3); 7.38-7.47 
(5H, m, Ar-H); 4.37 (2H, s, 1-H2); 3.84 (3H, s, O-CH3); 2.98 (3H, s, N-CH3); 13C NMR (100 MHz) C 131.2 (2 x 
Ar-CH); 128.9 (3 x Ar-CH); 127.2 (Ar-C); 63.7 (O-CH3); 50.6 (1-CH2); 39.1 (N-CH3); max (solid, cm-1) 1339 & 
1153 (sulfonamide S=O); m/z (ESI+) calculated for C9H13NO3S [M+NH4]+ 233.0954, found 233.0948.      
 
N-Methoxy-N-methyl-4-phenylhepta-1,6-diene-4-sulfonamide (99l) 
 
N-Methoxy-N-methyl-1-phenylmethanesulfonamide (109 mg, 0.5 mmol, 1 eq) and allyl acetate (57 mg, 0.5 
mmol 1.1 eq) was reacted following general procedure A to yield N-Methoxy-N-methyl-4-phenylhepta-1,6-
diene-4-sulfonamide as a yellow oil ( mg, 34 %); RF = 0.6 (toluene:EtOAc 95:5); 1H NMR (400 MHz, CDCl3) H 
7.69-7.72 (2H, m, Ar-H); 7.35-7.42 (3H, m, Ar-H); 5.87 (2H, ddt J 6.9 Hz 10.2 Hz 13.9 Hz, 2-H, 6-H); 5.20 (2H, 
dd J 1.5 Hz 17 Hz, 1-Htrans, 7-Htrans); 5.15 (2H, dd J 1.5 Hz 10.2 Hz, 1-Hcis, 7-Hcis); 3.66 (3H, s, O-CH3); 3.42 
(2H, dd J 6.9 Hz 15 Hz, 3-H, 5-H); 3.18 (2H, dd J 6.9 Hz 15 Hz, 3-H, 5-H); 2.23 (3H, s, N-CH3); 13C  NMR (100 
MHz) δC 134.5 (Ar-C); 132.1 (2-CH, 6-CH); 129.7 (2 x Ar-CH); 128.8 (Ar-CH); 128.3 (2 x Ar-CH); 119.5 (1-CH2, 
7-CH2); 73.1 (4-C); 63.4 (O-CH3); 38.7 (N-CH3); 37.5 (3-CH2, 5-CH2); max (oil, cm-1) 1334 & 1150 (sulfonamide 
S=O); m/z (ESI+) calculated for C15H21NO3S [M+K]+ 334.0874, found 334.0875. 
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N-Methoxy-N-1-phenylbut-3-ene-1-sulfonamide (100a) 
 
N-Methoxy-N-methyl-1-phenylmethanesulfonamide (108 mg, 0.5 mmol, 1 eq) and allyl acetate (57 mg, 0.55 
mmol, 1.1 eq) was reacted following the general procedure B, to yield N-methoxy-N-1-phenylbut-3-ene-1-
sulfonamide (73 mg, 57 %) as a colourless oil; RF = 0.55 (Petrol:EtOAc 95:5); 1H NMR (400 MHz CDCl3)H 
7.43-7.46 (2H, m, Ar-H); 7.33-7.37 (3H, m, Ar-H); 5.51 (1H, ddt J 6.9 Hz 10.1 Hz 14.0 Hz, 3-H); 5.04 (1H, dd 
J 1.3 Hz 17.0 Hz, 4-Ha); 4.97 (1H, bd J 10.1 Hz, 4-Hb); 4.62 (1H, dd J 3.9 Hz 11.5 Hz, 1-H); 3.74 (3H, s, O-
CH3); 3.10-3.18 (1H, m, 2-H); 2.88-2.96 (1H, m, 2-H); 2.53 (3H, s, N-CH3); 13C NMR (100 MHz) C 132.8 (3-
CH); 132.2 (1 x Ar-C); 130.2 (2 x Ar-CH); 129.0 (1 x Ar-CH); 128.7 (2 x Ar-CH); 118.6 (4-CH2); 63.7 (1-CH); 
63.5 (O-CH3); 38.9 (N-CH3); 34.5 (2-CH2); max (oil, cm-1) 1341 & 1145 (sulfonamide S=O); m/z (ESI+) 
calculated for C12H17NO3S [M+Na]+; 278.0821, found 278.0822. 
 
(E)-N-Methoxy-N-methyl-1-phenylpent-3-ene-1-sulfonamide (100b) 
 
N-Methoxy-N-methyl-1-phenylmethanesulfonamide (109 mg, 0.5 mmol) and crotyl acetate (63 mg, 0.55 mmol) 
was reacted following the general procedure B to yield N-methoxy-N-1-phenylbut-3-ene-1-sulfonamide (73 
mg, 57 %) as a colourless oil; RF = 0.5 (Petrol:EtOAc 95:5); 1H NMR (400 MHz CDCl3)H 7.33-7.48 (5H, m, 
Ar-H); 5.48 (1H, dt J 6.5 Hz 13 Hz, 4-H); 5.03-5.16 (1H, m, 3-H); 4.57 (1H, dd J 3.8 Hz 11.4 Hz, 1-H); 3.74 
(3H, m, O-H3); 3.03-3.13 (1H, m, 2-H); 2.82-2.97 (1H, m, 2-H); 2.53 (3H, s, N-H3); 1.52-1.56 (3H, m, 5-H3); 13C 
NMR (100 MHz) C 132.4 (1 x Ar-C); 130.2 (2 x Ar-CH); 129.3 (4-CH); 129.1 (1 x Ar-CH); 128.6 (2 x Ar-CH); 
125.1 (3-CH); 64.2 (1-CH); 63.5 (O-CH3); 38.7 (N-CH3); 33.4 (2-CH2); 17.9 (5-CH3); m/z (ESI+) calculated for 
C13H19NO3S [M+Na]+ 292.0978, found 292.0978. 
 
(E)-N-Methoxy-N-methyl-1-phenylhept-3-ene-1-sulfonamide (100c) 
 
N-Methoxy-N-methyl-1-phenylmethanesulfonamide (109 mg, 0.5 mmol, 1 eq) and (E)-2-hexenyl acetate (78 
mg, 0.55 mmol, 1.1 eq) was reacted following the general procedure B to yield N-methoxy-N-1-phenylbut-3-
ene-1-sulfonamide (73 mg, 57 %) as a colourless oil; RF = 0.6 (Petrol:EtOAc 95:5); 1H NMR (400 MHz 
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CDCl3)H 7.42-7.44 (2H, m, Ar-H); 7.34-7.36 (3H, m, Ar-H); 5.39-5.49 (1H, m, 4-H); 5.09 (1H, dt J 7 Hz 14 Hz, 
4-H); 4.58 (1H, dd J 3.8 Hz 11.5 Hz, 1-H); 3.75 (3H, s. O-CH3); 3.04-3.10 (1H, m, 2-H); 2.82-2.90 (1H, m, 2-
H); 2.54 (3H, s, N-CH3); 1.79-1.84 (2H, m, 5-H2); 1.17-1.25 (2H, m, 6-H2); 0.71 (3H, t J 7.6 Hz, 7-H3); 13C NMR 
(100 MHz) C 134.9 (4-CH); 132.4 (1 x Ar-C); 130.2 (2 x Ar-CH); 128.9 (1 x Ar-CH); 128.9 (2 x Ar-CH); 64.2 
(1-CH); 63.5 (O-CH3); 38.9 (N-CH3); 34.4 (5-CH2); 33.4 (2-CH2); 22.3 (6-CH2); 13.4 (7-CH3); ); m/z (ESI+) 
calculated for C15H23NO3S [M+Na]+ 320.1291, found 315.1747. 
 
(E)-N-Methoxy-N,4,8-trimethyl-1-phenylnona-3,7-diene-1-sulfonamide (100d) 
 
N-Methoxy-N-methyl-1-phenylmethanesulfonamide (109 mg, 0.5 mmol, 1 eq) and neryl acetate (108 mg, 0.55 
mmol, 1.1 eq) was reacted following the general procedure B to yield (E)-N-methoxy-N,4,8-trimethyl-1-
phenylnona-3,7-diene-1-sulfonamide as a yellow oil (118 mg, 67 %); RF = 0.45 (Petrol:EtOAc 95:5); 1H NMR 
(400 MHz CDCl3)H 7.43-7.46 (2H, m, Ar-H); 7.34-7.36 (3H, m, Ar-H); 5.06-5.07 (1H. m, 7-H2); 4.83 (1H, app 
t J 6.9 Hz, 3-H); 4.51 (1H, dd J 3.8 Hz 11.6 Hz, 1-H); 3.74 (3H, s, O-CH3); 3.09-3.15 (1H, m, 2-H); 2.83-2.89 
(1H, m, 2-H); 2.53 (3H, s, N-CH3); 1.92-2.04 (4H, m, 5-H2, 6-H2); 1.70 (3H, s, 8-CH3); 1.60 (3H, s, 8-CH3); 1.57 
(3H, s, 4-CH3); 13C NMR (100 MHz) C 139.0 (1 x Ar-C); 132.6 (4-C); 131.9 (8-C); 130.2 (2 x Ar-CH); 128.9 (1x 
Ar-CH); 128.6 (2 x Ar-CH); 123.9 (7-CH); 119.0 (3-CH); 64.3 (1-CH); 63.4 (O-CH3); 38.9 (N-CH3); 32.0 (5-
CH2); 28.6 (2-CH2); 26.3 (6-CH2); 25.7 (8-CH3); 23.3 (4-CH3); 17.7 (8-CH3); max (oil, cm-1) 1334 & 1143 (S=O); 
m/z (ESI+) calculated for C19H29NO3S [M+NH4]+; 369.2206, found 369.2199. 
 
1-(Cyclohex-2-en-1-yl)-N-methoxy-N-methyl-1-phenylmethanesulfonamide (100e) 
 
N-Methoxy-N-methyl-1-phenylmethanesulfonamide (109 mg, 0.5 mmol, 1 eq) and cyclohex-2-en-1yl acetate 
(147 mg, 0.5 mmol, 1 eq) was reacted following the general procedure B to yield 1-(Cyclohex-2-en-1-yl)-N-
methoxy-N-methyl-1-phenylmethanesulfonamide (d.r 62:38 determined by 1H NMR) (44 mg, 30 %); RF = 0.6 
(toluene:EtOAc 95:5); 1H NMR (400 MHz CDCl3)H 7.34-7.48 (5H, m, Ar-H); 5.76 (2H, app bs, 2-H2, 3-H2); 
4.56 (1H, d J 6.7 Hz, 1’-H); 3.73 (3H, s, O-CH3); 3.31-3.34 (1H, m, 1-H); 2.39 (3H, s, N-CH3); 1.89-1.99 (2H, 
m, 4-H, 6-H); 1.47-1.88 (3H, m, 4-H, 5-H2); 1.36-1.45 (1H, m, 6-H); 13C NMR (100 MHz) C 131.9 (1 x Ar-C); 
130.7 (2 x Ar-CH); 130.3 (3-CH); 129.3 (1 x Ar-CH); 128.9 (2 x Ar-CH); 126.5 (2-CH); 67.8 (1’-CH); 63.6 (O-
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CH3); 38.9 (N-CH3); 37.4 (1-CH); 27.8 (6-CH2); 24.7 (4-CH2); 21.9 (5-CH2); m/z (ESI+) calculated for 
C15H21NO3S [M+Na]+ 318.1134, found 318.1140. 
 
N-Methoxy-N,3-dimethyl-1-phenylbut-3-ene-1-sulfonamide (100f) 
 
N-Methoxy-N-methyl-1-phenylmethanesulfonamide (108 mg, 0.5 mmol, 1 eq) and 2-methyl allyl acetate (63 
mg, 0.5 mmol, 1 eq) was reacted following the general procedure B to yield N-Methoxy-N,3-dimethyl-1-
phenylbut-3-ene-1-sulfonamide as a yellow oil (91 mg, 67 %); RF = 0.58 (Petrol:EtOAc 95:5); 1H NMR (400 
MHz CDCl3)H 7.44-7.46 (2H, m, Ar-H); 7.34-7.36 (3H, m, Ar-H); 4.79 (1H, dd J 3.5 Hz 12.2 Hz, 1-H); 4.67 
(1H, d J 1.1 Hz, 3’-H); 4.61 (1H, app s, 3’-H); 3.76 (3H, O-CH3); 3.09 (1H, dd J 3.5 Hz 14 Hz, 2-H); 2.92 (1H, 
dd J 12.2 Hz 14 Hz, 2-H); 2.52 (3H, s, N-CH3); 1.62 (3H, s, 4-H3); 13C NMR (100 MHz) C 139.8 (3-C); 132.2 
(1 x Ar-C); 130.2 (Ar-CH); 129.0 (Ar-CH); 128.6 (Ar-CH); 114.7 (3’-CH2); 63.5 (O-CH3); 62.7 (1-CH); 38.9 (N-
CH3); 37.8 (2-CH2); 22.2 (4-CH3); m/z (ESI+) calculated for C13H19NO3S [M+Na]+; 292.0978, found 292.0981. 
 
(E)-N-Methoxy-N-methyl-1,4-diphenylbut-3-ene-1-sulfonamide (100g) 
 
N-Methoxy-N-methyl-1-phenylmethanesulfonamide (108 mg, 0.5 mmol) and cinnamyl acetate (88mg, 0.5 
mmol, 1 eq) was reacted following the general procedure B to yield (E)-N-methoxy-N-methyl-1,4-diphenylbut-
3-ene-1-sulfonamide as a yellow oil (98 mg, 60 %); 1H NMR (400 MHz CDCl3)H 7.19-7.50 (10H, m, Ar-H); 
6.43 (1H, d J 15.7 Hz, 4-H); 5.91 (1H, dt J 7.3 Hz 15.7 Hz, 3-H); 4.71 (1H, dd J 3.8 Hz 11.2 Hz, 1-H); 3.77 (3H, 
s, O-CH3); 3.27-3.34 (1H, m, 2-H); 3.06-3.14 (1H, m, 2-H); 2.56 (3H, s, N-CH3); 13C NMR (100 MHz) C 136.9 
(1 x Ar-C); 133.6 (4-CH); 132.2 (1 x Ar-C); 130.2 (2 x Ar-CH); 129.2 (1 x Ar-CH); 128.8 (2 x Ar-CH); 128.4 (2 
x Ar-CH); 127.4 (1 x Ar-CH); 126.2 (2 x Ar-CH); 124.3 (3-CH); 63.9 (O-CH3); 63.5 (1-CH); 38.9 (N-CH3); 33.9 
(2-CH2);  m/z (ESI+) calculated for C18H21NO3S [M+Na]+; 354.1134, found 354.1141. 
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N-Methyl-1-phenylmethanesulfonamide (101) 
 
Methylamine solution (5.25 mL, 2M, 10.5 mmol, 1 eq) was added slowly to a solution of phenylmethanesulfonyl 
chloride (2.0 g, 10.5 mmol, 1 eq) and triethylamine (1 mL, 10.5 mmol, 1 eq) in CH2Cl2 (50 mL) at 0 °C. The 
reaction was allowed to warm to room temperature and left for overnight. The organic layer was subsequently 
extracted from the aqueous, washing the organic layer with water (3 x 50 mL). The organic extracts were 
combined, dried over MgSO4 and evaporated to dryness to yield N-Methyl-1-phenylmethanesulfonamide as a 
colourless solid (980 mg, 50 %); 1H NMR (400 MHz CDCl3)H 7.39-7.40 (5H, m, Ar-H); 4.26 (2H, s, 2-H2); 4.00 
(1H, bs, N-H); 2.71 (3H, s, N-CH3); 13C NMR (100 MHz) C 130.5 (2 x Ar-CH); 129.4 (1 x Ar-C); 128.9 (2 x Ar-
CH); 128.8 (1 x Ar-CH); 57.7 (2-CH2); 29.8 (N-CH3); max (solid, cm-1) 3289 (broad, N-H) 1298 & 1090 
(sulfonamide S=O); m/z (ESI+) calculated for C8H11NO2S [M+Na]+ 208.0403, found 208.0404. 
 
N-Allyl-N-methyl-1-phenylbut-3-ene-1-sulfonamide (102) 
 
N-Methyl-1-phenylmethanesulfonamide (516 mg, 2.8 mmol, 1 eq) and allyl acetate (600 mg, 5.6 mmol, 2 eq) 
was reacted following general procedure A to yield N-Allyl-N-methyl-1-phenylbut-3-ene-1-sulfonamide as a 
yellow oil (690 mg, 93 %); RF = 0.3 (petrol:EtOAc 9:1); 1H NMR (400 MHz CDCl3)H 7.36-7.41 (5H, m, Ar-H); 
5.48-5.59 (2H, m, 3-H, 3’-H); 5.10-5.13 (2H, m, 4’-H2); 4.95-5.10 (2H, m, 4-H2); 4.12 (1H, dd J 4.10 Hz 11.2 
Hz, 1-H); 3.45 (1H, dd J 6.2 Hz 15.2 Hz, 2’-H); 3.22-3.25 (1H, m, 2’-H); 3.06-3.13 (1H, m, 2-H); 2.88-2.96 (1H, 
m, 2-H); 2.51 (3H, s, 1’-CH3); 13C NMR (100 MHz) C 133.3 (3’-CH); 133.2 (3-CH); 129.7 (2 x Ar-CH); 128.9 
(Ar-CH); 128.7 (2 x Ar-CH); 118.5 (4’-CH2); 118.2 (4-CH2); 67.7 (1-CH); 53.0 (2’-CH2); 34.3 (2-CH2, 1’-CH3); 
m/z (ESI+) calculated for C14H19NO2S [M+Na]+ 288.1029, found 288.1020. 
 
2-Methyl-7-phenyl-2,3,6,7-tetrahydro-1,2-thiazepene 1,1-dioxide (103) 
 
To an oven dried 10 mL round bottom flask, N-allyl-N-methyl-1-phenylbut-3-ene-1-sulfonamide (44 mg, 0.17 
mmol) was added to a solution of Grubbs 2nd generation catalyst (7 mg, 0.09 mmol, 0.05 eq) in CH2Cl2 (5 mL). 
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The reaction was allowed to stir at room temperature for 16 hours, after which the reaction mixture was 
evaporated to dryness. The crude mixture was purified by column chromatography to yield 2-Methyl-7-phenyl-
2,3,6,7-tetrahydro-1,2-thiazepene 1,1-dioxide (40 mg, 55 %); RF = 0.5 (petrol:EtOAc 9:1); 1H NMR (400 MHz 
CDCl3)H 7.33-7.42 (5H, m, Ar-H); 6.17-6.23 (1H, m, 4-H); 6.00-6.07 (1H, m, 5-H); 4.28 (1H, dd J 5.2 Hz 16.3 
Hz, 3-H); 3.90 (1H, dd J 1.2 Hz 12 Hz, 7-H); 3.53 (1H, dd J 6.6 Hz 16.3 Hz, 3-H); 3.11-3.19 (1H, m, 6-H); 2.89 
(3H, s, 2-CH3); 2.59 (1H, ddd J 1.2 Hz 9.0 Hz 10.2 Hz, 6-H); 13C NMR (100 MHz) C 133.9 (Ar-C); 132.9 (4-
CH); 130.0 (5-CH); 129.4 (2 x Ar-CH); 128.7 (2 x Ar-CH); 128.5 (Ar-CH); 63.2 (7-CH); 46.3 (3-CH2); 35.2 (2-
CH3); 29.8 (6-CH2); m/z (ESI+) calculated for C12H15NO2S [M+NH4]+ 255.1162, found 255.1162. 
 
1-(3-Fluorobenzyl)piperazine168  
 
3-Fluorobenzyl bromide (1.23 mL) was reacted following general procedure C.1 to yield tert-butyl 4(3-
fluorobenzyl)piperazine-1-carboxylate as an orange oil (1.43 g, 74 %); 1H NMR (400 MHz CDCl3) H 7.24-7.30 
(1H, m, Ar-H); 7.05-7.09 (2H, m, Ar-H); 6.95 (1H, td JHF 2.0 Hz 8.3 Hz, 2-H); 3.49 (2H, s, 1’-CH2); 3.43 (4H, t 
J 4.8 Hz, N-(CH2)2); 2.38 (4H, t J 4.8 Hz, N-(CH2)2); 1.45 (9H, s, C-(CH3)3). 
Tert-butyl 4(3-fluorobenzyl)piperazine-1-carboxylate (1.43 g, 4.8 mmol) was reacted following general 
procedure C.2 to yield 1-(3-fluorobenzyl)piperazine as an orange solid (0.93 g, 65 %); 1H NMR (400 MHz, 
CDCl3) H 7.07-7.13 (1H, Ar-H); 6.39-6.95 (2H, m, Ar-H); 6.78 (1H, td J 1.6 Hz 8.3 Hz, 2-H); 3.32 (2H, s, 1’-
H2); 2.73 (4H, t J 4.8 Hz, N-(CH2)2); 2.26 (4H, bs, N-(CH2)2); 2.03 (1H, bs, NH). 
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1-(4-Methoxybenzyl)piperazine168 
 
4-Methoxybenzyl chloride (1.35 mL) was reacted following general procedure C.1 to yield tert-butyl 4-(4-
methoxybenzyl)piperazine-1-carboxylate as a yellow oil (1.64 g, 82 %); 1H NMR (400 MHz CDCl3) H 7.22 (2H, 
app d J 8.5 Hz, Ar-H); 6.85 (2H, app d J 8.5 Hz, Ar-H); 3.80 (3H, s, O-CH3); 3.45 (2H, s, 1’-H2); 3.40-3.43 (4H, 
m, N-(CH2)2); 2.35-2.38 (N-(CH2)2); 1.45 (9H, s, C-(CH3)3). 
Tert-butyl 4-(4-methoxybenzyl)piperazine-1-carboxylate (1.5 g, 8.1 mmol) was reacted following general 
procedure C.2 to yield 1-(4-methoxybenzyl)piperazine as a yellow oil (0.84 g, 50 %); 1H NMR (400 MHz CDCl3) 
H 7.23 (2H, app d J 8.5 Hz, Ar-H); 6.85 (2H, app d J 8.5 Hz, Ar-H); 3.80 (3H, s, O-CH3); 3.43 (2H, s, 1’-H2); 
2.88 (4H, t J 4.9 Hz, N-(CH2)2); 2.39 (4H, bs, N-(CH2)2); 1.72 (1H, bs, NH). 
 
1-(3-Methylbenzyl)piperazine168 
 
3-Methylbenzyl bromide (1.35 mL) was reacted following general procedure C.1 to yield tert-butyl 4-(3-
methylbenzyl)piperazine-1-carboxylate as a yellow oil (1.48 g, 77 %);  1H NMR (400 MHz CDCl3) H 7.19-7.23 
(1H, m, Ar-H); 7.06-7.13 (3H, m, Ar-H); 3.47 (2H, s, 1’-H2); 3.43 (4H, t J 4.9 Hz, N-(CH2)2); 2.38 (4H, t J 4.9 
Hz, N-(CH2)2); 2.34 (3H, s, Ar-CH3); 1.45 (9H, s, C-(CH3)3). 
4-(3-Methylbenzyl)piperazine-1-carboxylate (1.48 g, 5.1 mmol) was reacted following general procedure C.2 
to yield 1-(3-methylbenzyl)piperazine as a colourless solid (0.97 g, 77 %); 1H NMR (400 MHz CDCl3) H 7.20 
(1H, t J 7.5 Hz, Arortho-H); 7.05-7.14 (3H, m, Ar-H); 3.45 (2H, s, 1’-H2); 2.89 (4H, t J 4.9 Hz, N-(CH2)2); 2.41 
(2H, bs, N-H, N-(CH2); 2.34 (3H, s, Ar-CH3); 2.19 (2H, bs, N-(CH2). 
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1-Benzyl-4-(benzylsulfonyl)piperazine (64a) 
 
1-benzylpiperazine (1 g, 5.7 mmol, 1 eq) was reacted following general procedure D to yield 1-benzyl-4-
(benzylsulfonyl)piperazine as a colourless solid (1.45 g, 77 %); mp: 125 - 129 °C; 1H NMR (400 MHz CDCl3) 
H 7.36-7.40 (5H, m, Ar-H); 7.26-7.32 (5H, m, Ph-H); 4.20 (2H, s, 1-H2); 3.49 (2H, s, 4’-H2); 3.15 (4H, t J 4.7 
Hz, 2’-H2); 2.41 (4H, t J 4.7 Hz, 3’-H2); 13C NMR (100 MHz) C 137.4 (1 x Ar-C); 131.6 (1 x Ar-C); 130.8 (2 x 
Ar-CH); 129.1 (2 x Ar-CH); 128.8 (2 x Ar-CH); 128.7 (1 x Ar-CH); 128.3 (2 x Ar-CH); 127.3 (1 x Ar-CH); 62.7 
(4’-CH2); 56.7 (1-CH2); 52.7 (2’-(CH2)2); 46.0 (3’-(CH2)2);max (solid, cm-1) 1147 & 1340 (sulfonamide S=O); 
m/z (ESI+) calculated for C18H22N2O2S [M+H]+; 331.1475, found 331.1476. 
 
1-Benzyl-4-([1-phenylbut-3-en-1-yl]sulfonyl)piperazine121 (104a) 
 
1-Benzyl-4-(benzylsulfonyl)piperazine (165 mg, 0.5 mmol, 1 eq) and allyl acetate (57 mg, 0.55 mmol, 1.1 eq) 
was reacted following the general procedure A, to yield 1-benzyl-4-((1-phenylbut-3-en-1-yl)sulfonyl)piperazine 
(141 mg, 76 %) as a colourless solid; RF = 0.45; mp: 74 - 78 °C; 1H NMR (400 MHz) H 7.36-7.39 (5H, m, Ar-
H); 7.23-7.31 (5H, m, Ar-H); 5.53 (1H, ddt J 7.0 Hz 10.0 Hz 14.0 Hz, 3’-H); 4.96 (1H, d J 10.2 Hz, 4’-H2); 4.07 
(1H, dd J 4.0 Hz 11.2 Hz, 1’-H); 3.44 (2H, bs, 1-H2); 3.05-3.13 (3H, m, 2’-H,3-H2); 2.85-2.94 (3H, m, 2’-H,3-
H2); 2.22-2.36 (4H, m, 2-H2); 13C NMR (100 MHz) C 137.4 (1 x Ar-C); 133.2 (3’-CH); 132.9 (1 x Ar-C); 129.8 
(2 x Ar-CH); 129.1 (2 x Ar-CH); 128.9 (1 x Ar-CH); 128.7 (2 x Ar-CH); 128.3 (2 x Ar-CH); 127.3 (1 x Ar-CH); 
118.2 (4’-CH2); 68.0 (1’-CH); 62.7 (1-CH2); 52.9 (2-CH2); 46.0 (3-CH2); 34.5 (2’-CH2); max (solid, cm-1) 1147 & 
1340 (sulfonamide S=O); 959 (mono-substituted alkene); m/z (ESI+) calculated for C21H26N2O2S [M+H]+; 
371.1788, found 371.1799. 
 
(E)-1-Benzyl-4-[(1-phenylhept-3-en-1yl)sulfonyl]piperazine (104b) 
 
1-Benzyl-4-(benzylsulfonyl)piperazine3 (165 mg, 0.5 mmol) and E-2-hexenyl acetate acetate (60 mg, 0.55 
mmol) was reacted following the general method, to yield  (E)-1-Benzyl-4-([1-phenylhept-3-en-1-
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yl]sulfonyl)piperazine (120 mg, 58 %) as a colourless solid; RF = 0.22 (95:5 toluene:EtOAC); 1H NMR (400 
MHz) H  7.34 (5H, m, Ar-H); 7.22-7.31 (5H, m, Ar-H); 5.38 -5.45 (1H, m, 4’-H); 5.05-5.13 (1H, m, 3’-H); 4.00 
(1H, dd J 3.9 Hz 11.2 Hz, 1’-H); 3.42 (2H, s, 1-H2); 2.99-3.08 (3H, m, 2’-H, N-CH2); 2.79-2.85 (3H, m, 2’H, N-
CH2); 2.22-2.32 (N-(CH2)2); 1.20 (2H, ddd J 2.4 Hz 7.4 Hz 9.8 Hz, 6’-H2); 0.74 (3H, t J 7’-H3); 13C NMR (100 
MHz) C  137.5 (Ar-C); 134.5 (4’-CH); 133.2 (Ar-CH); 129.8 (Ar-CH); 129.1 (Ar-CH); 128.8 (Ar-CH); 128.6 (Ar-
CH); 128.3 (Ar-CH); 127.2 (Ar-CH); 124.5 (3’-CH); 68.5 (1’-CH); 62.7 (1-CH2); 52.9 (N-(CH2)2); 46.0 (N-(CH2)2); 
34.4 (5’-CH2); 33.4 (2’-CH2); 22.3 (6’-CH2); 13.4 (7’-CH2); max (solid, cm-1) 1147 & 1340 (sulfonamide SO2); 
m/z (ESI+) calculated for C24H32N2O2S [M+H]+; 413.2257, found 413.2257.      
 
1-(Benzylsulfonyl)-4-(3-fluorobenzyl)piperazine121 (64b) 
 
Fluorobenzyl)piperazine (0.42 g, 2.1 mmol, 1 eq) was reacted following general procedure D to yield 1-
(benzylsulfonyl)-4-(3-fluorobenzyl)piperazine as a colourless solid (0.60 g, 90 %); mp: 125 - 129 °C; 7.36-7.39 
(5H, m, Ph-H); 7.25-7.30 (1H, m, Ar-H); 7.03-7.07 (2H, m, Ar-H); 6.94-6.99 (1H, m, Ar-H); 4.19 (2H, s, Ph-H2); 
3.54 (2H, s, 4-H2); 3.17-3.19 (4H, m, N-(CH2)2); 2.46 (4H, bs, N-(CH2)2); 13C NMR (100 MHz) C 162.9 (3’-CF, 
d JCF 246 Hz); 130.8 (2 x Ph-CH); 130.0 (5’-CH, d JCF 8.2 Hz); 128.9 (2 x Ph-CH); 128.8 (1 x Ph-H); 128.6 (Ph-
C); 124.9 (6’-CH, 1’-C); 116.0 (2’CH, d JCF 21.5 Hz); 114.6 (4’-CH, d JCF 21.5 Hz); 61.7 (4-CH2); 56.8 (Ph-CH2); 
52.5 (N-(CH2)2); 45.6 (N-(CH2)2); max (solid, cm-1) 1317 & 1155 (sulfonamide S=O); m/z (ESI+) calculated for 
C18H21FN2O2S [M+H]+; 349.1381, found 349.1381. 
 
1-(3-Fluorobenzyl)-4-([1-phenylbut-3-en-1-yl]sulfonyl)piperazine (104c) 
 
1-(Benzylsulfonyl)-4-(3-fluorobenzyl)piperazine (174 mg, 0.5 mmol) and allyl acetate (60 mg, 0.55 mmol) was 
reacted following the general procedure A to yield 1-(3-fluorobenzyl)-4-([1-phenylbut-3-en-1-
yl]sulfonyl)piperazine (130 mg, 67 %) as an orange oil; RF = 0.20 (95:5 toluene:EtOAc); 1H NMR (400 MHz, 
CDCl3) H 7.38-7.39m (5H, m, Ph-H); 7.17-7.27 (1H, m, Ar-H); 6.91-7.00 (3H, m, Ar-H); 5.54 (1H, ddt J 7.0 Hz 
9.9 Hz 17.0 Hz 3’-H); 5.0 (1H, d J 17 Hz, 4’-H); 4.96 (1H, d J 10.0 Hz, 4’-H); 4.08 (1H, dd J 3.9 Hz 11.0 Hz, 1’-
H2); 3.47 (2H, s, 1-H2); 3.06-3.16 (3H, m, 2’-H, N-CH2); 2.86-2.94 (2H, m, 2’-CH, N-CH2); 2.22-2.40 (4H, m, N-
(CH2)2); 13C NMR (100 MHz) C 164.1 (3’’-CF, d JCF 248 Hz); 161.7 (1 x Ph-C); 140.3 (4’’-CH, d JCF 6.7 Hz); 
117 
 
133.2 (2 x Ph-CH); 130.8 (1 x Ph-C); 129.0 (1 x Ph-CH); 128.7 (2 x Ph-CH); 124.5 (6’’-CH, d JCF 2.7 Hz); 118.3 
(4’-CH2); 115.7 (2’’-CH, d JCF 21.2); 114.3 (4’’-CH, d JCF 21.2); 68.1 (1’-CH); 62.1 (1-CH); 52.9 (N-(CH2)2); 45.9 
(N-(CH2)2); 34.2 (2’-CH2); max (oil, cm-1) 1486 (C-F); 1340 & 1140 (sulfonamide S=O); m/z (ESI+) calculated 
for C21H25FN2O2S [M+H]+; 389.1694, found 389.1695. 
 
1-(Benzylsulfonyl)-4-(3-methylbenzyl)piperazine121 (64d) 
 
1-(3-methylbenzyl)piperazine (0.80 g, 4.2 mmol, 1 eq) was reacted following general procedure D to yield 1-
(benzylsulfonyl)-4-(3-methylbenzyl)piperazine  (1.40 g, 57 %) as a yellow oil; 1H NMR (400 MHz CDCl3) H 
7.37-7.43 (5H, m, Ph-H); 7.20-7.28 (1H, m, Ar-H); 7.09-7.13 (2H, m, Ar-H); 4.02 (2H, s, Ph-H2); 3.48 (2H, s, 4-
H2); 3.18 (4H, t J 4.4 Hz, N-(CH2)2); 2.42-2.45 (4H, m, N-(CH2)2); 2.36 (3H, bs, 3’-H3); 13C NMR (100 MHz) C 
138.0 (1’-C); 130.8 (2 x Ph-CH); 130.0 (2 x Ar-CH); 128.8 (2 x Ph-CH); 128.7 (1 x Ph-CH); 128.3 (3’-C); 128.2 
(2 x Ar-CH); 126.5 (Ph-C); 126.4 (1 x Ar-CH); 62.6 (4-CH2); 56.6 (Ph-CH2); 52.7 (N-(CH2)2); 45.9 (N-(CH2)2); 
21.4 (3’-CH3); m/z (ESI+) calculated for C19H24N2O2S [M+H]+; 345.1631, found 345.1635.     
  
1-(3-Methylbenzyl)-4-([1-phenylbut-3-en-1-yl]sulfonyl)piperazine (104g) 
 
1-(Benzylsulfonyl)-4-(3-fluorobenzyl)piperazine (174 mg, 0.5 mmol, 1 eq) and allyl acetate (60 mg, 0.55 mmol, 
1.1 eq) was reacted following the general procedure A to yield 1-(3-methylbenzyl)4-([1-phenylbut-3-en-1-
yl]sulfonyl)piperazine (100 mg, 53 %) as an orange oil; RF = 0.35 (CH2Cl2:EtOAc 95:5); 1H NMR (400 MHz 
CDCl3) H 7.36-7.39 (5H, m, Ar-H); 7.20 (1H, t J 7.4 Hz, 3’’-H); 7.04-7.09 (3H, m, Ar-H); 5.54 (1H, ddt J 7.0 Hz 
10.0 Hz 13.9 Hz, 3’-H); 5.05 (1H, dd J 1.2 Hz 17.0 Hz, 4’-H); 4.96 (1H, bd J 10.5 Hz, 4’-H); 4.07 (1H, dd J 3.9 
Hz 11.2 Hz, 1’-H); 3.40 (2H, s, 1-H2); 3.05-3.12 (3H, m, 2’-H, N-H2); 2.85-2.93 (3H, m, 2-H, N-H2); 2.32-2.35 
(5H, s, Ar-CH3, N-H2); 2.23-2.28 (2H, m, N-H2); 13C NMR (100 MHz) C 137.9 (1’’-C); 137.2 (3’’-C); 133.2 (3-
CH); 129.9 (1 x Ar-CH); 129.7 (Ph-CH); 128.9 (Ph-CH); 128.7 (Ph-CH); 128.1 (1 x Ar-CH); 128.0 (1 x Ar-CH); 
126.3 (1 x Ar-CH); 118.2 (4-CH2); 68.1 (1-CH); 62.7 (Ar-CH2); 52.9 (N-(CH2)2); 45.9 (N-(CH2)2); 34.4 (2-CH2); 
21.4 (Ar-CH3); max (oil, cm-1) 1341 & 1145 (sulfonamide S=O);  m/z (ESI+) calculated for C22H28N2O2S [M+H]+; 
385.1944, found 385.1943. 
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1-(Benzylsulfonyl)-4-(4-methoxybenzyl)piperazine121 (64c) 
 
4-(methoxybenzyl)piperazine (0.62 g,  3.72 mmol, 1 eq) was reacted following general procedure D to yield 1-
(benzylsulfonyl)-4-(4-methoxybenzyl)piperazine (0.81 g, 75 %) as a colourless solid; m.p: 122 – 125 °C; 1H 
NMR (400 MHz, CDCl3) H 7.34-7.39 (5H, m, Ph-H); 7.19 (2H, app d J 8.4 Hz, Ar-H); 6.85 (2H, app d J 8.4 Hz, 
Ar-H); 4.18 (2H, s, Ph-H2); 3.78 (3H, s, O-CH3); 3.43 (2H, s, 4-H2); 3.14 (4H, t J 4.3 Hz, N-(CH2)2); 2.39 (4H, t 
J 4.3 Hz, N-(CH2)2); 13C NMR (100 MHz) C 158.9 (4’-C); 130.8 (2 x Ph-CH); 130.4 (2 x Ar-CH); 128.8 (Ar-C); 
128.8 (2 x Ph-CH); 128.7 (Ph-CH); 113.8 (2 x Ar-CH); 62.0 (4-CH2); 56.5 (Ph-CH2); 55.3 (O-CH3); 52.6 (N-
(CH2)2); 45.9 (N-(CH2)2); m/z (ESI+) calculated for C19H24NO3S [M+H]+ 361.1580, found 361.1567.        
 
1-(4-Methoxybenzyl)-4-([1-phenylbut-3-en-1yl]sulfonyl)piperazine (104h) 
 
1-(Benzylsulfonyl)-4-(4-methoxybenzyl)piperazine (180 mg, 0.5 mmol, 1 eq) and allyl acetate (58 mg, 0.55 
mmol, 1.1 eq) was reacted following the general procedure A to yield 1-(4-Methoxybenzyl)-4-([1-phenylbut-3-
en-1yl]sulfonyl)piperazine (71 mg, 37 %) as an orange oil; RF = 0.25 (CH2Cl2:MeOH 98:2); 1H NMR (400 MHz) 
H 7.34-7.43 (5H, m, Ph-H); 7.13 (2H, app d J 8.6 Hz, Ar-H); 6.83 (2H, dd J 1.9 Hz 6.7 Hz, Ar-H); 5.52 (1H, ddt 
J 7.1Hz 10.0 Hz 13.9 Hz, 3’-H); 5.02 (1H, dd J 1.7 Hz 17.1 Hz, 4-H); 4.96 (1H, dd J 1.2 Hz 10.4 Hz, 4-H); 3.78 
(3H, s, -OCH3); 3.36 (2H, s, 1-H2); 3.03-3.14 (2H, m, 2’-H, 3-H); 2.84-2.92 (2H, m, 2’-H, 3-H); 2.19-2.32 (4H, 
m,  2-(H2)2); 13C NMR (100 MHz) C 158.8 (C-OMe); 133.2 (3’-CH); 132.9 (1 x Ph-C); 130.3 (2 x Ar-CH); 129.7 
(2 x Ph-CH); 129.4 (1 x Ar-C); 128.9 (2 x Ph-CH); 128.7 (1 x Ph-CH); 118.2 (4’-CH2); 113.5 (2 x Ar-CH); 68.0 
(1’-CH); 62.1 (1-CH2); 55.3 (-OCH3); 52.7 (2-(CH2)2); 46.0 (2-(CH2)2); 34.5 (2’-CH2); max (oil, cm-1) 1339 & 
1150 (sulfonamide S=O).   
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Synthesis of 6-Oxabicyclo[3.2.1]oct-3-en-6-one169 (5) 
 
 
 
To an oven dried 500 mL round bottom flask, 3-cyclohexene carboxylic acid (15.3 g, 121 mmol, 1 eq) and 
NaHCO3 (30.2 g, 363 mmol, 3 eq) was added to H2O (100 mL) and stirred until homogenous and protected 
from light. After 20 minutes potassium iodide (120 g, 724 mmol, 6 eq) and iodine (32.1 g, 127 mmol, 1.05 eq) 
in H2O (300 mL) was added to the mixture in one portion. The reaction was allowed to stir at room temperature 
for overnight, after which the mixture was extracted with CHCl3 (3 x 500 mL), washed with 10 % Na2S2O3 (500 
mL), 10 % NaHCO3 (500 mL) and water (300 mL). The organic extracts were combined, dried over MgSO4, 
filtered and the filtrate was concentrated in vacuo to yield 4-iodo-6-oxabicyclo[3.2.1]octan-7-one (5) as a beige 
solid (28.4 g, 94 %). The product was used without further purification in the next step. 
To an oven dried 500 mL round bottom flask, 4-iodo-6-oxabicyclo[3.2.1]octan-7-one (22.5 g, 90 mmol, 1 eq) 
and DBU (20.1 mL, 135 mmol, 1.5 eq) was dissolved in dry benzene (250 mL). The reaction mixture was then 
heated to reflux for 16 hours, after which the mixture was cooled, filtered and the filtrate was concentrated in 
vacuo. The crude mixture was purified by column chromatography (CH2Cl2) to yield 6-oxabicyclo[3.2.1]oct-3-
en-6-one as a colourless oil (8.7 g, 78 %); RF = 0.4; 1H NMR (400 MHz CDCl3) H 6.22-6.26 (1H, m, 2-H); 5.84-
5.87 (1H, m, 3-H); 4.76 (1H, t J 5.4 Hz, 1-H); 2.90 (1H, bs, 5-H); 2.42-2.56 (3H, m, 5’-H2); 2.10 (1H, d J 11.2 
Hz, 4-H); 13C NMR (100 MHz) C 179.4 (6-C); 130.3 (3-CH); 129.3 (2-CH); 73.3 (1-CH); 38.0 (5-CH); 34.5 (4-
CH2); 29.1 (5’-CH2); max (oil, cm-1) 1770.6 (C=O); 720 (cis alkene); m/z (ESI+) calculated for C7H8O2 [M+Na]+; 
124.0524, found 124.0524. 
 
Synthesis of Methyl cis-5-acetoxycyclohex-3-ene-1-carboxylate39 (7a) 
 
 
To an oven dried 250 mL round bottom flask, bicyclo[3.2.1]oct-2-en-6-one (2.1 g, 18 mmol, 1 eq) and sodium 
metal (55 mg, 2.4 mmol, 0.13 eq) was added to freshly distilled methanol (100 mL) at room temperature. The 
reaction mixture was left to stir at room temperature for 9 hours, after which the solvent was removed. The 
residual oil was partitioned between ether and water, subsequently extracting with Et2O (3 x 50 mL). The 
120 
 
organic extracts were combined, dried over MgSO4, filtered and the filtrate was concentrated in vacuo to yield 
methyl (1S,5S)-5-hydroxycyclohex-3-ene-1-carboxylate (7a) as a colourless oil (1.7 g, 61 %). The crude oil 
was used without further purification in the next step.  
To an oven dried 50 mL round bottom flask, acetyl chloride (1.08 mL, 15.2 mmol, 1.3 eq) was slowly added to 
a mixture of methyl (1S,5S)-5-hydroxycyclohex-3-ene-1-carboxylate (1.64 g, 11.7 mmol, 1 eq) and pyridine 
(1.7 mL) in CH2Cl2 (10 mL) at 0 °C. The mixture was stirred for 15 minutes, neutralised with aqueous NaHCO3 
(2 mL) and diluted with Et2O (30 mL). The organic phase was successively washed with NaHCO3 solution (3 
x 25 mL). 10 % HCl (2 x 25 mL), NaHCO3 solution (25 mL) and brine (25 mL). The organic extracts were 
combined, dried over MgSO4, filtered and the filtrate was concentrated in vacuo. The crude product was 
purified by column chromatography (98:2 CHCl3:Et2O) to yield methyl (1S,5S)-5-acetoxycyclohex-3-ene-1-
carboxylate (cis:trans 98:2) as a colourless oil (1.03 g, 45 %); RF = 0.38; 1H NMR (400 MHz CDCl3) H 5.87 
(1H, ddt J 1.9 Hz 3.6 Hz 9.8 Hz, 3-H); 5.53 (1H, d J 9.8 Hz, 4-H); 5.26-5.32 (1H, m, 5-H); 3.58 (3H, s, CO2CH3); 
2.73 (1H, ddt J 2.3 Hz 7.8 Hz 11.4 Hz, 1-H); 2.22-2.27 (1H, m, 6-H); 2.17-2.20 (2H, m, 2-H2); 1.93 (3H, s, O-
CH3); 1.75 (1H, dt J 9.2 Hz 11.4 Hz, 6-H); 13C NMR (100 MHz) C 174.3 (CO2Me); 170.3 (C=O); 129.0 (3-CH); 
126.6 (4-CH); 68.9 (5-CH); 51.7 (O-CH3); 37.5 (1-CH); 30.3 (6-CH2); 27.0 (2-CH2); 21.0 (CO-CH3); max (oil, 
cm-1) 1770.6 (C=O); m/z (ESI+) calculated for C10H14O4 [M+Na]+; 198.0892, found 198.0889. 
 
Synthesis of (1S, 5S)-5-([{tert-butyldimethylsilyl}oxy]methyl)cyclohex-2-en-1-yl acetate,159,170 (111) 
 
 
 
To an oven dried 500 mL round bottom flask, bicyclo[3.2.1]oct-2-en-6-one (2.10 g, 17 mmol, 1 eq) was 
dissolved in dry THF (40 mL) and cooled to 0 °C. LiAlH4 (1.02 g, 26 mmol, 1.5 eq) in dry THF (30 mL) was 
slowly added to the reaction mixture and stirred for two hours at 0 °C. 1M solution of Rochelle ’s salt (20 mL) 
was added slowly to quench the reaction, once quenched the mixture was stirred for one hour. The reaction 
mixture was extracted with EtOAc (3 x 150 mL), washing with water (100 mL) and brine (100 mL). The organic 
phase was dried over MgSO4 and evaporated to dryness to yield cis-5-(hydroxymethyl)cyclohex-2-en-1-ol as 
a yellow oil (2.18 g, 86 %). The crude product was used without further purification in the next reaction.  
To an oven dried 50 mL round bottom flask, crude cis-5-(hydroxymethyl)cyclohex-2-en-1-ol (1.51 g, 11.8 mmol, 
1 eq) and imidazole (1.61 g, 23.6 mmol, 2 eq) was added to dry DMF (15 mL) and cooled to 0 °C. To this 
mixture, tert-butyldimethylsilyl chloride (1.77 g, 11.8 mmol, 1 eq) was added slowly, stirring at 0 °C for one 
hour. The reaction was warmed to room temperature and stirred for 16 hours. The reaction was quenched with 
ice cold water (20 mL) and extracted with Et2O (3 x 25 mL), washing with brine (100 mL). The organic phase 
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was dried over MgSO4 and evaporated to dryness to yield cis-5-([{tert-butyldimethylsilyl}oxy]methyl)cyclohex-
2-en-1-ol (2.85 g, 83 %). 
To an oven dried 25 mL round bottom flask, acetyl chloride (0.18 ml, 2.6 mmol, 1.3 eq) was added to a solution 
cis-5-([{tert-butyldimethylsilyl}oxy]methyl)cyclohex-2-en-1-ol (0.49 g, 2.0 mmol, 1 eq) in CH2Cl2 (3 mL) and 
pyridine (0.24 mL) at 0°C. The slurry was stirred for 15 minutes and quenched with aqueous NaHCO3 (1 mL) 
at 0 °C. The resultant mixture was extracted with Et2O (3 x 25 mL), washed successively with saturated 
NaHCO3 (2 x 20 mL), 10 % HCl (10 mL), aqueous NaHCO3 (20 mL) and brine (20 mL), dried over MgSO4 and 
the solvent was evaporated to dryness. The crude product was purified by column chromatography (9:1 
CHCl3:Et2O) to yield cis-5-([{tert-butyldimethylsilyl}oxy]methyl)cyclohex-2-en-1-yl acetate (0.34 g, 70 %) as a 
colourless oil; RF = 0.80; 1H NMR (400 MHz) H 5.86 (1H, ddt J 2.0 Hz 4.7 Hz 7.1 Hz, 2-H); 5.57 (1H, m, 3-H); 
5.26 (1H, m, 1-H); 3.51 (2H, d J 5.9 Hz, 5’-H2); 2.09-2.14 (2H, m, 4-H, 6-H; 2.05 (3H, s, COCH3); 1.85-1.95 
(1H, m, 4-H); 1.79-1.84 (1H, m, 5-H); 1.32 (1H, dt J 9.9 Hz 12.0 Hz, 6-H); 0.89 (9H, s, (CH3)3; 0.04 (6H, s, Si-
(CH3)2); 13C NMR (100 MHz) C 170.8 (C=O); 130.2 (2-CH); 127.1 (3-CH); 70.5 (1-CH); 67.3 (5’-CH2); 35.6 (5-
CH); 31.4 (6-CH2); 28.0 (4-CH2); 25.9 (C-(CH3)3); 21.3 (COCH3); 18.2 (C-(CH3)3); -5.4 (Si-(CH3)2); max (oil, cm-
1) 2953 (CH=CH, sp2 stretch); 1741.2 (C=O); m/z (ESI+) calculated for C15H28O3Si [M+Na]+; 307.1700, found 
307.1712. 
 
cis-Dimethyl 2-(5-{[(tert-butyldimethylsilyl)oxy]methyl}cyclohex-2-en-1-yl)malonate (112) 
 
To an oven-dried 25 mL round bottomed flask, a solution of dimethylmalonate (0.2 mL, 1.95 mmol, 3.5 eq) 
was sodium hydride, 60 % dispersed in mineral oil (65 mg, 1.63 mmol, 2.5 eq) in anhydrous THF (6 mL) was 
prepared and stirred at room temperature. To this, a solution of Pd(PPh3)4 (29 mg, 0.022 mmol, 0.033 eq), 
PPh3 (50 mg, 0.19 mmol, 0.29 eq) in THF (1 mL) was added. The reaction mixture was heated to reflux and 
left stirring for 7.5 hours, after which the reaction was cooled to room temperature, quenched with H2O (1 mL) 
and concentrated in vacuo. The crude product was purified using column chromatography (pentane:acetone 
95:5) to yield cis-Dimethyl 2-(5-{[(tert-butyldimethylsilyl)oxy]methyl}cyclohex-2-en-1-yl)malonate (130 mg, 56 
%) as a colourless oil and single diastereomer; RF = 0.6; 1H NMR (400 MHz) H 5.77-5.82 (1H, m, 3’-H); 5.50-
5.45 (1H, m, 2’-H); 3.76 (3H, s, O-CH3); 3.75 (3H, s, O-CH3); 3.49 (2H, m, 7’-H2); 3.28 (1H, d J 8.8 Hz, 1-H); 
2.95-3.02 (1H, m, 1’H); 2.08-2.13 (1H, m, 4’-H); 1.79-1.89 (2H, m, 6’-Heq, 5’H); 1.66-1.76 (1H, m, 4-H); 1.04 
(1H, dt J 11.6 Hz 12.6 Hz, 6’-Hax); 0.91 (9H, s, Si-(CH3)3); 0.05 (6H, s, Si-(CH3)2); 13C NMR (100 MHz) C 168.9 
(C=O); 168.8 (C=O); 128.6 (3’-CH); 127.5 (2’CH); 67.8 (7’-CH2); 56.9 (1-CH); 52.4 (O-(CH3)2); 36.6 (5’-CH); 
36.5 (1’-CH); 30.1 (6’-CH2); 28.3 (4’-CH2); 25.9 (Si-(CH3)3); -5.35 (Si-(CH3)2); max (oil, cm-1) 1736 (C=O). m/z 
(ESI+) calculated for C18H32O6Si [M+Na]+; 379.1911, found 379.1919. 
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cis-([{Tert-butyldimethylsilyl}oxy]methyl)cyclohex-2-en-1-yl)-N,N-dimethyl-1-
phenylmethanesulfonamide (113) 
 
N,N-Dimethyl-1-phenylmethanesulfonamide (212 mg, 1.0 mmol, 1 eq) and (1S, 5S)-5-([{tert-
butyldimethylsilyl}oxy]methyl)cyclohex-2-en-1-yl acetate (310 mg, 1.1 mmol, 1.1 eq) were reacted following 
general procedure A to yield 1-(5R)-([{Tert-butyldimethylsilyl}oxy]methyl)cyclohex-2-en-1-yl)-N,N-dimethyl-1-
phenylmethanesulfonamide as a mixture of diastereomers (d.r 1:0.5) (0.37 g, 85 %); This was further purified 
to obtain the pure major diastereomer (71 mg) as a colourless oil; RF = 0.51 (major isomer) 0.47 (minor isomer) 
(pentane:acetone 98:2); data for major diastereomer 113a: 1H NMR (400 MHz MeOD) H 7.47-7.49 (2H, m, 
Ar-H); 7.36-7.39 (3H, m, Ar-H); 5.70-5.74 (1H, m, 4-H); 5.65-5.67 (1H, m, 3-H); 4.21 (1H, d J 7.2, 1-H); 3.45-
3.51 (2H, m, 6’-H2); 3.19-3.23 (1H, m, 2-H); 2.45 (6H, s, N-(CH3)2); 2.11-2.14 (1H, m, 7-Heq); 1.97-2.00 (1H, 
m, 5-H); 1.77-1.84 (1H, m, 6-H); 1.57-1.64 (1H, m, 5-H); 1.00 (1H, dt J 11.6, 12.5, 7-Hax); 0.86 (9H, s, C-
(CH3)3); -0.03 (6H, d J 2.4, Si-(CH3)2); 13C NMR (100 MHz) C 134.5 (Ar-C); 131.7 (Ar-CH); 129.9 (Ar-CH); 
129.6 (4-CH); 128.2 (3-CH); 72.2 (1-CH); 69.0 (6’-CH2); 39.8 (2’-CH2); 38.0 (6-CH); 37.8 (N-(CH3)2; 32.7 (7-
CH2); 29.2 (5-CH2); 26.4 (C-(CH3)3); 19.2 (C-(CH3)3); -5.3 (Si-(CH3)2); data for minor diastereomer 113b: 1H 
NMR (500 MHz CDCl3); 7.36-7.44 (5H, m, Ar-H); 6.27 (1H, dd J 0.8 Hz 10.2 Hz, 3-H); 5.82 (1H, ddd J 2.2 Hz 
4.9 Hz 7.5 Hz, 4-H); 4.00 (1H, d J 9.3 Hz, 1-H); 3.40 (1H, dd J 6.4 Hz 10.0 Hz, 6’-H); 3.33 (1H, dd J 6.4 Hz 
10.0 Hz, 6’-H); 3.25-3.27 (1H, m, 2-H); 2.46 (6H, N-(CH3)2); 2.03-2.08 (1H, m, 7-Heq); 1.76-1.79 (1H, m, 5-H); 
1.60-1.66 (2H, m, 5-H, 6-H); 0.81 (9H, s, C-(CH3)3); 0.75 (1H, q J 12.1 Hz, 7-Hax); -0.063 (6H, d J 9.1 Hz, Si-
(CH3)2); 13C NMR (100 MHz) C 133.3 (Ar-C); 129.9 (Ar-CH); 128.7 (Ar-CH); 128.6 (4-CH); 128.8 (Ar-CH); 
128.2 (3-CH); 72.6 (1-CH); 67.7 (6’-CH2); 37.8 (2-CH); 37.5 (N-(CH3)2); 36.8 (6-CH); 31.0 (7-CH2); 28.3 (5-
CH2); 25.8 (-(CH3)2); 18.2 (-C(CH3)2; -5.5 (Si-(CH3)3); m/z (ESI+) calculated for C22H37NO3SSi [M+H]+; 
424.2336, found 424.2342. 
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(1R,5R)-5-{[(R)-(N,N-dimethylsulfamoyl)phenyl]methyl}cyclohex-3-en-1-yl)methyl 4-bromobenzoate 
(116) 
 
A solution of the pure major diastereomer 1-(5R)-([{Tert-butyldimethylsilyl}oxy]methyl)cyclohex-2-en-1-yl)-
N,N-dimethyl-1-phenylmethanesulfonamide (41 mg, 0.1 mmol, 1 eq) and TBAF (50 mg, 0.19 mmol, 1.9 eq) in 
THF (2 mL)  was stirred at 0 °C for 15 minutes. The reaction mixtures was warmed to room temperature for 
overnight and passed through a silica plug to yield a crude mixture of the corresponding alcohol. 
The crude alcohol 110 (29 mg, 0.09 mmol, 1 eq) was added to a solution of CH2Cl2 (5 mL), triethylamine (9 
mg, 0.09 mmol, 1 eq) and p-bromobenzoyl chloride (10 mg, 0.45 mmol, 5 eq) at room temperature. The 
reaction mixture was stirred for 2 hours, prior to the addition of H2O (10 mL) and DCM (10 mL). The organic 
phase was extracted and washed with H2O (3 x 10 mL), dried over MgSO4 and evaporated to dryness to yield 
(1R,5R)-5-{[(R)-(N,N-dimethylsulfamoyl)phenyl]methyl}cyclohex-3-en-1-yl)methyl 4-bromobenzoate (42 mg, 
95 %) as a brown crystalline solid. 1H NMR (400 MHz CDCl3) H 7.88 (2H, app d J 8.5 Hz, Ar-H); 7.57 (2H, app 
d J 8.5 Hz, Ar-H); 7.36-7.42 (5H, m, Ph-H); 5.71-5.75 (1H, m, 4-H); 5.62-5.64 (1H, m, 3-H); 4.18 (2H, d J 6’-
H2); 3.97 (1H, d J 7.9 Hz, 1-H); 3.34 (1H, app bs, 2-H); 2.45 (6H, s, N-(CH3)2); 2.30-2.33 (1H, m, 7-H); 2.11-
2.20 (2H, m, 5-H, 6-H); 1.69-1.76 (1H, m, 5-H); 1.16-1.22 (1H, m, 7-H); 13C NMR (100 MHz) C 170.3; 165.8; 
133.0; 131.9; 131.7 (2 x Ar-CH); 131.1 (2 x Ar-CH); 130.2 (2 x Ph-CH); 128.8 (Ph-CH); 128.7 (2 x Ph-CH); 
128.2 (4-CH); 127.2 (3-CH); 71.7 (1-CH); 69.4 (6’-CH2); 38.2 (2-CH); 37.5 (N-CH3)2); 33.6 (6-CH); 31.6 (7-
CH2); 28.3 (5-CH2); m/z (ESI+) calculated for C23H2679BrNO4S [M+K]+; 30.0398, found 530.0416.     
 
3.2 Alternative Methods for -Alkylation 
3.2.1 General Procedures 
 
General Procedure E: Alkylation of sulfonamides via nucleophilic substitution method 
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To an oven-dried 25 mL round-bottomed flask, flushed with nitrogen, dry diisopropylamine (0.32 mL, 2.2 mmol, 
2.2 eq) in anhydrous THF (8 mL) was added, stirring at –78 °C. To this solution n-BuLi (1.6M in hexanes, 1.38 
mL, 2.2 mmol, 2.2 eq) was slowly added and the reaction mixture stirred at –78 °C for 10 min followed by 0 °C 
for a further 10 min to generate LDA. The LDA solution was cooled to –20 °C and N,N-dimethyl-1-
phenylmethanesulfonamide (0.20 g, 1mmol, 1 eq) dissolved in anhydrous THF (2 mL) was added dropwise. 
The reaction mixture was left to stir for 1 hour after which time a solution of allylic bromide (1 mmol, 1 eq) in 
anhydrous THF (1 mL) was added dropwise. The reaction mixture was left to stir for a further 3 hours at –20 
°C. The resultant mixture was quenched by addition of saturated aqueous NH4Cl solution (2 mL) and separated 
between CH2Cl2 (25 mL) and H2O (25 mL). The aqueous layer was extracted with CH2Cl2 (3 x 25 mL) and the 
combined organic layers were dried over MgSO4 and concentrated in vacuo. The solid mixture was purified by 
column chromatography to yield the titled compound. 
 
General Procedure F: Synthesis of arylmethane sulfonamides 
 
To an oven-dried 100 mL round bottomed flask, substituted-benzylsulfonyl chloride (2 mmol, 1 eq) was 
dissolved in CHCl3 (50 mL). To this, dimethylamine (8M, 10 eq) was slowly added at room temperature and 
allowed to stir for overnight, after which the organic layer was extracted from the aqueous. The organic extracts 
were washed with H2O (2 x 100 mL) and brine (25 mL) successively, dried over MgSO4 and evaporated to 
dryness to yield the titled compound.  
 
3.2.2 Experimental Data 
 
N,N-Dimethyl-1-phenylbut-3-en-1-sulfonamide (90a) 
 
Allyl bromide (120 mg, 1 mmol, 1 eq) was reacted following the general method E to yield N,N-dimethyl-1-
phenylbut-3-ene-1-sulfonamide (220.4 mg, 92% yield) as a colourless solid; all data matches that of general 
procedure A. 
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(E)-N,N-Dimethyl-1-phenylpent-3-ene-1-sulfonamide (90b) 
 
Crotyl bromide (135 mg, 1 mmol, 1 eq) was reacted following the general procedure E to yield N,N-dimethyl-
1-phenylpent-3-ene-1-sulfonamide as a mixture of isomers (E:Z 6:1, determined by 1H NMR) (218 mg, 86 %) 
as a colourless solid; all data matches that of general procedure A. 
N,N-4-Trimethyl-1-phenylpent-3-ene-1-sulfonamide (90c) 
 
Prenyl bromide (150 mg, 1 mmol, 1 eq) was reacted following the general procedure E to yield N,N,4-trimethyl-
1-phenylpent-3-ene-1-sulfonamide 187 mg, 70 %) as a colourless solid; all data matches that of general 
procedure A. 
 
(E)-N,N-Dimethyl-1,4-diphenylbut-3-ene-1-sulfonamide (90e) 
 
Cinnamyl bromide (202 mg, 1 mmol, 1 eq) was reacted following the general procedure E to yield (E)-N,N-
dimethyl-1,4-diphenylbut-3-ene-1-sulfonamide (195 mg, 61 %) as a colourless solid; all data matches that of 
general procedure A. 
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(E)-N,N-Dimethyl-1-phenylhex-3-ene-1-sulfonamide (117) 
 
1-bromo-2-pentene (153 mg, 1 mmol) was reacted following the general procedure E to yield (E)-N,N-dimethyl-
1-phenylhex-3-ene-1-sulfonamide (237 mg, 88 %) as a colourless solid (E:Z ratio = 90:10 by 1H NMR); RF = 
0.53 (9:1 toluene:EtOAc); mp: 75 - 76 °C; 1H NMR (400 MHz, CDCl3)  H 7.34-7.41 (5H, m, Ar-H); 5.46-5.53 
(1H, m, 3-H); 5.07-5.15 (1H, m, 4-H); 4.10 (1H, dd J 4.0 Hz 11.0 Hz, 1-H); 2.98-3.04 (1H, m, 2-H); 2.80-2.88 
(1H, m, 2-H); 2.54 (6H, s, N-(CH3)2); 1.87 (2H, quint J 7.25 Hz, 5-H2); 0.82 (3H, t J 7.44 Hz, 6-H3); 13C NMR 
(100 MHz) C 136.1 (4-CH); 133.4 (1 x Ar-C); 129.6 (2 x Ar-CH); 128.8 (1 x Ar-CH); 128.6 (2 x Ar-CH); 123.4 
(3-CH); 67.5 (1-CH); 37.6 (N-(CH3)2); 33.2 (2-CH2); 25.5 (5-CH2); 13.6 (6-CH3); max (solid, cm-1) 1314 & 1133 
(sulfonamide S=O); m/z (ESI+) calculated for C14H21NO2S [M+Na]+; 290.1185, found 267.1295. 
 
1-(Cyclohex-2-en-1-yl)-N,N-dimethyl-1-phenylmethanesulfonamide (90g) 
 
3-Bromocyclohexene (167 mg, 1 mmol. 1 eq) was reacted following the general procedure E to yield 1-
(cyclohex-2-en-1-yl)-N,N-dimethyl-1-phenylmethanesulfonamide (d.r: 71:29, determined by 1H NMR) (248 
mg, 89 %) as a colourless solid; RF = 0.42 (95:5 toluene:EtOAc); mp: 104 - 106 °C; data for major diastereomer: 
1H NMR (400 MHz, CDCl3) H 7.34-7.40 (5H, m, Ar-H); 6.19 (1H, dd J 2.2 Hz 10.5 Hz, 2’-H); 5.76-5.80 (1H, 
m, 3’-H); 4.05 (1H, d J 9.8 Hz, 1-H); 3.10-3.15 (1H, m, 1’-H); 2.40 (6H, s, N-(CH3)2); 1.71-1.94 (2H, m, 4’-H2); 
1.54-1.61 (2H, m, 6’-H, 5’-H); 1.41-1.48 (1H, m, 5’-H); 1.07-1.14 (1H, m, 6’-H); 13C NMR (100 MHz) C 133.5 
(1 x Ar-C); 130.1 (2 x Ar-CH); 129.8 (3’-CH); 128.8 (1 x Ar-CH); 128.7 (2 x Ar-CH); 127.3 (2’-CH); 72.6 (1-CH); 
37.4 (N-(CH3)2); 26.7 (6’-CH2); 25.0 (4’-CH2); 20.6 (5’-CH2). Data for minor diastereomer: 1H NMR (400 MHz, 
CDCl3) H 7.34-7.40 (5H, m, Ar-CH); 5.66-5.69 (1H, m, 3’-H); 5.45-5.48 (1H, m, 2’-H); 3.97 (1H, d J 8.4 Hz, 1-
H); 3.16-3.19 (1H, m, 1’-H); 2.42 (6H, s, N-(CH3)2); 2.07-2.13 (1H, m, 6’-H); 1.66-1.73 (2H, m, 5’-H2); 1.51-1.61 
(1H, m, 6’-H); 13C NMR (100 MHz) C 133.3 (1 x Ar-C); 129.9 (2’-CH); 129.8 (2 x Ar-CH); 128.7 (1 x Ar-CH); 
128.6 (2 x Ar-CH); 127.0 (3’-CH); 71.8 (1-CH); 36.6 (N-(CH3)2); 28.0 (6’-CH2); 24.9 (4’-CH2); 21.2 (5’-CH2); 
max (solid, cm-1) 1320 & 1130 (sulfonamide S=O); m/z (ESI+) calculated for C15H21NO2S [M+Na]+; 302.1185, 
found 302.1192. 
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N,N-3-Trimethyl-1-phenylbut-3-ene-1-sulfonamide (90i) 
  
3-bromo-2-methylpropene (273 mg, 1 mmol, 1 eq) was used following the general procedure E to yield N,N-
3-trimethyl-1-phenylbut-3-ene-1-sulfonamide (253 mg, 99 %) as a colourless solid; all data matches that of 
general procedure A. 
 
(E)-N,N,4,8-Tetramethyl-1-phenylnona-3,7-diene-1-sulfonamide (90j) 
 
Geranyl bromide (219 mg, 1 mmol, 1 eq) was reacted following the general procedure E to yield (E)-N,N,4,8-
tetramethyl-phenylnona-3,7-diene-1-sulfonamide (296 mg, 88 %) as a colourless solid; all data matches that 
of general procedure A. 
 
3-Bromo-N,N-dimethyl-1-phenylbut-3-ene-1-sulfonamide (118) 
 
 
2,3-Dibromopropene (200 mg, 1 mmol, 1 eq) was reacted following the general procedure E to yield 3-bromo-
N,N-dimethyl-1-phenylbut-3-ene-1-sulfonamide (245 mg, 77 %) as an orange solid; RF = 0.59 (90:10 
toluene:EtOAc); mp: 100 - 102 °C; 1H NMR (400 MHz, CDCl3) H 7.37-7.44 (5H, m, Ar-H); 5.46 (1H, s, 4-H); 
5.30 (1H, d J 1.0 Hz, 4-H); 4.53 (1H, dd J 4.0 Hz 11.0 Hz, 1-H); 3.37 (1H, dd J 4.0 Hz 14 Hz, 2-H); 3.26 (1H, 
dd J 11 Hz 14 Hz, 2-H); 2.57 (6H, s, N-(CH3)2); 13C NMR (100 MHz) C 132.2 (1 x Ar-C); 129.6 (2 x Ar-CH); 
129.1 (1 x Ar-CH); 128.8 (2 x Ar-CH); 128.5 (3-C); 120.6 (4-CH2); 65.3 (1-CH); 41.8 (2-CH2); 37.7 (N-(CH3)2); 
max (solid, cm-1) 1324 & 1133 (sulfonamide S=O); m/z (ESI+) calculated for C12H1679BrNO2S [M+Na]+; 
339.9977, found 339.9978. 
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(E)-4-Bromo-N,N-dimethyl-1-phenylbut-3-ene-1-sulfonamide (119) 
 
1,3-Dibromopropene (200 mg, 1 mmol, 1 eq) was reacted following the general procedure E to yield (E)-4-
bromo-N,N-dimethyl-1-phenylbut-3-ene-1-sulfonamide (Z:E 66:44, determined by 1H NMR) (251 mg, 79 %) 
as a colourless solid; RF = 0.50 (90:10 toluene:EtOAc); mp: 90 - 92 °C; data for E-isomer; 1H NMR (400 
MHz, CDCl3) H 7.36-7.43 (5H, m, Ar-H); 6.10 (1H, d J 7.1 Hz, 4-H); 5.92 (1H, ddt J 4.0 Hz 7.3 Hz 11.0 Hz, 
3-H); 4.22 (1H, dd J 5.1 Hz 10.6 Hz, 1-H); 3.17-3.23 (1H, m, 2-H); 3.02-3.09 (1H, m, 2-H); 2.57 (6H, s, N-
(CH3)2); 13C NMR (100 MHz) C 132.9 (1 x Ar-C); 132.5 (3-CH); 129.5 (2 x Ar-CH); 129.4 (1 x Ar-CH); 128.9 
(2 x Ar-CH); 110.7 (4-CH); 65.6 (1-CH); 37.7 (N-(CH3)2); 30.6 (2-CH2). Data for Z-isomer; 1H NMR (400 MHz, 
CDCl3)H 7.36-7.34 (5H, m, Ar-H); 6.09 (1H, d J 13.5 Hz, 4-H); 5.92 (1H, ddt J 4.1 Hz 7.3 Hz 11 Hz, 3-H); 
4.12 (1H, dd J 4.1 Hz 10.8 Hz, 1-H); 3.02-3.19 (1H, m, 2-H); 2.84-2.92 (1H, m, 2-H); 2.52 (6H, s, N-(CH3)2); 
13C NMR (100 MHz) C 132.6 (1 x Ar-C); 129.9 (3-CH); 129.3 (2 x Ar-CH); 129.1 (1 x Ar-CH); 128.8 (2 x Ar-
CH); 107.8 (4-CH); 66.6 (1-CH); 37.6 (N-(CH3)2); 33.6 (2-CH2); max (solid, cm-1) 1317 & 1134 (sulfonamide 
S=O); m/z (ESI+) calculated for C12H1679BrNO2S [M+Na]+; 339.9977, found 339.9980. 
 
4-[(4-Methyl-1-phenylpent-3-en-1-yl)sulfonyl]morpholine (124a) 
 
4-(Benzylsulfonyl)morpholine (121 mg, 0.5 mmol, 1 eq) and prenyl bromide (75 mg, 0.5 mmol, 1 eq) was 
reacted following the general procedure E to yield  4-[(4-Methyl-1-phenylpent-3-en-1-yl)sulfonyl]morpholine 
(115 mg, 74 %) as a colourless solid; RF = 0.41; mp: 98 - 100 °C; 1H NMR (400 MHz, CDCl3)H  7.35-7.40 
(5H, m, Ar-H); 4.84 (1H, t J 7.3 Hz, 3-H); 3.99 (1H, dd J 3.9 Hz 11.3 Hz, 1-H); 3.54 (2H, ddd J 3.0 Hz 6.5 Hz 
11.5 Hz, O-H2); 3.44 (2H, ddd J 3.0 Hz 6.3 Hz 11.4 Hz, O-H2); 3.01-3.08 (3H, m, 2-H, N-H2) ; 2.76-2.85 (3H, 
m, 2-H, N-H2); 1.56 (6H, 4-(CH3)2); 13C NMR (100 MHz) C 135.1 (4-C); 133.3 (1 x Ar-C); 129.7 (2 x Ar-CH); 
128.9 (1 x Ar-CH); 128.7 (2 x Ar-CH); 118.7 (3-CH); 68.2 (1-CH); 66.7 (O-CH2); 46.1 (N-CH2); 28.9 (2-CH2); 
25.7 (4-CH3); 17.9 (4-CH3); max (solid, cm-1) 1335 & 1106 (sulfonamide S=O); m/z (ESI+) calculated for 
C16H23NO2S [M+Na]+; 332.1291, found 332.1295. 
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(E)-1-[(1,4-Diphenylbut-3-en-1-yl)sulfonyl]pyrrolidine (124b) 
 
1-(Benzylsulfonyl)pyrrolidie (113 mg, 0.5 mmol, 1 eq) and cinnamyl bromide (99 mg, 0.5 mmol. 1 eq) was 
reacted following the general procedure E to yield (E)-1-[(1,4-diphenylbut-3-en-1-yl)sulfonyl]pyrrolidine (98 mg, 
57 %); RF = 0.33; mp: 118 - 121 °C; 1H NMR (400 MHz, CDCl3) H  7.44-7.36 (5H, m, Ar-H); 7.15-7.24 (5H, m, 
Ar-H); 6.43 (1H, d J 15.8 Hz, 4-H); 5.94 (1H, dt J 7.4 Hz 14.9 Hz, 3-H); 4.24 (1H, dd J 4.1 Hz 11.7 Hz, 1-H); 
3.17-3.29 (3H, m, 2-H, 2’-H2); 3.05-3.13 (1H, m, 2-H); 2.81-2.86 (2H, m, 2’-H2); 1.63-1.74 (4H, m, (3’-H2)2); 13C 
NMR (100 MHz) C 137.0 (1 x Ar-C); 133.6 (1 x Ar-C); 133.1 (4-C); 129.7 (2 x Ar-CH); 128.9 (1 x Ar-CH); 128.7 
(2 x Ar-CH); 128.4 (2 x Ar- CH); 127.3 (1 x Ar- CH); 126.1 (2 x Ar-CH); 125.1 (3-CH); 67.4 (1-CH); 48.2 (2’-
(CH2)2); 33.4 (2-CH2); 25.8 ((3’-CH2)2); max (solid, cm-1) 1315 & 1137 (sulfonamide S=O); m/z (ESI+) calculated 
for C20H23NO2S [M+K]+ 380.1081, found 380.1091. 
 
1-[(3-Bromo-1-phenylbut-3-en-1-yl)sulfonyl]piperidine (124c) 
 
1-(Benzylsulfonyl)piperidine (120 mg, 0.5 mmol, 1 eq) and 2,3-dibromoprop-1-ene (99 mg, 0.5 mmol, 1 eq) 
was reacted following the general procedure A to yield 1-[(3-bromo-1-phenylbut-3-en-1-yl)sulfonyl]piperidine 
(133 mg, 71 %); RF =  0.55 (toluene:EtOAc 95:5); mp: 77 - 79 °C; 1H NMR (400 MHz, CDCl3)H 7.35-7.41 (5H, 
m, Ar-H); 5.42 (1H, s, 4-H); 5.27 (1H, d J 1.3 Hz, 4-H); 4.42 (1H, dd J 4.0 Hz 11.4 Hz, 1-H); 3.37 (1H, dd J 4.0 
Hz 14.4 Hz, 2-H); 3.23 (1H, dd J 11.4 Hz 14.4 Hz, 2-H); 3.01-3.06 (2H, m, 2’-H2); 2.81 (2H, bs, 2’-H2); 1.39-
1.46 (6H, m, 3’-H2, 4-H2); 13C  NMR (100 MHz) δC 132.3 (1 x Ar-C); 129.7 (2 x Ar-CH); 129.0 (1 x Ar-CH); 
128.7 (2 x Ar-CH); 128.6 (3-C); 120.5 (4-CH2); 65.8 (1-CH); 46.9 (2’-(CH2)2); 42.1 (2-CH2); 25.8 (3’-CH2); 23.7 
(4’-CH2); max (solid, cm-1) 1321 & 1158 (sulfonamide S=O); m/z (ESI+) calculated for C13H2079BrNO2S [M+Na]+; 
380.0290, found 380.0288. 
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1-Benzyl-4-([1-phenylbut-3-en-1-yl]sulfonyl)piperazine121 (104a) 
 
A: 1-Benzyl-4-(benzylsulfonyl)piperazine (165 mg, 0.5 mmol, 1 eq) and crotyl bromide (67.5 mg, 0.5 mmol, 1 
eq) was reacted following the general procedure A to yield (E)-1-benzyl-4-[(1-phenylpent-3-en-1-
yl)sulfonyl]piperazine (107.6 mg, 56 %). 
 
1-([1-Phenylbut-3-en-1-yl]sulfonyl)-1,2,5,6-tetrahydropyridine (99j) 
 
1-(benzylsulfonyl)-1,2,3,6-tetrahydropyridine (116 mg, 0.5 mmol, 1 eq) and allyl bromide (61 mg, 0.5 mmol, 1 
eq) was reacted following the general procedure E, to yield 1-([1-phenylbut-3-en-1-yl]sulfonyl)-1,2,3,6-
tetrahydropyridine (113 mg, 82 %) as an orange oil; all data in accordance with general procedure A. 
 
N,N-Dimethyl[-1-(4-trifluoromethyl)phenyl]methanesulfonamides (120) 
 
(4-Trifluoromethyl)benzylsulfonyl chloride (0.50 g, 1.9 mmol, 1 eq) was reacted with dimethylamine 2.4 mL, 
8M, 10 eq) following general procedure F, yielding yielding N,N-dimethyl[-1-(4-
trifluoromethyl)phenyl]methanesulfonamide as a colourless solid (0.42 g, 82 %); mp: 174 - 176 °C; 1H NMR 
(400 MHz, CDCl3) H 7.66 (2H, d J 8.2 Hz, Ar-H); 7.54 (2H, d J 8.2 Hz, Ar-H); 4.26 (2H, s, 1-H2); 2.78 (6H, s, 
N-(CH3)2; ); 13C NMR (100 MHz) C 133.1 (app q, J 1.3 Hz, Ar-C); 131.9 (q J 33 Hz, C-CF3); 131.0 (app s, 2 x 
Ar-CH) 126 (q J 271 Hz, CF3); 125.7 (q J 3.8 Hz, 2 x Ar-CH), 55.2 (2-CH2); 37.8 (N-(CH3)2); max (solid, cm-1) 
1329 & 1117 (sulfonamide S=O); m/z (ESI+) calculated for C10H12F3NO2S [M+Na]+ 290.0433, found 290.0417. 
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(E)-N,N-Dimethyl-4-phenyl-1-[4-(trifluoromethyl)phenyl]but-3-ene-1-sulfonamide (124d) 
 
N,N-Dimethyl-1-[4-(trifluoromethyl)phenyl]methanesulfonamide (130 mg, 0.5 mmol) and cinnamyl bromide (99 
mg, 0.5 mmol) was reacted following the general method E to yield  (E)-N,N-dimethyl-4-phenyl-1-[4-
(trifluoromethyl)phenyl]but-3-ene-1-sulfonamide (119 mg, 63 %) as a colourless solid and (1E,6E)-N,N-
dimethyl-1,7-diphenyl-4-[4-(trifluoromethyl)phenyl]hepta-1,6-diene-3-sulfonamide as a colourless oil (65 mg, 
13 %); RF = 0.18 (monoallyl), 0.57 (diallyl); data for mono-allylated product; mp: 100 - 102 °C; 1H NMR (400 
MHz, CDCl3) H 7.67 (2H, d J 8.2 Hz, Ar-H); 7.59 (2H, d J 8.2 Hz, Ar-H); 7.19-7.27 (5H, m, Ph-H); 6.42 (1H, d 
J 15.6 Hz, 4-H); 5.89 (1H, dt J 4.1 Hz 10.9 Hz, 3-H); 3.23-3.29 (1H, m, 2-H); 3.03-3.11 (1H, m, 2-H); 2.61 (6H, 
s, N-(CH3)2); 13C NMR (100 MHz) C 137.4 (1 x Ar-C); 136.6 (1 x Ph-C); 133.7 (4-CH); 131.2 (q J 33 Hz, C-
CF3); 130.0 (app s, 2 x Ar-CH); 128.6 (2 x Ph-CH); 127.6 (2 x Ph-CH); 126.1 (1 x Ph-CH); 125.5 (q J 3.6 Hz, 
2 x Ar-CH); 124.0 (3-CH); 123.9 (q, J 273 Hz, CF3); 66.9 (1-CH); 37.7 (N-(CH3)2); 33.8 (2-CH2); max (solid, cm-
1) 1320 & 1113 (sulfonamide S=O); m/z (ESI+) calculated for C19H20F3NO2S [M+Na]+ 406.1059, found 
406.1066. 
 
N,N-Dimethyl-1-(p-tolyl)methanesulfonamides (121) 
 
p-Tolyl-methanebenzylsulfonyl chloride (0.50 g, 2.3 mmol, 1 eq) and dimethylamine (2.85 mL, 8M) was reacted 
following general procedure F, yielding N,N-Dimethyl-1-(p-tolyl)methanesulfonamide as a colourless solid 
(0.46 g, 96 %); mp: 81 - 83 °C; 1H NMR (400 MHz, CDCl3) H 7.28 (2H, d J 7.9 Hz, Ar-H); 7.19 (2H, d J 7.9 Hz, 
Ar-H); 4.19 (2H, s, 1-H2); 2.72 (6H, s, N-(CH3)2); 2.36 (3H, s, p-CH3); 13C NMR (100 MHz) C 138.6 (1 x Ar-C); 
130.5 (2 x Ar-CH); 129.5 (2 x Ar-CH); 125.9 (1 x Ar-C); 55.7 (1-CH2); 38.8 (N-(CH3)2); 21.2 (p-CH3); max (solid, 
cm-1) 1317 & 1139 (sulfonamide S=O); m/z (ESI+) calculated for C10H15NO2S [M+Na]+ 236.0716, found 
236.0717. 
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N,N-4-Trimethyl-1-(p-tolyl)pent-3-ene-1-sulfonamide (124e) 
 
N,N-Dimethyl-1-(p-tolyl)methanesulfonamide (106 mg, 0.5 mmol, 1 eq) and prenyl bromide (74 mg, 0.5 mmol, 
1 eq) was reacted following the general procedure E to yield N,N-4-Trimethyl-1-(p-tolyl)-pent-3-ene-1-
sulfonamide as a colourless solid (69 mg, 49 %); RF = 0.4 (95:5 toluene: EtOAc); mp: 45 - 47 °C; 1H NMR (400 
MHz, CDCl3) H 7.28 (2H, d J 7.9 Hz, Ar-H); 7.16 (2H, d J 7.9 Hz, Ar-H); 4.85 (1H, t J 7.3 Hz, 3-H); 4.03 (1H, 
dd J 3.9 Hz 11.2 Hz, 1-H); 3.00-3.06 (1H, m, 2-H); 2.76-2.85 (1H, m, 2-H); 2.54 (6H, s, N-(CH3)2); 2.36 (3H, s, 
Ar-CH3); 1.58 (6H, bs, 4-(CH3)2); 13C NMR (100 MHz) C 138.6 (4-C); 134.8 (Ar-C-CH3); 130.5 (1 x Ar-C); 
129.5 (2 x Ar-CH); 129.3 (2 x Ar-CH); 119.0 (3-CH); 67.1 (1-CH); 37.7 (N-(CH3)2); 28.2 (2-CH2); 25.7 (4-CH3); 
21.2 (Ar-CH3); 17.9 (4-CH3);  max (solid, cm-1) 1321 & 1130 (sulfonamide S=O); m/z (ESI+) calculated for 
C15H23NO2S [M+K]+ 320.1081, found 320.1082. 
 
1-(4-Chlorophenyl)-N,N-dimethylmethanesulfonamide (122) 
 
(4-Chlorophenyl)sulfonyl chloride (0.50 g, 2.22 mmol, 1 eq) and dimethylamine (2.8 mL, 8M) was reacted 
following general procedure F, yielding 1-(4-chlorophenyl)-N,N-dimethylmethanesulfonamide as a colourless 
solid (343 mg, 66 %); mp: 108 - 110 °C; 1H NMR (400 MHz, CDCl3) H 7.32-7.38 (4H, m, Ar-H); 4.18 (2H, s, 1-
H); 2.76 (6H, s, N-CH3)2); 13C NMR (100 MHz) C 134.9 (1 x Ar-C); 131.9 (2 x Ar-CH); 129.0 (2 x Ar-CH); 127.6 
(1 x Ar-C); 55.1 (2-CH2); 37.8 (N(CH3)2); max (solid, cm-1) 1329 & 1140 (sulfonamide S=O); m/z (ESI+) 
calculated for C9H1235ClNO2S [M+H]+ 234.0350, found 234.0353. 
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3-Bromo-1-(4-chlorophenyl)-N,N-dimethylbut-3-ene-1-sulfonamide (124f) 
 
1-(4-Chlorophenyl)-N,N-dimethylmethanesulfonamide (117 mg, 0.5 mmol, 1 eq) and 2,3-dibromoprop-1-ene 
(100 mg, 0.5 mmol, 1 eq) was reacted following the general procedure E to yield 3-bromo-1-(4-chlorophenyl)-
N,N-dimethylbut-3-ene-1-sulfonamide as a colourless oil (89 mg, 53 %); RF = 0.4 (toluene:EtOAc 95:5); 1H 
NMR (400 MHz, CDCl3) H 7.37 (4H, s, Ar-H); 5.46 (1H, bs, 4-H); 5.31 (1H, d J 1.7 Hz, 4-H); 4.50 (1H, dd J 
3.9 Hz 14.5 Hz, 1-H); 3.34 (1H, dd J 3.9 Hz 14.5 Hz, 2-H); 3.20 (1H, dd J 11.3 Hz 14.5 Hz, 2-H); 2.62 (6H, s, 
N-(CH3)2); 13C NMR (100 MHz) C 135.1 (C-Cl); 130.9 (2 x Ar-CH); 130.7 (1 x Ar-C); 129.1 (2 x Ar-CH); 128.1 
(3-C); 120.9 (4-CH2); 64.5 (1-CH); 41.8 (2-CH2); 37.78 (N-(CH3)2); max (solid, cm-1) 1330 & 1138 (sulfonamide 
S=O); m/z (ESI+) calculated for C12H1579BrClNO2S [M+Na]+ 373.9588, found 373.9601. 
1-(4-Bromophenyl)-N,N-dimethylmethanesulfonamide (123) 
 
(4-Bromomethyl)sulfonyl chloride (0.5 g, 1.85 mmol) and dimethylamine (2.3 mL, 8M) was reacted following 
general procedure F, yielding 1-(4-bromophenyl)-N,N-dimethylmethanesulfonamide as a colourless solid (440 
mg, 86 %); mp: 147 - 149 °C; 1H NMR (400 MHz, CDCl3) H 7.55 (1H, bs, Ar-H); 7.51 (1H, d J 7.8 Hz, Ar-H); 
7.35 (1H, d J 7.8 Hz, Ar-H); 7.24-7.28 (1H, m, Ar-H); 4.17 (2H, s, 1-H2); 2.77 (6H, s, N-(CH3)2); 13C NMR (100 
MHz) C 133.5 (1 x Ar-CH); 131.8 (1 x Ar-CH); 131.3 (1 x Ar-C); 130.3 (1 x Ar-CH); 129.3 (1 x Ar-CH); 122.7 
(C-Br); 55.2 (1-CH2); 37.8 (N-(CH3)2); max (solid, cm-1) 1329 & 1138 (sulfonamide S=O); m/z (ESI+) calculated 
for C9H1279BrNO2S [M+Na]+ 299.9664, found 299.9653. 
 
(E)-1-(4-Bromophenyl)-N,N-dimethylpent-3-ene-1-sulfonamide (124g) 
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1-(4-Bromophenyl)-N,N-dimethylmethanesulfonamide (139 mg, 0.5 mmol,1 eq) and crotyl bromide (68 mg, 0.5 
mmol, 1 eq) was reacted following the general procedure E to yield (E)-1-(4-bromophenyl)-N,N-dimethylpent-
3-ene-1-sulfonamide as a yellow oil (cis:trans 1:2 as determined by 1H NMR) (64.2 mg, 38 %); RF = 0.38 
(toluene:EtOAc 95:5); Data for major trans isomer; 1H NMR (400 MHz, CDCl3) H 7.49-7.56 (2H, m, 2 x Ar-
H); 7.34-7.38 (1H, m, Ar-H); 7.24-7.28 (1H, m, Ar-H); 5.45-5.54 (1H, m, 4-H); 5.08-5.17 (1H, m, 3-H); 4.05 (1H, 
dd J 3.9 Hz 11.2 Hz, 1-H); 2.95-3.07 (1H, m, 2-H); 2.75-2.91 (1H, m, 2-H); 2.59 (6H, s, N-(CH3)2); 1.54-1.59 
(3H, m, 5-CH3); 13C NMR (100 MHz) C 135.8 (Ar-C); 132.6 (Ar-CH); 131.9 (Ar-CH); 130.2 (Ar-CH); 129.4 (4-
CH); 128.3 (Ar-CH); 125.1 (3-CH); 122.6 (C-Br); 67.0 (1-CH); 37.7 (N-(CH3)2); 32.2 (2-CH2); 17.9 (5-CH3); 
max (solid, cm-1) 1329 & 1138 (sulfonamide S=O); m/z (ESI+) calculated for C13H1879BrNO2S [M+Na]+ 
354.0134, found 354.0174. 
 
N,N-Dimethyl-1-phenylethane-1-sulfonamide (125a) 
 
N,N-Dimethyl-1-phenylmethanesulfonamide (0.15g, 1.5 mmol, 1 eq) and iodomethane (0.71g, 5 mmol, 4 eq) 
was reacted following general procedure E, for an extended reaction time of 16 hours at room temperature, to 
yield N,N-dimethyl-1-phenylethane-1-sulfonamide as a colourless oil (0.18g, 86 %); RF = 0.6 (95:5 
toluene:EtOAc); 1H NMR (400 MHz, CDCl3) H 7.35-7.45 (5H, m, Ar-H); 4.28 (1H, q J 7.1 Hz, 1-H); 2.59 (6H, 
s, N-(CH3)2); 1.77 (3H, d J 7.1 Hz, 2-CH3); 13C NMR (100 MHz) C 135.3 (1 x Ar-C); 128.9 (2 x Ar-CH); 128.8 
(1 x Ar-CH); 128.7 (2 x Ar-CH); 62.1 (1-CH); 37.7 (N-(CH3)2); 16.2 (2-CH3); max (oil, cm-1) 1321 & 1137 
(sulfonamide S=O); m/z (ESI+) calculated for C10H15NO2S [M+Na]+ 236.0716, found 236.0722.    
 
N,N-Dimethyl-1-phenylpropane-1-sulfonamide (125b) 
 
N,N-Dimethyl-1-phenylmethanesulfonamide (99.6 mg, 0.5 mmol, 1 eq) and iodoethane (78 mg 0.5 mmol, 1 
eq) was reacted following the general procedure E to yield N,N-dimethyl-1-phenylpropane-1-sulfonamide (43 
mg, 40 %); RF = 0.47; 1H NMR (400 MHz, CDCl3) H 7.36-7.40 (5H, m, Ar-H); 4.00 (1H, dd J 3.9 Hz 11.2 Hz, 
1-H); 2.53 (6H, s, N-(CH3)2); 2.33-2.45 (1H, m, 2-H); 2.11-2.21 (1H, m, 2-H); 0.85 (3H, t J 7.5 Hz, 3-H3); 13C  
MR (100 MHz) δC 133.5 (1 x Ar-C); 129.5 (2 x Ar-CH); 128.9 (1 x Ar-CH); 128.7 (2 x Ar-CH); 69.1 (N-(CH3)2); 
37.6 (1-CH); 23.3 (2-CH2); 11.4 (3-CH3); max (solid, cm-1) 1319 & 1139 (sulfonamide S=O); m/z (ESI+) 
calculated for C11H17NO2S [M+Na]+ 250.0872, found 250.0870. 
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N,N-2-Trimethyl-1-phenylbutane-1-sulfonamide (125c) 
 
N,N-Dimethyl-1-phenylmethanesulfonamide (100 mg, 0.5 mmol, 1 eq) and 2-bromobutane (343 mg, 0.5 mmol, 
1 eq) was reacted following the general procedure E to yield N,N-2-trimethyl-1-phenylbutane-1-sulfonamide 
as a colourless oil and mixture of diastereomers (77:23, determined by 1H NMR) (101 mg, 80 %); RF = 0.63; 
1H NMR (400 MHz, CDCl3) H 7.34-7.44 (5H, m, Ar-H); 4.05 (1H, d J 6.6 Hz, 1-H); 2.47-2.52 (1H, m, 2-H); 
2.46 (6H, s, N-(CH3)2); 1.60-1.70 (1H, m, 3-H); 1.27-1.30 (1H, m, 3-H); 0.93-0.97 (5H, m, 4-H3, 2’-H2); 13C  
NMR (100 MHz) δC 132.9 (Ar-C); 130.3 (2 x Ar-CH); 128.6 (Ar-CH); 128.6 (2 x Ar-CH); 71.1 (1-CH); 37.6 (N-
(CH3)2); 36.1 (2-CH); 27.7 (3-CH2); 16.3 (2’-CH3); 11.1 (4-CH3); max (solid, cm-1) 1320 & 1140 (sulfonamide 
S=O); m/z (ESI+) calculated for C13H21NO2S [M+Na]+ 278.1185, found 278.1180. 
 
N,N-Dimethyl-1,2-diphenylethane-1-sulfonamide (125d) 
 
N,N-Dimethyl-1-phenylmethanesulfonamide (99.6 mg 0.5 mmol, 1 eq) and benzyl bromide (86 mg, 0.5 mmol, 
1 eq) was reacted following the general procedure A to yield N,N-dimethyl-1,2-diphenylethane-1-sulfonamide 
as a yellow oil (101.7 mg, 70 %); RF = 0.39; 1H NMR (400 MHz, CDCl3) H 7.31-7.39 (5H, m, Ar-H); 7.11-7.17 
(3H, m, Bn-H); 6.98-7.00 (2H, m, Bn-H); 4.32 (1H, dd J 3.2 Hz 11.4 Hz, 1-H); 3.71 (1H, dd J 3.3 Hz 14.2 Hz, 
2-H); 3.40 (1H, dd J 11.4 Hz 14.2 Hz, 2-H); 2.54 (6H, s, N-(CH3)2); 13C  NMR (100 MHz) δC 137.2 (Bn-C); 133.0 
(Ar-C); 129.7 (2 x Ar-CH); 129.0 (2 x Bn-CH); 128.9 (1 x Ar-CH); 128.7 (2 x Ar-CH); 128.3 (2 x Bn-CH); 126.6 
(Bn-CH); 68.9 (1-CH); 37.7 (N-(CH3)2); 36.4 (2-CH2); max (solid, cm-1) 1382 & 1131 (sulfonamide S=O); m/z 
(ESI+) calculated for C16H19NO2S [M+Na]+ 312.1029, found 312.1031. 
 
1-Cyclopentyl-N,N-dimethyl-1-phenylmethanesulfonamide (125e) 
 
N,N-Dimethyl-1-phenylmethanesulfonamide (99.6 mg, 0.5 mmol, 1 eq) and bromocyclobutane (373 mg, 0.5 
mmol, 1 eq) was reacted following the general procedure A, for an extended reaction time of 16 hours at room 
temperature, to yield 1-cyclopentyl-N,N-dimethyl-1-phenylmethanesulfonamide as a colourless oil and single 
diastereomer (55 mg, 41 %) RF = 0.65; 1H NMR (400 MHz, CDCl3) H 7.34-7.39 (5H, m, Ar-H); 3.92 (1H, d J 
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10.2 Hz, 1-H); 2.68-2.79 (1H, m, 2-H); 2.43 (6H, s, N-(CH3)2); 2.21-2.58 (1H, m, 3-H); 1.60-1.72 (2H, m, 4-H, 
5-H); 1.51-1.59 (2H, m, 4-H, 5-H); 1.43-1.49 (2H, m, 3-H, 6-H); 0.95-1.0 (1H, m, 6-H); 13C NMR (100 MHz) δC 
134.9 (1 x Ar-C); 129.5 (1 x Ar-CH); 128.6 (4 x Ar-CH); 72.9 (1-CH); 41.7 (2-CH); 37.5 (N-(CH3)2); 32.2 (3-
CH2); 31.9 (4-CH2); 25.3 (5-CH2); 23.9 (6-CH2); max (solid, cm-1) 1339 & 1131 (sulfonamide S=O); m/z (ESI+) 
calculated for C14H21NO2S [M+Na]+ 290.1185, found 290.1180. 
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CHAPTER 5 APPENDIX 
5.1 NMR Data 
Compound 90a 
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Compound 90b 
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Compound 90c 
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Compound 90d 
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Compound 90e 
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Compound 90f 
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Compound 90g 
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Compound 90h 
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Compound 90k 
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Compound 99f 
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Compound 99g 
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Compound 99h 
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Compound 99i 
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Compound 99j 
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Compound 99k 
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Compound 99l 
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Compound 100a 
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Compound 100b 
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Compound 100c 
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Compound 100d 
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Compound 100e 
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Compound 100f 
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Compound 100g 
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Compound 103 
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Compound 104a 
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Compound 104b 
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Compound 7a 
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Compound 111 
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Compound 112 
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Compound 113a 
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Compound 113b 
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Compound 118 
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Compound 124a 
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Compound 124b 
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Compound 124c 
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Compound 124d 
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Compound 124e 
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Compound 124f 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
190 
 
 
Compound 124g 
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Compound 125a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
192 
 
Compound 125b 
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Compound 125d 
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Compound 125e 
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5.2 Crystal Data 
  
 
 
 
Compound Reference 116 
Chemical Formula C23H26BrNO4S 
Formula Mass 492.42 
Crystal System triclinic 
a/Å 5.756 (6) 
b/Å 14.466 (12) 
c/Å 14.824 (12) 
/° 112.17 (4) 
/° 98.81 (4) 
/° 94.47 (5) 
Unit Cell Volume/ Å3 1117.1 (17) 
Temperature/ K 150 (2) 
Space Group P 1 
Number Formula Units Per Unit Cell, z 2 
Radiation Type MoK\a 
Absorption Co-efficient, /mm-1 1.963 
Number Reflections Measured 18818 
Number Independent Reflections 5198 
Rint 0.1015 
Final R1 Values (I>2(I)) 0.1138 
Final R(F)2 Values (I>2(I)) 0.1775 
Final R1Values (all data) 0.1922 
Final R(F)2 (all data) 0.1998 
Goodness of Fit on F2 1.168 
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5.3 HPLC Data 
 
HPLC Method: 
 
Compound 90a 
Enantiomer 1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chiral HPLC 
Instrument Agilent 1100 Series 
G1311A Quat Pump 
Column Type OD-3 
Particle Size 3 m   
Solvent Hexane:IPA (95:5) 
Temperature 25 °C 
Injection Volume 5 l 
Flow Rate 1 mL/min 
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Enantiomer 2: 
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Compound 100a 
L19a & L19b = 4 % ee 
 
 
 
 
 
 
 
 
 
 
 
 
L19f = 8 % ee 
 
 
 
 
 
 
 
 
 
 
 
